var title_f16_62_17376="Ankle position for US";
var content_f16_62_17376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Positions for puncture of tibiotalar joint with ultrasound guidance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient and needle positioning for puncture of tibio-talar joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17376=[""].join("\n");
var outline_f16_62_17376=null;
var title_f16_62_17377="Salter I fracture reduction";
var content_f16_62_17377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Salter I fracture reduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 418px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGiAVoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poooJoAKKTJozQAtFJn2ozQAtFJn1pc0AFFFJmgBaKDRQAUUUUAFFFFABRSA0ooAKKrx3cUkioDhmLAA8E461YoAKKO9FABRRRQAUUUUAFFFFABRRmgGgAoopAc0ALRRmjNABRSZ9aXNABRSA0tABRRRQAUUUUAFFFFABSHrS009aAAdaKKO1AB9KXPFRLNG8rxJIplTG5QeVz0zVfVLoWVqbmSaKG3i+aZ5P7vt70AXc0ufSq1lObm1jmKGMuu7aTyAelT9aAFpO/FFFACk0DrSZooAXNGfWkIooAU0dKQ0UARXU/2a2eUqW2/wjqah0u4lnshLcYD7myAMcA1B4gYrp3BABkQNlc8bueKzvCurrqmgXl0GYCKeePLdtpI7UAZWi69Dqus6fP8AZ5oYXkmhtWYYLkD5yR6ccV3PYV4lazXH/CUeGrvTtRW8sTf7b9+QY3ZSEQD074r23mgbF6UhPvR1FBoELRRRQAUUUUAFHNFFABRSd81Q1G/Npd2kQUFZt+7JwQFXPFAGgaSs66vj/YE19GCjCBpFB5wcZpdGvlubWBHkDXXkJJIMYI3DrigDR/nSe9BNA9KADPrQfalApO9AB0NKKTvSigAooooAKKKKACiiigApp606kPWgBKMUjdDQDkZoA8z164ltfEXjgwvJG66dbTIyHnIyMirPxO1yfTtK8PCO3+2LdzAS25GfOAjzt+pNcr8Xdfn0TxjfWUEDXB1bR9gWMEvHsZjv4/hA61seMrie4tvArWsbSXZjaeHb/wA9BCNufbJ5pjNf4ay3S6pq1tdXUlynlQTxFznYGB+Qf7uMfhXf15T8PJIbf4hX0MMjtNcWAku0J+WOdX+YAduterUhAKVe9JRQAUUUUAHJopR1pOpoAKKMe9FAHOeOozLpdovneSn22Eu+cfKDk1h+D54F8NeKltjm3ivLoqR3BXP9af8AGbyx4RjaeGWe3S7ieWOJtpZQckZrE8CeIbLWvCnjC+0lCtoHYxBlwceUO34UxnL2kVpeWehXVsW0yGwvrdJYmyftcucBvU4B619A9q+evEV0JtF0i81w/Y9agubaCC1hOdy71JcjuCOc9q+hD7UgYvagdKO1FAgooooAKKKKACiiigArkPF7SDxFo4UKYxBdM2ev+r4xXXk4rjPF5c+LfDqKxCPFdq3HX93xQBLc3H/FsXnhySbDK7upJWs/wBqUuoa1cPcWzWsy2MKNExyflJGar3008nwVJt2C3LWixoW4+beAKp+Bdbt9S8ZxMYVi1J7BoLvb0Z42HP60DPUcjFBo7dKPSgQmDS8g0Yo64oAO/NKKQ0AcUALRRRQAUUUUAFFFFABTT1p1NPWgBKWiigDxb4yT6hYeOdOk0OAXOp3+lzWccDLwy7ssS3bAOaRpLy/8P+APsUqw3klpLCHL48tlUAt742nir/xf16Tw54u0C8s4PtmoS209vBZBctOSV4Hp659q5jS4LnXNG8JadMxs5I5r4XDYwYtrZwPTrj6UxnW+E51m8a6PPbQhI2tbi2mc/eeRSCWPrk5wa9V715JpF/bXHjXw1MM20u64tVtxxvAT7xHpxxXrdDEFHWiikAUdaKKACgUUdaAA9aBRRQBwnxnks4vBqtqayNZfbIPNVDgld2TXKeG9Y07U9K8by+GrdI7SW1WSEgbUkbYVzjt0rsvi1ZRah4SWC4V2g+1wNIE6lQ/Nee6pf6baW3iePw8Ujs7jSDsEPAEiuF+Uf8CpjRg65azy6N9tupRd+LBHGsgiGIrC3UqSvPrjqeTX0havvtYXHIZFbP4V4B4gskt/BeoSaDdJc3U9l52ozSvgzhR69iMYx7V7l4an+1eHNKnH/LS1if8ANBSYGkTmlpBmloEFFFFABRRRQAUYoooATFcV48vEsPEPhSWVysT3UsLYGc7oziu2rz74tTWVqfDNxqUhitl1NYy4/hLKwB9uaARz+sXc9p8Drl7RGmnhnMcaj7xxP296n0HUtGvvFPhm+0bIYrJBNg8bmTJDf7QI5rN1ttQt/hfqtto+LzUYNZ2Qq7AGQmQMBn1INUPC1pp1jq3h+60Wfy4r3UBJdWrctHPhgykfw85oGe9jpSdBzR3o60CDrR0oozmgBe9ITzR6UtAB2oooFABRRRQAUUUUAFNPWnU09aACiiigDyL426g2i+IPDOoWERm1dvPhsoQm7zZGUYQ+g7k9q4i5sdS1c29nqt2LHVLe7ubi5WLhXfYjbBjqpPFemfFkW0Wp+G726mS3+ySTzJM38LCP+vSvB38Was/xJTVrqwkiaRPtsFiyHMsYGzK+pIGc0IZ6Vp97Fqus+F9cuEa21eK/S2ltk4ECEFdrD3617seteAeILV4rvS9e0yRWubm8t7jUUB+XygwCn6jOPevfzTYgozRRSAM0UUD3oAXFJRRQAUUUUAcj8VI5ZfBV4sEqwyF4tsjfw/OBXkvxRa00y006001IDcy5tCMYDMWVsNjoTtr0/wCNkMlx8MdaigkWOZkQI7dFJcYNfPurX0ehTeHvDOueZc3NjqUV7daohyjLgkBvVj6U0M7mPUbCew1SewtlXw2ttI1wVXHl3G0gj3XNexfD6f7T4G0GbAAaziOAc/wivE9QvrqzvX1BbFh4f1ZXK6ci/vDNt+WXb/dbuPxr174RytN8NtAZyN4twrY7EEjH6UMDr80tJS0hBRRRQAUUUUAFFFFACE/nXnfxtksodB0mXVo99gNShWYY6K2Rn8M5r0XGa4D4y26XehaVbSuiJNqcEbFxkbTkEflQCPNF1Cz8J6JrIku5NQtYdctLiF0OSyOvy4P4Vc13SE0TWtL8Smcx6hq+oW/2m2UZjA3cMuOhA6nvXJ+K0074fa9Np+rySXnh+V7aSCHGXhQb1x7hSc5rftBeWGgX7+JLiMz4ik07c/Itw6kAep9aBn0XQaZE4eNGB4YA04CgQHrQBmg8mg8dKADGaB6UE+lL2oAO1ApORSigAooooAKKKKACmnrTqaetAAKKKCaAOC+J9vaXOoeGEv445I2u3UK/QnYcD9K818bX62PxZ0C4soFuZ4NMlSWELk+WXA/D1+ldz8c1lez8Pi0tpLm9F9utkQ4PmBDgk+g715pBbzeHvGGiXmtGS58QXkc6XMmP3bM+Aqg9AgpoZp67ay6JpmpWNpN5qXm28aY8rEFYHZ7DjivoG0cS2kEg6Oit+Yrwy4sfs1hf6XM5lhaKSVrg9HlAJEQ9l7V7D4QuDd+FNHnJyXtIiT/wEUMRr0uaSikAUUUUAGKCKKKACiiigDhfjjA9x8KfEMcaF2MAO0HBPzDp718/efaaP4b8N2OrFr/SLvU1JvwpMhJUjZIDyGBOPwr6I+MM80Hw51g2uz7S6JHF5n3d5cAZ9s186+N9c0u41jRdNu7W5g1lrxV1HTol+QybCFkT1JJ4I/GmhnT6Hc3nh68uLHWg9z4k/wBTpQkbcpgPCke4716x8DzOvgCC3u3V7m1uZ4JCowNwkPT868g0fThdSXaeOZZIvEOnor2EpbBSMfcZSOrZ4Ir0/wCAj3qaHrdpqrK97DqUjSFVwDvAb+tDA9PPSlpDS0hBRRRQAUUUUAFBoooAQ8CvNvjuFPhbThIxSP8AtODe4GSoyea9JFebfHu1mvfBlrbWsohmk1K3VWIzzu4oBHg9zr8sHxJ8Oz+OIFNhcpPbBZFz8mMISPx6+9b9y89hp+o2PiZP+JcsEj6DO4yVA58tj/ex09RVvxXa6Z418Q+GtF1nFtqMKXEbxgYIcIMFT6ZGakk1OTxTomp+CtVjVdV0yFheS4ABRR8kie54+lAz6E0GX7ToenTE8yW8bfmoq/3rm/hxcC68BaBMDuDWcYz9Fx/SukA9aBCHkUoNGBR1oAO/FFJSj60AFB60HrRmgBaKTijPNAC0UUUAFNPU06kNADRxS0p+tJQB5X8eY742/hqXSiTcwagZAoOCwCEkflmvLNX8TWvjPxjp1hZoEsbmyltZLtmx5UpIJwPVSMA+ter/AB2W3+xeHXu5ZoYjqIhMkJwyh0K8V5reWnh/T/G8/h+3jSGX+y1aBIyMiUPlcf7R600M6XSZWfTpfCWp4OrQoV8zH+tjxgTA+vr716V8LJN/gDR0LbmhiMBPqUYr/SvMtAtX1SMTaxL9l8TWR+eZeMIOi+6nvXefBuST/hGbu2mK+ZBfTL8pyu1m3DHtzQxHeUUhzuGOlLSAM0DpSjpSUALjnFNGe4xTu/FFAByKO1Ic4oPSgDzr9oOaW3+FWrTW8scUyNEyvJ90ESLXhviK30i5tPDS6lOIfEtzdtdSTSNiWIhCRz/cBxgV7V+0nEZfgx4hx1RY3A+ki189+IGm1zxD4VlnsZB4hihe7ltmTgIijYv+7gE/jTQ0dj4Y+2fEFJdS1Mx2mqaQ2y3hYYKuOd7Z6q35V6L8BNdXXLvxdLt2SLeRiRe27y8Ej24ryrXo9R1aeG98Ma08+tXVoTNbxwqiJCOqtjkHsM81337PN6lxr+uBLM2Jks7Zmt26qy7kJ/HrQwPc+1KOlNpRxSELRRRQAUUUUABNIelH4Umc0ALXnvx0vRpvgJr7aWa3vLeRVAyWIccD3xmvQvyryb9pW3vL3wHY2ennE1xqltHndjue9AI8d1+Wbxhrema5oM0Vv4lmSU2UDOA8aJ2YevWt+ayi8X6LZt4fm+yeKrbct3NjBL4xJFL6g1m+K/DljZeJtHj8JxSW2uQWkkyKTlzICBls+vPtWnoyzaNG3jDTYy90x2a7YjrgdWX/AGh196BnsHwRneX4Y6KsoxNArwuv91lcgiu7BOa83+Amq2+seBZrqycPbnULjYQMcF8jPvzXpGeKBMMc0HpR0oNABR3oPSgUAH1pe1IOKXPrQAh60d6WkHXpQAtFFFABTT1p1NPWgAFAFFHegDyv9omITeFNMiCb3k1CNEG7adxDAc/XFeBaToOq6V4yuI72GW78WWtmL5b4HemAehz/ALPyge1fQn7QWjnWvBVpCszwOmowOkqdUbJAP5kV5JoOv6onj/VvtFt/xMPKg0+4brHGQCRKT6H096aGa8emXniiO3v7PXZmuZowLmRYwixL3jAH8WeOe1dt8Cbu+/tLxbpupOsr211GY5VTaHUpjOOnbtXDzu3w/wBU+w2rbrHW5MQFz/qbk/eZv9k9a774drFpnj2505HDGTTEc/NyWVyCSPfNAHqtL25pKKQgFKOtJRQAuaD05pKKAF7c0cUlFAHm37RRK/B/XXXb8gic59BIprwnQ/GV/ffEfT7+901IWl05bW3icY8sucqzN6MBmvof4326XPwp8RpLD5yrb7/L/vFWBx+leEWN9pXimTX5bR/LdrS0eAYw8UyAgJt6ggjFNDRtQeR8PNauZbjbJHrUm8yIMETdlA7Lk12HwwtWs/ijqXmYM91pSTzEdC/m9voK4vw/Nb6z4Z1HU/FoSW9CmCS26GDHAA9GPrWt8G7TUdJ+INmmqtLL9t06QW8sjZZUVgQje4FDA+g6UdKCKUCkIM0g70tJQAtIKBwKDQAZo6GkFKffrQAD6V5X+0VD9p8H6ZCWkjD6pB88f3lIyVI/HFepg15l+0JaXF74KsksnCXI1S2aNj0BDcZ9qAR4RbeJvEmheO5NW13THuJobJYbjaANyM+EZPTNbOuzeJF1Q69p+lKlmQG1KxtpvNZ4+74HG4DsKWw1RPFnj3xBp95bPFfPYx2E0bfwKMlyPxI5rd8K6i3hZH8I3LFtXTm3nxnz4j90/UdMUDO6/Z9n0+bQdbXRmj/s/wDtJ5IVTjarKpwR2PXivU+K8y+EdpDpeveKLGKKONnaC6cxjAZmQgnH1Fem0CYD3pRxxSUvWgA70HigelAH5UAAPrS/ypPwpT0oAT1xSg8UlGaAFooooAKQ9aWmnrQAUUUUAeefHyK6l+F+pjTW23yvE0DZxhxIMV4p4B1Gysb7WrW9aV9Su4IWlR+ZZpsHcVHsele9/GMonw11yaRiiwRCYkdtrA/0r5ugXUF8Y6h4vaO3WaC3hu1jjIINswIIz645zQkPoegQWwutF1CbxaqtegeU8eQfLX+AJ7njn1q18MdNudI8caG+pzNLfXlvcqzucnYACifgKy/tg10W3i22Q/2bbKXSFus693I9R2FbOlai0vifwfqrFTHcXjxR8YKRvGcA+/FMD3TksDkBfSloopCCl/nSUUAFAorJ8U65beG9AvdWvdxhtk3bF+87dAo9ySBQBrmkrzKy8XfEKWzju5vAUPlyDcIV1FRKoPTcCMZqd9d+JN6yCx8JaXYq3Je91Dfj8EFAGz8WXEfw38QsWKBbViWH8I45r5f0PVLmw+JI1y8sUis5LGIXDIgA2McJN9TjJPvXu/j3W9bj8Ba9Y+K9F8ozWUiJdacxmhJI6MCNy/jxXgvhSS4n8UxaUtnceIbW50tY2trWdS8aoclXHoM+tNaaj6HTeKlt4vEdt4ohhaXQFcC7KfdlYdHA7getdP4Q1KfU/iP4W1lpGWyvDcRWsfbZ5fX8cfpXJWsPieF/7Ct/CXiC48PuT8kluEkUf888k42+9dJoPhrxLpHjXwvqGr6fDpXhtL3bDZicSSQyuhC5I4Ck9qNgPo7vRRRSENP5UvJo70HigApBSnrQBigAPA4o96M5BpCe1ABXmH7RWoT6Z8PFurUZmj1C2I9vnr0/tXn3x2jifwC/nlBELy3L7umPMGaAR4vf26eG5LvxDbTfatSjulklYHLTq6AsOO1but2A1PQLfxDbuU1sgS2THqp/u/SuW8PXunaR481QXzM+hzlVt3lTCq+DwfXI6GtTRp30vxHJ/akrRaFKxksi33FPoT2/xoKOx+BOoXN34t1RL9GjvDp8RnRuocOQf517iDXivw2uPtPxM/tDyzEt9p8iqOm5UkGCfzr2mgkUjmigdaBQAgPNL0oOKOc0AB570vQUlH15oAO/FAFFB7UALRRRQAVS1nUbfSdNuL+9fZbwLuYgZPsAPUnirtcr8SVx4aM7LI8FtcQ3EyxjJMauC3Hf1oAda6v4hlRZn8PxiGQbkUXQDgHpuBHBqT+0fEUyZh0OCE+k92P/AGUVuWlzDeWsVzaypLBKodJEOQwNTUAebfEPV7k+BPEFn4l0h7dJLKQCWE+dC/y9CRyPxFeOaX4YtLrxJ4Xi8CaxZXtrf2Bkn068dmSHYA2ARzjcTwelfUOsW/2vSL62wCZoHjwe+VIrxWwvotM8M/DHWILfdcQ3Z0yWKJBvfcGRh74K5oGUNO+Gvjax12UwQaamhyHzjYi6OwS+o4zt74q3qnhLV/DmveHNX1q9sm0g6pH9osrdCFjdgQjhjzw2MivdLafz0LeVLFg4xIME1z/xI0Y694J1axQHzzCZYSOokT5lx+IFO4jpT1orA8Ba6niXwdpOrLw1xApkXusg4YfmDW/SATpS0UUAFcX8WbGW88LxSxo0kdlewXk8ajJeON8sMd+Oce1dpSEZBBGR6UAVdL1G01WwhvdOuI7i1mG5JIzkEVbyBnPavCrvRv8AhGfHWvi28YHwxLeSreWcEm02k0ZXDDy24BDdcetbN14b8eeJdHLQ/EKwa3k5U6fZhVlHdS4JIB9qB2PTdaYPoOoMg3g20hAx1+U14fpVvpnhLWvhnrdppiwi/tJrS6NrBlyzIGDsF5IBHJ969Z0XWY5Nuh6xb/YNREWwRM25JlxjMbfxfTrXnXwuur6TxjZaTqNjLAuiQXlrDcEgpOolADL9AQDQB7PaXMd1As0JYo3TIIP5GuY+KdjNe+B9Ra0JF1aBbyEj+9GQ/wDIEV1fesrxPdLa6POv2eW6kuAYI4IxzIzDGPb60CLOiX6apo9lfxcJcwpMB6bgDV7HrXnvwPvZ5vA0Wm36GO/0ieTT50JztKNxz34Ir0KgBOnSikA5pelACdKU9qBzQKAKer6la6Rp09/qEwhtoV3Ox5x/ia5lPiHpTgZstaU56Np8n+FVvi6yjTNCWfi0fWbVZyem3ccZ9s4ruyaAOTPjzSQygwapkkD/AI8ZP8K4f4069onir4YaxZ2eoiOZJIfMVwY5Iv3i/MVbBx717IK4r4s+GdG17wZrDarp8dzJFayMjqMSKQMjDDnqOlAHzhLf6TeazNoPjC9s7FIbSICRH+WRlyFZWHAyOaz5vGul68jeF9cvoTp9n9y8tlLG5A+6FA7/AM69q+Hvw88K6fqosP7Hgnt73Rba4kW6Hm73zyfm6de1eiWPgTwpZSCSy0DTYW7MkIFAzwT4O6/rt98T9At76wmt9Litri3hu5YypuQFBAx0BAAr6grgfinB/ZemaT4hs4lA0K8W4eNRgGFvkk6exz+Fd5E6TQpLEQyOoZSO4PSgQ80HtSUDjmgBc5o4oHNLQAg4oPalpO9ACik60nSnUAFFFFABTHAYFWAKkYIPQin1l+JdYtfD+hX+rX5ItrOJpXx1IHYe5oA4TQ/Do0Hxhq1hY3N9psN0ftto6PvtyD99Nh4Ug89uDXRXem+Jrq0nW18R2y7hhHS0GfxOa858NaVrHxgtBrniXU57Lw1K5FrpljIYy6g4zIw5qxcaLqXw6uZW8KLNdGFWuBYySkrewD76jOcSp1BHUUxnpuk60itHY6ojWd+oACyNlZfdW6GvGYJJf+Eo0LTWs5hYW3i+4aG4yNh+Qtt9Rgk16Vo/jTQPFcFla3VtKlzeIHjtpoiSR3KsODj1BrzbxFCuh6dfW2nBpLrS/FlvcW8HmfMRLjAyfUE0Aj6BNVtRuHtrOSSGEzygYSMHG4npzWdpOtXN9fzW1zo97YhOkk2Cr/Qg1ssuQR37H0pCPM/gj52mReJPDd9sF5pupPKRGcr5c3zrj25Ir02vJ72JvB3xk069EbppOvwGyurmR877peYyfTI+WvWKACiiigArjviz4tbwV4Gv9XhQSXYxDboehkY4GfYdfwrsa4r4v6TJq3ga7NvEJriydL6OMjO8xncV/FcigDz34VfD618WaUniTxksuo311l1knO4sD3Geg9AOKuadF/wqjXr4QpK+gsBPdRRjISMnHnovbaeHA9jXWeGNYGl6Fay2avc6BdQiWwmjQt5G4f6pwOcA8A1a0a1fV/En2648ye2gtngeSVNqSs5G5VU/wgD8aYyGXxN4J8bzwaPa6jb6pcyDzYxaMS8I/wCem4cp9a4HTNUg8C6hpFzerqF5D9u1G0do0M82NwYMwHJHHWtDUfDa+CPGFkuiiCyh1BmTTrgIAIpvvG2kI6xv/DnkGqvgO3gu/jFPqstpdWeou1yJ7eZyVRwiA7R0x7jrQB7Joer2etWCXmnyM0TDPzKVYexB6GptTW5NlL9ieKO4x8jyjcq++KsIqqDgAZ9BTu3TikI8c+H7nw/8VdT08y3ctjrtv9riuLjgXFzGcSso7Agj8q9jrzn422MsWgWHiOwU/bfD10l8uzq0QOJV+hX+Vd7pt7BqWn217aOJLe4jWWNh0KsMigCzml7c0Gk4oAOlFJ/KlxgUAZniTRLLxFo1zpepxl7WdcNg4KkHIYHsQec1574T1rxra/b7JrWz12DTrl7XJm8i6Crjazgja2R3712PxA8TxeEfDFxqbxiaUFYoIs4EkjHCgnsO5+leXf8ACF+KtfnbXG1K5i1a7iAE0UxtolA5UBF5IHQFuTQNHXeIfG/iiy0W6msvA2pNeKCEzNG6L/tHByQOuBW/4WWLU/BSQ/2guoyzwMs8+esjA7uOq4JxiuO8HfEhtKum8PfEaeHT9VhbZDeSHZFdD69A38+tdJq2kaTfail3oWtLpmsXKkJLZyKwnwM/NH0b60AeceE5LXxt4l0bSbi4v7ebStJlhuWtpGhLOsoTG4feGBXutjaxWVrDbW6lYolCqCcnH1rw74c6ja6D4x0ePXL2GCS60eWFJpyIxLMtyxfGeAe+K9o03WdP1OWVNOuo7nysbmiO5R/wIcE0Axdf0+PVdEv7CZQ0dzA8RB91IrnPhBfvf/DnRnmffPDEbaQk87o2Kf8AstdlnmvOPh5IfDninXvCV2BGrzvqWmt2lhkOXA91bOR70AejUY460UooEA7UtN78U6gBPrSCl+tA6UAIeaUCg4oWgBaKKKACuY+JehSeJvAmt6RAcT3NuwiJ/vjlf1Arp6a3WgDyr4Z66lpoNpemJ/7Ju1CziNCfsV2g2yIyjkKSM1vQzt4h8Y6fdWVxLNYWQd3ZV2xAsNoXJ5Y9/asnR3Phb4x6jpDLs0vxFB9vtR/CLlOJVHuRhq6271sebLFYCKO3hYrPdzHbGh9F/vNQByPiXQm8KXj6rYCSTw/NN5l5bJ9+yY9Z4T2GeWXp3rz74jpf2vjZZ3uo5rGW/wBJuWmRcb03MoJ/SvdNO1G3voxZXDtMZkYASJjzUxgtjsp6c18//EK1uNJu/EXhyZpcwaM15p0zDIZIJRIgz6ryuKYz6b9aK534e+IovFfgzSdZhIzcwKZF7pIBhgfxzXRUhHMfEjw2PFXg+/01DsuivnWso6xzJ8yMPxH61X+FPid/Fngmxv7kBb+PNteJ/cmQ7WH6Z/GuvryjwHGPD3xm8aaBH8tpqEUWsQIOis3yyY+p5oGer0UUUCCkZVdWVgCrDBB7ilooA8q+Esj+GvE/iXwLdOQlrMb/AEwMfvW0pyQP91sj8a7DUfFdvBcPDZqsqxNslmZsRqf7oxyzewqj8Q/CUuuLbarokws/E2m5eyuezjvE/qjdKz/hxd6Z4nshqNvb/YNVspDa3tkeTbSqfmVQemTznvQMqeKRe+M7W50eCMxySr59szLg2jp8ySMex3AAL1wTXD+GvHEaeK9O1LxII9P1JdUbSbyKQ7dkjQgBv90lc5969/tLS3s1dbaFIw7F22jlie5PevM/i18PbXV7uDxNp+lW19qtmCJ7SUfLewkYZfZwOVbrTuB6mMHGO9Ka4v4YeINN1vRVTSJrl7e2URiO6jZZYscbGJ+8QeM12nU0hEN5bRXdrNbTqHhmRo3U91IwRXmvwCnktfDmreG7hy83h/UprIEn/lnncn6H9K9QPSvKfBDfYfjr4+09cCO6t7W+2/7WNpNAz1Yn2oPvQaQ0CF6Cg88ilJ9aQ0AcP8ZtDXXvh3qkBRmlt1F3Ft6hozu4/DNXPB/iMal4ZtpMxm9WFPkLYDAjKt9CK6p0WSN0kUMjAqwPcGvM/hzptosur+GdZtoprrRblhbM45a1kJaPHqBkj8KAINf8Lnx5d6vDerYMYIojbXEab1S5UkjOeGGOD7Gsvwhpdub2TV/D2lW+k+MNMH2fVNK+7HOvqn90HGVYfQ16nd6jp+iwpAqhW25S3gTLEfQdPqa4jxx51mdO8dWMAtrzTyFvoQwYzWTHDBsd1+8PTBoGcL4JgsfGfju2tdb0RmsLRL5rdLxQSSZlzlexBJFe9WOmWunWcNppsMdpbRcJHCoVR+FeUaIwtPilYPHh4Lq6vVRweCkkaSL+eDXsmRQDD61w3xZ0qebQV1zSRjWtDb7basBy6j/WRn2ZcjFdz1psqLJGyOAUYEMD3BoEUtB1OHWtFsdStGDQXcKTKR6EZxV8ivPfg9u02x1vwzISTomoSRRZ/wCeL/PH+hI/CvQh70AIKcKTPNKOlACGkpx6U0UAA+lAFKTjpR3oAWiiigApD1paQ9aAOb8deHD4h0pBay/ZdVs5BcWN1jmKUdM/7J6EehrlvC+pJ4yknt72Mab4n0zEV5ZTLvWFs/62NejBuoY16ZXk3xjil8L63ofxA01SGspls9TVf+W1pIcZP+6cEUDPSNI0e303e6tJNcyY82eU5d/8B7CsP4meB7LxzoEthcSPa3YU/Z7uI4eInt7qe4711cciyxpJGwZHUMpHcHpTqBHjvwv1uz8NanceHvEZk0zXyEWSDyyLW4YfKJ4mAwN4xketexVn3+k2l9e2l3cRAz2pJjfHOD1B9R7VoUAFeW+MQmkfHDwXqzfKmpW1xpbn1bG9K9Srzb4/W8q+AjrNopN7ol1DqERHUBWAYf8AfJNAI9J70d6raZeJqGnWl5D/AKu4iWZfowBH86s0AKQaSiigBMZOa8v1lI/Cfxl0fULfEVp4njeyu1HAa4jG6N/qRkV6jXlH7Q+bbQ/DOpouZLHXbWQEHGAWINAI9Xope+aSgDO0zR7fTLu+ntAyreSCV4/4VfGCQO2e9aPSl5xS9qAGnk15SUFh+0sHYYGp6Bhfdo5P8K9XIryr4rk6V8RPh1rwOEF7Jp0x/wBmZOP1FA0eqCl6YpMUvU0CDg0e1H86M89KAD2rhfH1jPpWp2XjDSoTJc2KmK+iTrPaH73HcqfmH413XOaR1VlIcAqRgg9xQByum2bGH7dpcq3/ANuj8zz5cbZA3TJ64A/hFalnokK6fdW16RdG7QpOWGFZSMbQOy4Nc18OmOj6trvhSaQlbCUXVmD/AM+0uSAPZWyK7ygD5r8S6dqvgfWdO0+/lvG00ajC+l6lbKGeKNVZTG+eCwBAx3Ar6E0G7S90i1uY7tLxXQHz0XaHPrjsfapNV0611Wwmsr+FZreUYZWH6j0PvXl/g/wzd6P4h1HQxqupWM0Z8+2uIyGju4T/AHlIxvU8Ejr1oGeuDnrRmmIGWNQW3sBgk8ZNOHQHoaBHA2xXTPjVeRA4XWNKSfH+3C+3P/fLCu/7da898a/6L8UfAd2uMzG7tGPqDGGx+Yr0EUAGOacKQ0D0oAWm06migApeaM+1LQAUUUUAFNNOpp60AFcX8Z9g+FXigygFBYufx7frXaY964v402jXvwp8UwICWNjIwA745/pQNbm94SZn8KaKznLGyhJ+uwVrVz/w/vI7/wADeH7qIgpJYQkYOf4AK6D60CCiilIoASsTxvZDUPBuuWZAPnWUyYPqUOK26gv08ywuU/vRMPzBoA474I3hvvhP4XmZizizWNiTnlcr/Su4FeZfs4H/AItNpibs+VNcR/TErV6bQAUUUUAFeWftJox+GEsq5BgvrWXI7YlHX869TrhPjnaNe/CXxMiLudLQyqPdCG/pQCO3gbfBG553KDn8KkzWL4Kv11bwhot/GwZbizikyPUoM/rW1QAoNGc0lLxQAZ4ryv8AaQTZ8PIr0Ntex1K0uVb0xIB/WvVDzXnH7Q6K3wh14v1VY2X6iRcUDR6LGwkjRxyGAIp2PWqmksX0mydurQIT/wB8ireM0CDqaQUp4oFAB0oPQUdaBQB5345DaP8AELwfrsIwLqZ9JuufvJICyfkw/WvRMeledfHGTyPDmj3GQrRa1ZsGPb95j+tei96BhzSbVLZwMjoaUcGj6UCA+1JTjzSDrQB578V91nqPgzV8gRWesRpKx7JKpT+ZFehdM1x3xfsft/w215BxJFbm4jPcPGQ4P6V0Hh+8N/oGm3jHJuLaOU/UqDQBoUdTRThQAgozSc0o9TQAlOpp5PtS+lAC0UUUAFJ3paQ9aAEPWq+pWkeoadc2cwzFcRNE30YEf1qwKD0oA8u/Z0uJk+H76NdkG40S+n08/wC6r5X9DXqPFeS/D6Y6V8avH+huuxLsQarCOzbl2sR+NetUAwxS5/Gk7CsLxF4mstC1Xw/YXf8ArdYuzaQnONpEbvk+vKqv1cUAbtIRuUjHWlpRQB5Z+zo5TwTqNpIAJbTV7yFl9P3mf616pjivKPhoy6N8U/H/AIeyFWWaLVYF/wBmRcN+uK9VoGwxzS0D9aSgQvaqmq2UWo6Zd2U4BiuYmhYH0YY/rVqigDyb9m+/lXwZeeHLwn7b4evpbBwf7gYlD9MH9K9ZrxWxU+Cv2jLuBz5el+LrbzYyT8v2qPqPqR/Ovau1ABSjpzSUA0AL3rjPjPZm/wDhZ4mt1XcxsnYD3X5v6V2ZHSs/XbaO80y4tZn2xTRNG/qVIwRQBR8CXq6j4J0G7Q/LNYwt/wCOCt/PFeY/s/Xch8Dy6NdH/SdEvJtPYHrtVsp+hFem4oBhmg+1GDQaAAYBoOMigCg9aAPPPj5atP8ADHUp413SWUkN6o/65yKx/TNd3p1yt5YW11GQUniWQH2IB/rUGv2CatoeoadKuUurd4SP95SK5n4N6g1/8OdIEmfPtEaylB6h4mKH+QoA7XNJz2oPWlHHWgAyaBkUetB60AYPjxgngnX2OMCwm6/7hpvw+Ro/Avh9W5YWEOf++BTPiSufAHiEA4P2Cbn/AICat+DiD4R0QoRt+xQ4/wC+BQBrindqTtzzRntQAEE0dBQOvtRQAZ4pMc0uOKUUAFFFFABSHrS009aADFBoooA8f+M6T+FPFPh74iWUTPb2BNlqqJ1Nq5+9/wABPNes2N3Bf2cF3ZyrLbToJI5FOQykZBrK8cJDL4M11LpFkhNjNvVhkEbDXiX7Pmt+I9E8C6Qbi1m1jw/PxH5PM9lkkYI/iT+VAz6K5xXy/wDtT3HidviJ4Nk0DRtVu49KK3MEtvayOklyz7vLDKMFgsIOBzgn3r6eVtyqw4BGea5fxv8A8hHwf/2Gl/8ASeegR0ttMLi2hmCSRiRA+yRSrLkZwwPQ+oqSnHpTfwoA8f8AG7t4f+OHhLXOBbagj6RcsBjJb5o93417B3ryr9oTT5LnwbLeW67bvTWS/t3B53xNkj8s16L4e1KPWdB07UoSCl3bpMMf7Sg0DNLHFIetJSLkDk5NAhaO9L2pMUAeHftVKY9E8K3llIYdYh1iJbOUfwsev4cCvWPCmqT6ppEL38P2fUEXbcRHsw6kex6ivKPj7I9149+GmlxoJGa/kufLPQ7QK9pt4kRjIEVZCMHFAE/tRjmszW9e0rQoVl1jULazRjhfNcAt9B1Nc83xP8JLv/4mmVQ4LCFyP5U1FvZCukdryKjlXeNpAKkEdM1zujeO/DGs3gtNN1q0luinmeSW2tt9cHFdIxJTMeDkcHsaTVtxnkPw/kGi/Gnxbowf9zqVvFqMXGAzr8j4/SvYAO2a8g8YBtH+NvgnUyUVb0T6fIR0O5dyj8xXr/fmgbDvR0o7UvtQIT6UfWgdeKCMUAH1rzbwrPH4X+JeteG5WKW2r51bT93QseJkHvkBse9ek59q8w/aE0t5fAU+vWEht9Z0FhfWdwnDIQRuX6EdRQB6gKQ1xXwv8YXPirRIn1bTZ9P1RIkeVWX91KGGQ8bdCD6dq7bFACDpSikPWjHpQBk+LbWK98M6paTk+XPbSRnBx1UisT4QX39ofDbw/KWBZLYQtj1Qlf6V0OquyW8m1fMcAFVIwPzriPgU8ieE76wnx5tjqdzCcdMbtw/9CoGekUhoo4zQIO2aBQT6c0gGRQAvWgDFJnBpQOaAFooooAKQ96WmnrQAoFIaXORSGgDkvi3dGz+GPii4U4KafNj8VI/rWZ8BLZrT4R+Go35b7KpzjHXnH61X/aJuHtvg14maPOXgWPg9mdQa6b4eRrD4L0WFHVglpEMJ0X5RxQB0Vcv44/5CPg//ALDS/wDpPPXUd8Vka7/ZLyWM2rXkEBsbgXURknVAHCMnOTyMO1AEPiTxf4e8NzQQ67q9pYyz/wCrSV8M3vj0961rK7t762jubOeOe3kG5JI2DKw9iK+P/E2rWUHx/wBWu7+/0/Ube5Zfs8nmrIghK4CKeQGBzxXqekwaj4Pl/tTwirXGmS/PdaQT8rju0Wfuv7dDXTHD81Pmi9exm52lZnq3j20W88JanAysyvCykKMkgjHH51yP7OWoG8+FGmQyEmWwklsm3dRscgfpiu10PWbHxJoKahpsnmW8yHgj5kYdVYdiD2rzX9nNvIj8bad8wW01yUgMMEbwDXMa9D2GlxxSUUCFooHFB60AeG/EgPc/tDeDYgSVttNnm4OCuSQSPevbLQYt48HIKjvnt6141q8azftR2AlTeE0I7B7mQ5NeyhvKgBKk4AGBQB8veJZNV0j4s61f+LdKub+Fps2DtC0iLF/D5WAQPcetZHjnUtU1xJf7H1TxJosJ/wCXZ9HKqP8AtquGA/Ou2/aF8X61D420bw5pVxNb2Rt/tN0IZPLeUkkAF+wGM1Ui8M2U8UbX0l5eyFQSZ7p3H869GhSq1IWTsjCpKMXdrUw9OnvLnUvDX9iaxbXl21ylrO9/pZWIIRtZZGGC2egU/eJ7V7ZYnV9KvYLG40xdKnkg+yWNzp7yXOmBgSyh7f5TE3UZxg9N/wB0V4LKZfCHxS0GTRFMMbTReYkbHbKjttZWHfrxX1PbaDa2f2ddOe4soIZWl8iCTEbluoZTnj2GMdq58VCUJ2k7l05KUdDyP4537LH4d1EoyXej69bJNuUomSFJZM/eUhxz9QeQa9yBzyOleH/tK6bBp/wnJja5l+zXsUqyzzNK+4ygnJYk456dB0GK9Ri8V6FayWdjf6xYWt/LbpKkFxMsTSKRwyhiNw69M1zGpv59KM0gIdQyEFSMgg8GlzQIBxQe1GMjigc0ABrzL9om/Nr8MbyxiBa51WaKwiUdSXYZ/QGvTDXj/wAZZGuPiN8N9PcE232yW6YAZyyKNvH40DR6N4QsF07RbW3BfdFEkZzwOFA4FbWRkAnmo7Y5iGRg+hqR8hSQMkDgetAhGKqpLsAPUnFEbq4yjBh6g5r5Ei1u68cXfiKXxDeztq9ncyLFZSvIltAitgLtTnPvz9KzvCdxria7dxvomsada28WfO0i5kf5yRhsM3zLjPABbpxW6w7aTvuQ6luh9XeIrieBT5GzaWHO453e4/pXJfA5y8HithtMZ1qYqV6dFz+tecT/ABPvLDTLiG7u11oqhS3kKGG6glPCrPEQDgk8Niuk+D/hLxfovhi4is/ElrHcC9lae3msw6eYcE/NkN3rGUXF2Zaaaue4d6O1cO+v+KdDUtr+hRX1qvLXOlOWKjuTG3P5GtXRvG/hvWYQ9lrFnuOMxSyCORfYq2DSA6PIo9KajK6BlIZTyCOQaXrQAvHWgHmkzgUoFAC0UUUAFIcUtIeuKADp0pCaKKAPPf2goFn+DnihSpbba78D2YGtX4XTLc+CdGnQyqrWkeEkGMDaOce/rTviva/bfhp4ngCg79PmwD7KT/SsL4AXov8A4X+H5WnDSLaLGYweRjjJ79qB9Bf2g/Euo+Ffhbqeo6PIYr0tHAkoHMYdsFh74rwnwd4KsNX0a21DWLdL+adRIZZ5XkZjnnOTivf/AI86T/bPwk8SWy8ulsZ14zyhDf0rwbwNfTah8J7gWks0dzBaSrFKBtIfYSCp74NehgOW8ro5sReysHj7wZpy+GJY9OtdPtCjhj+5Ubl/ug9Qaf8ACvXvFGhaBpK34TUNJvWmisJpWIZZI8/uWPqcfL+VdH4lEeoeDJ7t32J9nF0CP93IH612/wAHPDdlrfwM0ew1SHdBdK0+VOGVi5Kup7EdQa1x0uRqUSaCuncyPgTr1xq3jbxCTp76bBc2kN1JbFsgTbipYehIHP0q/wDBZGg+IvxNhLZU38UuB0BKGu/8G+D9N8KJcmxa4nubpgZ7m5ffI+OAM+g9K4L4RMv/AAtf4nBVIP2qA/8Ajhry5O7udS2PYRzSdaXBoxjmkAnNLiikNAHiPjmMWX7SnhC6f7l3pssGS+0ZVs/j16V7amMfKe9eMfHWAW/jz4b6qyrhL+S3YsMgBlBGfyr2dCWXPrzQB8wftJ28Fl8TNIv72PfZzWyCUf3kViCP1FdbbGMwwtDgQsg2Y6YxxUP7WGno+iaHqO0F4p3gJx2Zc/zFU/BaO/hTS2kB3iIDnr7V7OAl+7scmIWtzltQsmvfjL4chIBV7iFQM9Ap3E/pX1fivnTRYPO+PWgh0zHHbu6k/wB7aa+ij0rixrvVNqPwHj37VSM/wi1E7sKskZIAySN4rovFXgHRfiL8P9O0/WIQJBaRta3aAeZbOUHzKe44GV6H8iMH9qRxF8ItXYZO/wAuPpnHzj8q9H8If8ilou7r9ih/9AFcZsfBfirT/HXwb8Rtpa6vqNgp+eCezuHSC5TP3gM4PupHB/An6v8A2e/Hi+IfC8WneIfEIvfF0Tubm0uYVt5ohn5VC7V3gAAlhnk89q9G8R+HNI8SWsFvr2nwX0ME6XESyrnZIpBBH5YI6EZByCRWN47+HXhvxvGja1Y4vouYb+2byrmEjoVcc8ehyPagR2A4pDXl3hqx+I/hPXbPTby6t/F3hmeQR/brhxBe2Sf3pOolHvyxPpXqJ9KAEHFeRfFV2tvix8PLjcVWRrmAdMZKggc969ex615D+0EjQSeCNTTA+ya3GrEjPyuCDQCPWoHZ0JfbnPY5Fch8SfiDpvgW1s/tcb3N/ev5draRsFaQ9ySeAB610+mptEhBLKx3A4wPwFfOX7Stqf8AhbfgW5nw1sY2Xaw4yH/+uK0pQU5qLJk7Jsh1fVbXxLqk1+PAOlC6nbEk51FkLt/thAM1zd3q9noGo+Zc2VrZRwyBLn+zLmdbiAE/fBclXA7gjmvT44lQttAHsABXmHxQtLJbi7KRMt3LColYodr7sgc9M8dK9aeEpRjp+ZyxrSb1O6+I2izw6boup6w1jqWn22o2k0GoQoFmkjZxjeuML1GSp5r1i/sta0LVbzU9Bji1Cwu2Etxp7HZIHxgtE3TJAHBrPv8AwdFrHwitPDs8xRzp0UKzEfMrhQVI9wQKm+E3iifW9EfTtYj8jX9JItb2JuC2OFkA9GHNeM5N7nYlbY1NO8ZaBq0bW8l7HaXJBWS0vD5MqZGCCG/pXE634d8LahqWh6deWmm6vq8VwPLMKguLbnJlI7Aev4V6TrGg6TrIA1XTbS79DNEGI/HrSaH4d0jQlcaPptrZ7/vGKMAt9T1pAcjJ8K9Otm3aDrOvaMM5EdpesYx/wFsisnxTovinwh4fv9dsfG9/fPYxGY2t/bo8cwH8PGCM9MivWKralYW2qWUlnfRLNbyY3oehwc/zFFgOQ+HXjS718vpviPThpHiKGFLiS037lkibpIh9OxHY13PevBvGupf2V8SNG8aXbmzsor9NCgV8qZoWB8xyPQNjH0r3kHIBB4oAWiiigApCcGlpD1oACaCeKSjvQBW1S0W/0y7tJPu3ELxH6MpH9a8d/ZeK2/hK40yUKbzT7me1kbuAkhwD+de1+hrxfwSP+EY+OPjHRnGy11ER6pbjbx8w2vg/71AHreuWwvNFv7ZhkTW8kZHrlSK+Yfg26TeBEtW5FtNLbsp6jBPBr6sxkYNfKngVf7DvviFYG3lmbTdSmnEMQBd1ILADJ6muzAy5ajT7GNdXiTRJLd/CGSAfNKmlmA+7Iuw/qpr234ISLL8JfCrIAALFFwPUcGvn74WeKYvGFtrGiWVrNbRr58yzuQcLLMzKm32DYzntXuf7P5ZPhdpts7bntJJrc+22RqvFSU4RkhUVZtM9FPTPp6V458JJzJ8YPiaqxGNBPbnkYJO017Eeh5x715R8OY4YvjN8QvLYGSVbaQlc4PBH51wG56yfrQD60Uc4oAM0dTSYpQKAPKP2jLb/AIpLSdQC7m0/V7abOcbVLbSf1r06zkEkUbK4YMoYYOa5T4y6U2tfDHxFaRpul+ytLGB/eT5h/Kp/hZqy614C0a+TpJbpz74Gf1oGcf8AtOQeb4Cs5GyUj1CEsPY5H9aoadD5WnW0cYwiRqBj0xXQ/tEQCf4XX5wxMU0Mgx7OP8axdJYPpVmw53Qof0r08C/daOWvujn9Mge3+N3hu5O8iZJI8Y+VcRnvX0J3rwDUrlrb4neCCWCk3TIQOpDKRzX0BiufG/xDSj8J5F+1LAJfg/qrH+F4sD33rXpvh5dmgaYp/htYhx/uCvN/2nyn/CoNWRyAGkhAPPXzFr0vRRt0awA5xbxjP/ARXIal3IPFGaOlFABmge9JS0AHFecftBac1/8ACvVpI8+dYmO9jI6gxsD/ACzXo/aqGvacmraHqGnzDKXUDwkf7ykUAU/CMqTaFYToS5ngSQuCSCSoP9a8w/aatTFp/hnWkQMbHUlRhjPyuMfzFbHwM1M3HgCytbh8Xmns9lKQOQY2IIOfYCrX7Qlv9p+FeplSA0bxSqT6hxWlKVppimtGjmgpfDAe9cd8SoFe20aNzhJdRhjfnsWFdhozNPpFnKzZ3wox+uK5L4tRgaLp0pGBFqEL59MMK9yq7waOCHxI+mPLXy1ReAoABHavD/jjbal4ba38a+EmEWqWbiG+iOQt1Ax2hW9cE9e1e4QtviRv7yg/pXJfFHTU1DwZrMDIzma0kQKOTkLkYH1Ar589A434efE6G8V4L0TRrB8lxazL/pNi/o4/ij9HFetWV5b3sCzWkySxtyGU5ryHR/B1h8RfAXhnxHDPJpfidLNFj1O2xv3KNpWQdHXI6GuL1nWfEXgDV7Wy12CezluGcQ6jYKZba5br9wco3crSGfTPagCvC/D/AMQNUgvbF9U8QWU8JbEsLWsgdlPp8vBFe4wTJPCksTB43G5WHcUxHB/FTwVb+LbGWXUUR0sLSd7Re4nK8N+GK6D4e6m2seCNCv3OXntI2c/7QGD+oNbsiCWN0cZVwVI9jXA/A92TwQbBuDpt9c2eD2CyHH6EUAehUUUUAFNPWnUhoATFHTmlxSUAFeUfEyMaR8T/AAVr29Y0uPN0yVicAlhuTP4g16vXmH7Rdo83w2kvoWKTaZdwXquv3l2uAcfgaAR6ZA4eJGByGAOa+crWD7B8evG1t937UI7gZ75UV9A6FOtxpNtMgfa6BlL9WBGc/rXh/jmBrP8AaLtJRgR3+mAH3Kkj+lb4Z2qIiorxZifDHwgfCvi3xgUi2WtxPC9qcceXhmIHsC23/gNelfAaTy9L8SWBPNrrE/HoGww/nQYuPlJ/EU34Sg2vjPxrZk8SS290v/Akwf5V1YmKVKyMqTvK7PUXHyHvxXk/gVhH8b/FiMx3T6bbTAEY6MQa9ZLBVJboOTXkFqwtP2joGAYLqWiOOe5STP8AKvOOlHr4NLn1pMUd+aBBSijpQKAI7iJJ4JYXGUkUow9iMV5L+zhi18N6tpBYmbTdSnt3VmJKgOdoIPQYr17p2ryP4Y4sPi78SNNC7VkuIbxQe+9OSPxoGdL8a4jN8L9f5I2QeZx7MDXGeEnE3hvS5FGA1uh/SvRviTALv4f+IIcZ3WUvH/ASa8x+G+T4I0jedzJAEODnFd+ClZNHPXWxi+OWNr428GXoYhVvUU/TeP8AGvov1r53+K8axwaLcOTtjvUOffcpr6IU7kDDoRms8X8aKo/CeTftO27zfCXVWjlZBE0UjAdHAkHBr03RG36NYHGAbeM4/wCAiuA/aKG74ReI15x9m3e3DrXceFWL+GNIY9TZwnP/AAAVyGpqE5opAM04UAIDSA06igBtFKelJQB4/wCD4W0b4seNdFWQRxXLx6nbr/10HzdP9oV1/wAXLc3Pw01xDhmWDeeODgg/0rlfFUY0/wDaA8NXaylP7Q02aCRQMlzG24AfnXfeJ4PtvgvV4MLiSzlUBen3TTWjBnlXg9ZX8NWAlKlxHt4ORjPFYfxciU+Cbl+jJKjDI6EGuj8GyC48KaTIuCHt0OR9Kz/ijam48E6hHG2G+Vhkehr227o4UrM9t0Gb7RoWnTHrJbRt+airVwnmQSJnG5SKwfh3P9p8CaBLx81lEOPZQP6V0VeI9zuPMP2e5mXwVe6dIW8zTdTurXDDBADlhx+NVv2k98Hgaxv4ADc2mpQNGcZxklT/ADqT4SEWnjv4jaaCQo1CK6RSegkTn9RXSfFzR31r4fatbwqWniQXEQHUtGd39KQ+ozwP4f02fwvpdzd2onuHhDO82WJJ9jXZRokaBI1CqowFAwBXCfBzURc+FY7aSQtNCA/zHko4yprvKBC+hrz/AOFbhdU8b2ijasGuSkD/AHlVq7/t1rz34eZh+IXxDtiuAb23nB9d0Q/woA9EooooAKQ0tJ3oABmjFLSfhQAfyrmPidZf2j8PPEdpjPmWMuB7hSR/KuoFUtZgF1pF9b4/10Dx/mpFAHOfCe6N98PtCuWBzJaRk59QoB47VwnxztVtfG/gnWACGWV7ZjnHBwf6muk/Z9laT4VaKkm/fArwMW9Udhx+VZ37RFvnwzpN7tz9k1GNs+gORWlJ2mmKWzL+371UPAzCD4taxHz/AKVpUMo9yrlf61pxfPBG6fddQ2fqKxrEiy+MWgSF/wDj80+4tyB0O0hxXdiNabOen8R65jPWvMPHVsmm/FfwBqce79/NcWL55Hzx5H6ivUM5FebfG8/ZNO8M6rj/AI8NbtXLeis20/zrzTqR6TjNJjJB9KXmgdaBCfWlHFH1pCaAFNeUaZJJbftH67CiAQ3OjQSu23ncrEDmvVq82igc/tAXUgLKh0JM/wC0fNNAzvdYhFzo17AeRLbun1ypFeMfC2++2+Eog0aIbZzAdgwDt7n3r3JgGUg9CMV4H8JEEVnrlsBhodSlUj/gRrqwrs2Y1VoN+MoVfBwkP/LOdGz6V7rpUgm0uzlHIeFG/NRXl3jawF94W1WFlVs27sNy5wQpOfrXf+BZ/tPgzQ5Sc7rKI5/4AKeK3TFR2MT42QG6+FvieBYw+6wlPPYgZ/pWn8NZ1uPh94bmRtytp8PP/ABWh4rtFvvDGrWrcrNaSoePVDXLfAabz/hF4YJ6pbeWf+AsR/SuQ36HfDFH0oA/OjGKBC0GkBpaAEJ5oHNGOeaBxQB5J8W2az+JXw5vETcXubi2JA5G5Af6V6nJEslpLFtUI6EYHcEV5/8AGONVvfBN2w4h12Fd3oHBWvRwBwMcDtQM8U+HYB8G2MZABjMkfH+y7CtfULGO/sJ7OdN6SoVYE9az/A0Kx6bf2+0D7PqNzGMHp+8J/rXRhCsoIORXrQl7qOJ7lv4MSmT4baOjDDQK8BHptdh/Su2xxmuE+D5WPQdTtF62up3Cfm27+td3mvLnpJnWtjyPwSBb/tBePIeQZrK2mxjGe1euEAgqQCDwa8tS1fT/ANozz2J8vU9DKqc9THIMg/ga9SqRnlvwtik03xT4g0u6t2RLe6ljsrhR8rw5DeW3upbj2NepEVBbWcFtLO8KbXnfzHPq2MZqwBQAfSuf0vQmsvGWt6uGHl6hFAm30aMEZ/Wug6UtABRRRQAUd6KDQAnrQOO9HGKKADr0pGHBA70vHWjpQB5l+z0SPAl1Ex+aHVLyMj0/enj9au/HKBZ/h5d+YCUjnhdiOw8wDP61m/AZx9l8YWy8LD4gugPxINdV8T7P7d8P9et+fmtWYEdQRz/SnF2aG9zIsoAljBGp+VUAHfIArC15PJ8b+CLzAULfSQFumN8RAH44roPD0KLoOnBJHdPs6EO3VvlHNYHxL3W2kaZf/wDPlqlrLn0G/af513TleLOaKtI9arz749wvL8LNYkQEtbmK446gJIpJ/IV6F7iuc+I1kdR8BeIbUDmWwmAz67Ca4DpRtabcLdada3MZyk0SSA+oIBqwDXL/AAtvBqHw48NXIbO+wiBPuFAP6iuoNAgoFHaigAIrgbMNJ8cdSZ2G2LRIgg+spz/Ku/zXC2C7fjRqxx9/RoTn6SNQM7n05rwj4ahl8S+NLckgpqDttA45Y17vXjHg+AwfFHx3AD8rXCybfTIBrag7SM56xsdLrUQ/sbUAccW0n/oJrc+GLCT4feH2Axmyj4/Cqd3aCe3mjYEq8bIc+hBo+DsnmfDbRAGB8uJouv8Addh/Srru9iaasdfcLuhkXGcqRj8K83/Z3ct8L7ONhtMN1cxEemJWr0we9eZfAYmHR/EdgxP+h67dxgHsCwb+tcxt0PTc0tNpRQIKWk9KU0AIetJS55o69KAPN/juFTwlps7A/uNYs5OP+uoH9a9H71578fYmf4X6m6DLQyQTD22yqc131s++3ifP3kB/SgDybwdEqah4riBOY9Zn49M4NdMkWX9Kx9Ggjg8c+NLZB87XMFyRn+/H1/SulWEc4PzV3Qn7qMJR94yvhedmr+MIMY2air/g0a/4V6AAK4DwWywfEPxTbDhpYbW4/wDHWX+ld/XJU+Jm0djzzxPiL4zeC5GOBJaXsQ9ztU4r0Mewrzn4l4g8a/Dy8xyupyW5PtJER/SvRucVAxf50gzRjmjmgAJoBpKdmgAooooAKQnmlpDQAgpwx2pBxSjmgBO9B6UHrzSdaAPK/g2q23i74lWeTlNa87HoHQGvRfEEP2nQdRhIyJLaRPzU1wPwzTb8SfiW54zfW4x/2yr0uRd8br1yCMUDPKPg1dy3/wAPtPNxK0s0JaAs3X5TgD8qvfFG2M/w91sKPnjg84HHQoQw/lWZ8D8nw9qVuVwbbUJUIz05rtfEtkbvw3qtuBnzbSVceuVNdPNoY21N3Rrj7Xo9jcAg+dBHJkd8qDVi8hFzaTwOPlljZCPYjFc18K7o3vw58OTk8myjU/VRtP8AKuqPXNcxqedfAGUt8MrG2YktZTz2hz22SsP5Yr0SvM/gswtrrxtpS4AstcmZV/uiQBh/WvTSaBsKBR1pSOKBDT+lcTZKw+MmpMR8h0aLH/f0121cbYozfF3U5N3yppMKY9CZGNAHZg5rx2wQwfHjxNEZv+PiyhkWMD0UZNexY5ryG7Hl/tEOCcefpK4H97BNXTdmKWx3nlg4UAn61k/BweX4Iih2hTDdXEZA7Ylauj8tIxvf7uR0rlPhJcxLp2uW6tkxazcrxyBlgR/OqqSuiYKx346815t8Kk+zeMfiLac4XVlnA9njB/pXpNcB4ODRfFTx3EVADizlHvmMj+lZGh6BwaO/FBFH0oELikPWigmgAPWge1GeKBQBwfx3bZ8J/ELcEiFcZ9d612OkktpVmzcEwIT/AN8iuM+OxX/hVPiDzBlTGg6f9NFrtNN4020A6eSn/oIoGcKpKfFrW4CoAuNNt5wfXazKa6cR5ABHFc3qx8v4zaYu0YutHlXOepSQH+tdj5OG5HFaxlZGbWpx+nKLX4uScD/TNHH5pJ/9eu/FcLqxFt8UfDDBeJ7S6h3e42sB+ld1US1dylsedfGsm30zw5qA62euWkh+hYqf516NmvPvjsjH4b30yDJtp7ef8FlUmu/hcSwo69GUMPxFSUOoo6/WkPSgQvekAINAOKUHJoAWiiigApD+tLSHrxQAY9aO3FJRQAUUUUAeZ/Dd2l+J/wASSThVu7ZAo9outem+leX/AA2JPxU+JYGNoubbj38qvTxQNnlHwUtpYLnxaJlZd2qykcfL1PAr02RA0MigBiUIx+Fch8Nh5d/4vtCwIh1iVlHoHVW/rXcAAVTZLOH+Cbl/hxpilssjzIQP4SJWGPwruu1cJ8Ike20vXbFwR9l1i6RcjHyltwx+dd2DUjPL/h6xh+LnxItn+QvJaTqvqDHjdXqHavLbWQWP7Rt/CBgaloSSn3aOTH8q9S4zQNgegpRSdTSgYoEI1cho8Yb4leIpyfmS0togPb5jmuwrlNDhx4+8TSc/PFbD8lNAHVdBXk2tMy/tDaOGACvpjKCO/LV6zivNPE2i31z8aPDmp21rK1pBZuJ5h9xfmOAffmmgPRAoBAxxXFfDZFTWPGkGwKU1hnwOnzIpBruttc1oGjXWn+MPEt64H2LUDBJFg871Qq3H5UXBHT4rgtACr8YvFe44drG0YAdCvzDJ9813oHeuGs444/jPqTg/vZdGiJHsJSP60gO5BpB19qU0CgA70mPWlPrQaAA80AUA9qOlAHnXx/aQfCzVVjOA7wI5/wBkyrmu/tFCWsKL0VFA+mK89/aDYL8L9QyM5ntx/wCRlr0SDiGP/dH8qB9DhfEESn4weFnbr9gu1XHr8tdwsfPPSsjVPD8d/wCKNG1kzukumrMqxgcSCRQDn6Yrc/CncRxHjNRH438DykkD7VPHkepiOAfyruAO1VrmytruW3luIUkkt38yFmHKNjGR+BqzjFIDkPi7A0/wy8RpHy32RmH4c/0rf8PyibQtNlByHto2/NRTfE8H2rw3qsGP9Zayr+aGs74bzG48BaBI33jZxg59QuP6UDOj7Ug60GlHSgQH0pB1peKPegBaKKKACkPWlpp60AOHrXK65q2uf8JVFo+hRab/AMeRu5JLwv8A39mBtrqBXH31wbX4i3NysMk7Q6C0giiXc74mJ2qO5OMAUAVLHXfEd/qt7pllqHhGfULLH2m2jkmLw56bh1Fbfg3Vr7VrK/8A7Vito7uzvZbR/sxYo2zHI3c968G+Fvhjxv4c+IGieK9X0JlGvyXMerNDI0kqee3mI0ke0eWEYKOp4z0r3DwF08R/9hq5/wDZaAOU+F65+KnxOcNlftluuPfy69Uryv4RqG8ffE+Yc51ZEz9I69UoBkFvaW9tLcS28KRyXDb5WUYLtjGT+FT9aKXFACKqrnaACeTgdaBxSkUYoA8s8Vr9m/aA8FXQ4W5067tifXGGAr1MYrzX4oReV43+HV+Af3eqPbsR6SRkf0r0o+lAzmvFWrarZ6ro2naJFYtcX7TZe8L7UEaBv4ecnNcpbePrq51kaTB4k8CvqZlMAthdSeYZAcbMZ+9njFdN4h/5Hrwh/wBvn/ooV86QeFfFf9tyQQ6JrU8sXix9Ut7W502NLFl83iV7nIkA25OASOBwc0CPpHwpq2q3mq6zp2txWK3Fg0OHtC+1xIhb+LnIxTNF48deIxn/AJZ2xAx0+U0zw9/yPfi7/tz/APRRo0MsfH3ibcAFEVttOevymgDquc0H3oGaD0oAWk70Ec0Y5NAB14ri2iVPjAkpGC+ilQfXE1dqMVzl7Z58d6behDxZzQlh05ZTj9KAOiPSgdaSlHWgBT0qjrV21hpF9eIodreB5gp6EqpOP0q9WV4s/wCRV1n/AK8pv/QDQBxWoeLdd0fw7Z6zruoeEtMs7lEZGuZJlyWXcFHqcdh6U/TPGWrXkGjajb3XhzU9Hv75LMzafJKzKWz68ZGOQa5vxFY31jr/AMNvFZ0e91rR9N05oJoLKHz5raSSJNsyxjlumCRyMfSukv8AUItU0vQL2DRbzR0m8QQt5N5biCWQ8/vGTqCffnjn0oA0vi54ev8AxP4Nk0zSxGbh7mCQiQ4BRZAzfoK7JQAoA7DFOxQeelACdqKO3vRQAClPNJQKAGTLvhdexUj9K5/4cDZ4L02MfwKyccdHNdIeRiszw5Yy6dpUdtNtDK7n5emCxI/nQBp4oFGPWjvigBeKTOaM0LQAtFFFABSH6UtFACYrn9b8LW+rapHqP27UrK7SE2++zuPL3Ju3YPBzzXQ0UAcp/wAIacf8jH4k/wDA7/7GtXw5odvoNlLb20t1N507XEktzJvd3bqSfwrWooA8/wDhT4e1LRZ/Ft1q8Aim1PWJrqPDht0WAEP/ANau/paKAEP0oOaWigBO3Sg0tFAHIfEXw/e67BobaZ5YuLDVILw+YcAopO7Hvg112DzS0UAYniPw7b65NZTS3N9aXFmXaKW0m8thuGGBODxis/8A4Q3/AKmPxL/4Hf8A2NdXRQBh+HvDlvoc17NDdX13cXjI0st3N5jHaMKM4HGKmsdLa317U9QZ1K3axKFA5GwEf1rWooAOaO4oooAMc0UUUAH0pNo64GR0paKADFIBS0UAAqC+to72yuLWcExTxtE+Dg7WGD/Op6KAORt/A0dtbxQQeIfEaRRKERRfcKoGAPu09PBVv9ss7i61fXLz7JOtxHFc3e9N65wSMc9a6uigBPwo79KWigBPej86WigBoo/OnUUAJ+dJinUUAJ+FH4UtFACY9qBmlooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acceptable method of closed reduction of distal physeal fractures of the radius. Panel A) Position of the fracture fragments as finger trap traction with countertraction is applied (arrows). Panel B) Often with traction alone the fracture will reduce without external pressure (arrows). Panel C) If the reduction is incomplete, simply applying direct pressure over the fracture site in a distal and volar direction with the thumb often completes the reduction while maintaing traction. This technique theoretically decreases the shear forces across the physis during the reduction process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17377=[""].join("\n");
var outline_f16_62_17377=null;
var title_f16_62_17378="Parasternal long axis color flow Doppler I";
var content_f16_62_17378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Parasternal long axis view with color flow Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis parasternal view with superimposed color flow Doppler mapping of the left ventricular inflow and outflow tracts was obtained during diastole. The color bar in the left side of the image indicates that red designates flow towards the transducer and that orange shades of red indicate velocities at the preset Nyquist limit of 0.75m/sec; blue identifies flow that is away from the transducer. Normal diastolic mitral inflow from the left atrium (LA) to the left ventricle (LV) is color coded in shades of red. At the point flow crosses the mitral valve (MV) plane it becomes bright orange, ie, flow accelerates as it crosses the narrower diameter of the mitral valve ring, reaching a velocity that is at the upper limits of the instruments ability to measure. There is a small diastolic signal in blue that arises from the central portion of the coapted aortic valve leaflets and represents mild aortic regurgitation (AI); at its point of origin, this flow is characterized by red, white and blue dots that, by convention, identifies the flow as being \"disturbed\" or chaotic and high velocity. As the flow decelerates it becomes blue identifying it as flow that is away from the transducer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17378=[""].join("\n");
var outline_f16_62_17378=null;
var title_f16_62_17379="Scarred tympanic membrane";
var content_f16_62_17379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Scarred tympanic membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tympanic membrane with a scar. Chalky white marks usually reflect evidence of scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17379=[""].join("\n");
var outline_f16_62_17379=null;
var title_f16_62_17380="Osteitis fibrosa cystica x-rays of the phalanges and clavicles";
var content_f16_62_17380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Osteitis fibrosa cystica: Findings on x-rays of the phalanges and clavicles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 301px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEtAlUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6C+IHjOy8EaXaX2oWl9drdXItI47MRl95jeTJ3uoA2xt39K4Rvj7oa/e8O+JB/wAAtf8A4/S/tNnHhbw6f+oyv/pJc1578Mvh/pXi/wAPa9rWvazqunxafeNARatAI0iS3ikLHfExzl279MUAd637Qnh9evh/xIP+2dr/APH6af2h/DoPOgeJP+/dr/8AH64z4YeAvAfxL029vdD13xjF9kmEUsV2bNJBlQVbCxMNp5xz/CeK8UsZ2msLWSQ7pHiVmPTLYBNAH07/AMNE+HP+gB4l/wC/Vt/8fo/4aJ8Of9ADxL/37tv/AI/XzKznGOQO4FRmXk8nrxjrQB9O/wDDRfhv/oA+JP8Av1bf/H6T/hovw3/0AfEn/fq2/wDj9fMXmcevGKZ5pJyetAH1Cf2i/DYHOg+JP+/dt/8AH6T/AIaL8NY/5APiT/v3bf8Ax+vl8SnIzwKPNPTNAH1B/wANF+Gv+gD4k/79W3/x+l/4aL8N/wDQB8Sf9+rb/wCP18xCX5Tgc4xTTJu5wPzoA+nv+GjPDX/QC8Sf9+7b/wCP0f8ADRnhrOP7C8SZ/wCudt/8fr5f3nBweO4pN/Of0oA+oD+0b4ZHXQvEn/fq2/8Aj9B/aO8MjroXiT/v1bf/AB+vl93wODj2qNpOck9O1AH1H/w0f4Y/6AXiT/v1bf8Ax+j/AIaP8MZx/YXiT/v1bf8Ax+vlkyfL1+nvSCXHAHPvQB9T/wDDR/hj/oB+JP8Av1bf/H6T/hpHwv8A9APxJ/36tv8A4/Xyz5n4nvRCskz7IxkmgD6l/wCGkvC3/QE8Sf8Afq2/+P05f2jvDLfd0HxMfpDb/wDx+vn/AEzQk+8/zsOuea349NVV+VSccYHFAHsJ/aP8MjroPiYfWG2H/tem/wDDSXhf/oB+JP8Av1bf/H68VurCPaVaPPrjvXMavpoiJMIAbrjPBoA+kR+0j4XP/MD8Sf8Afq2/+P0o/aP8MHOND8Sf9+rb/wCP18ph2yQeCDj3qRZDjAGfSgD6qH7RvhknA0LxJn/rlbf/AB+l/wCGjPDX/QC8Sf8Afu2/+P18srLnrUsZP15oA+oR+0X4aJ40HxJ/37tv/j9A/aL8N/8AQB8Sf9+rb/4/XzKWyhz2qMyEADOSKAPp/wD4aK8N/wDQB8Sf9+7b/wCP0D9orw2Rn+wPEv8A36tv/j9fMQbPfrxinrJk/wAjQB9Nj9onw4RxoPiT/v3bf/H6P+GiPDmM/wBg+JMf9c7X/wCP180BhgcnmnF8jBP/ANegD6X/AOGhfD2P+Rf8Sen+rtf/AI/Qf2hfDwOD4f8AEn/fu1/+P182b+uTxj1o80enPX6igD6T/wCGhvDv/QA8Sf8AfFr/APH6Q/tD+HR10DxIP+2dr/8AH6+bA5Ocnj8qMnJxj2560AfSn/DQvh7P/Iv+Jf8Av3a//H6X/hoXw9x/xT/iT/v3a/8Ax+vmxTk9akDkEdCO+aAPpAftBaAenh/xJ/3xa/8Ax+n/APC/tC/6F3xL/wB8Wv8A8fr5wVsEHg+/SpVcnvkg/lQB9GD496Ienh3xJ/3zaf8AyRTl+PGjN08OeJP++bT/AOSK+fY23KRgfiKtwN93cMd/p/npQB9R/D/4g6f43uNSgsdP1KxlsEheRb1YhuWQyBSvlyP3ibOcdqy7n4rWsd3eQw+GvEFzHbXM1qZ4vsgR2ikaNiu6dWxuRsZArj/2b+fEPi3/AK9dP/8AQ7uuSuriaTVbzT4bma1N54pnszLEFLKkuqMjld6lc7WOCQaAPUj8ZLJTz4X8R/nZf/JFMPxo08Ak+GPEnBx/y59f/AivOfFth4a0HW9esbvUvH11/YcUM9/c2y6Z5cSSgbWG5FZuo+6pNUvif4ct/Cd54dl03WNVv7bVbW4nb7f5QK7DBsI2RoRxK2c57dKAPTH+OekoxVvDXiQEe1p/8kVD/wAL90Pdt/4R3xJn/ctf/j9eBXF++TjcSw2gZHNZs10cDC9B6/55oA+iJP2h/DsYy+geJAP+udqf/a9M/wCGjPDX/QC8Sdcf6u2/+P182Xcm7JLA7u+etUBOA5PPXn6UAfUY/aK8Nt00HxJ/37tv/j9H/DRXhv8A6APiTpn/AFdt/wDH6+XjeZxuOSKYbgfOTgnGQaAPqVf2ifDbAkaF4j46/Ja//H6e/wC0J4eTbu0DxHyMj5LX/wCP18qtdFcYxjuc9KkhuyDnJ9MdeaAPqb/hoTw9tJ/sDxHgf7Fr/wDH6B+0J4eOcaB4j46/Ja//AB+vmCO5x82RnOKk+1AAkPncOuMc0AfTP/DQ/h3n/iQeJP8Av3a//H6Q/tE+HA2DoPiTJ6fu7Xn/AMj18xmbcw+cDHY9/wAe9Mkl+YY6dOBQB9Ot+0X4aXOdB8SZH/TO2/8Aj9J/w0b4ZyP+JF4k5/6ZW3/x+vmCSUZILHIOAfSo2ccANx9KAPqQ/tGeGhn/AIkPiTj/AKZW3/x+nf8ADRPhzn/iQ+JOP+mdt/8AH6+WPNG373epobnPy+nvQB9Rn9oXw8MZ0DxJyM/6u1/+P03/AIaI8OAZ/sHxJ/37tf8A4/XzN5yMindgjPfrUUlwpHy8EcZzQB9Nr+0d4ZbONC8SHH/TO2/+P0p/aM8NA4OheJP+/dt/8fr5cWRdpHygn0P6U8zAxjuV6YNAH1D/AMNF+Gv+gD4k/wC/dt/8fp3/AA0P4d/6AHiT/v3a/wDx+vl9JfmxkGrHn8ZztOAM9KAPpc/tEeHAMnQPEuP+uVt/8foP7RPhwf8AMB8Sen+rtv8A4/Xzck6kc88ckio5HAfkgsPTtQB9Kr+0R4dbpoHiT/v3bf8Ax+iX9onw5DDJLJoHiQRxqWY+XbcAdf8AlvXzRuwcg5FRak4Oj3w/6YSf+gmgD9BaKKKAPHP2n/8AkU/D3/YZX/0lua474caDrPin4K+M9D8O3Fpa3d/rBgkmuWZVWE21t5mNqkklcjHuea6/9qI48IeHyDj/AInK8/8Abrc18y31laSytJNa27yEjLtGCTjjrigD6q8CfDLUPA/xCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXyJpjkaZaAf8APFOf+AilfT7P/nztgP8Arkv+FPIVFCqoVQMBQMAD6UAKzH5sn61G54OOh64pjnk46daazY60AOyQeSR70hbk5z+NRZ/znpQcnFAEiOMmlZgCQfTpUHAyc/lRk8Y/KgCdX9+tO3cc1ADjjAGe1PB59z/nNAEhbj/EUwnpz+XrSZ5OeT3qN2GM8HBoAkL447Y9aaxGPWm/qPeg4+9nn+VADWOc4POMc0oYYOT05phPzcd6YXwDz1PJoAmLZxgfQe9dZoGnhI/McfMRknvXKabGJryNT0HNeg2YC2oPTb154/8Ar0Aa9qi+UPlxgcHtWnaWM90QI9uCdoJ4HTmsrTf39zDbL0Zs89cDrXdaBACWUoF8vOzngH0/HIoA5G+0yZFPy9yFAOSce1cvd24AIkxjPftXqGrRMpdMFSnTcvPP+TzXmuqfu5pM4bdluOnXpQBw2qxiG6Y45P6+9VlcEfjV/X8NK5B6YPSslDx1/OgC1G3I6D2qeJh1yTz1qquMDjkCpI2GAABnPagC8WIiPoRjA5qIPyTxTlYBcngcZPpUSjjGO1AEgbnsDinKw6Hg1Fk5I7GnAkkZxxxQBOGH+FPUhjyM47GoAcnIyacrY4NAFgN3pxcZ/TFQb+oPQ+tKeR7+9AEofJIxgU48ZI4PWosDBPel3HcORz60AS7s444HTino/UngioVGMBj+X86ehwOh4OKALAI4YDJHf2qVHx9SKrIxOe30qYdV3bef1oAvxEkcE8jFXID2H5VnRcHO3r3q/CG4JzhuM+tAHsX7NZB8QeLiP+fXT/8A0O6rlJYz/wAJPC/Uf8Joe/T/AInBrq/2ahjX/FowR/oun8H/AH7quY1OG3uBrcOowRT2j6xqQKSoGB/06bHX3AP4UAdd47+FGsa74y8X6rb2Phu8i1qzgtrS4v5pFn090jCmVAIW+bPIw69Bk9q5T9pCym0ey+Hlhd3kl7cWmn3UEl1J96ZlFqC59yRnvXA6/wCHNKjjMtvpliI8EqywKOB7YrkpLW2tHVraCGNiCpKxhT9OKAD7XIrbT0HY9jUcl6W55z9OlVp3JYfLg46561DjOORQBLLdtuJA46c96rtKSTnB+vrTnyc5Ocf54qHZx6Y7UANMrHOKb5rAcilAIY9Qf51G8Zznkj+VAD/PI54/wpPOYjgkfQ1BtPfGPc05dq4Jb8FFAFkzMD/OnLO5B+bH9faqoZf9rHvinBsEkc+v/wBagCz5zqcOcEdqlNySRgkGs9T7VLECWGATzxQBPLKQ/B5yeaZ5hDH5vxp6WssrYA79DVmPS5XzluPQDrQBReTJ+b+dPEhC/eP8q1E0mIbWZmPfk9K0bTTLNYzlQxxjJ6UAc8r7sk7vbFNPmHIwxPTAFdW1rBHFiNAdvYjOT7V0Hh3wN4p8RaVFqejeGri80+VpEjmW4tow+x2RuHlDfeUjkdqAPL3YpKqSHYzD5cnGfxq9FazNxtbHfFe8fDrwJ4z0XxdZT6l4QlOlzk219HNc2kkbQOQG3L5p3BSFfGCTtxiu88W/AXw/qO6bw3PNoN11EceZbYn/AK5E/L/wAqPagD5ds9IncZYfKM5qW9tHhC71yuM5/pXpmv8AgrxT4TLNq2kG7sUH/H9pwNxGB6smN6fUqQPWuV1NbG709J7OZJIj3jYMCR2JHSgDkOpzkKTwBnNSKpAznOOMUs0a7zgHdTlJAXt/WgBM7SRxk9/SotSXbpV6eQDA/wD6CatqoJOSB61DqKN/ZF+cbcQSAg/7poA/QWiiigDxv9qH/kUfD/8A2GV/9JbmvmuYY6AYz09K+k/2ozjwh4fPXGsr/wCktzXzXcMSTgE85NAFSU44JH4cVWZiScnHY1NKeTzk9vpVV85PNADCRn5uCOnPWo2PBwferFvby3LhUB69fSteHRUAG8bj3zzQBzuQ2c0ZHbNdRJpEITaqgDqKx7/THg+ZQSPTrigCgPuj1pAcHOAe+DyDTT05GKMjIx9cCgCQHqWx9PegHg80hGRwaX0zjGKAFOcHPAPem45xjH9KfjJz2ppOSTnk0AA6c8e1NKnODjNGeM56etHXIz2z0oAjOc+wppXr+lSlScY+90x6UkUM9zPHBaW8txcSMESKJdzsewAHU+woAu+HY995ke1d0dqwqn98Asa4vwvhppCMegHofSuxBJA6EnAoAl0eULfbWPLDaSeMe9epW919mt1kcA4WMAAfeJGRnHXoDmvImUrKCh5b5Wwc55xmvUL44trOwVgG8tG+YYHIwM/gKALWvXZufDszsVaZVCuxwdnPJ9hj+VeRahOryueijjgda9MeM3FnqCSENtjZcD2H+NeQzOCPrnr2oAxdaOfN7c8VkxnkVqamP3TkgDdzislCB060AWUOMYqVRgAHINQR8YIGcdqnU5HJHXoKALOS2cn5QMn8qYpyKC3y7R1/pSdDhhjHFADuCfelzjgD2pgBHPf1pSwB478UAPRscZxg09WwKhVwGPAz69KcGGQDn1waAJsgZHUU4MMjvjoag3dz1+lP3D0Gc0ATlh6Uoz1PUVCpJznsO9OXoD265oAlGepByKlDcDge+agwPpn2qZevI56igCeJS3QZz2qVQuDk/jT4ipXp1/SpAuTnPUdDQBJESD834HFXrZto4Aznj3rP+bg5Ixxn096uWwxncOuBg+voKAPZv2ayD4g8XYx/x66f/wCh3VY80StHrDjJP9s6pkDnH+mz/wD1q1v2af8AkYPF/wD17WHX/fuq5hr6S31XW0BYx/23qOVzx/x+TUAc3qR2zMCjGIdQea5HWtNlU+ZGpMX8Jr0HV4oL2232/O0/d7j3+tYHlF5dsrfIeCPfoCBQB54ydRtO4GmFGUZBwT611OtaQFkV4SvI59vrWSYVZPLIAlUkknuPSgDLKkI27AIxwP6UMmGIORwOKueSR8y5+uKiZMZA4459aAKbKuAc5J6H0qN+V9fYVZkUmQZAANQyIAcIuT3zyaAKTLl+aaBxwK0IbWW4KqqjPTOME1oWuhsSDLt2+5xQBhrE0mMKWz3q7Bpsrkh+M10a2ltbKFONw6jFLujCIUAO0Yz0BNAGbbaQkahnZTgck9qnFvFFKFDDJ5qeUlmCjcMdgPWq7RbW5PQ4HHWgBssoX5FA9fQVGZSSvLfn0qc2bvHuG5Qf73r6UGwkL5IO08ntQBEhyeGPXPPWr1q5ERALhs8gj/PFQnTZFKgdepBPB+tatjZ7VJeQHk8j+WaAD5ysbpwqjqRXTeH/ABX4r8O6Wmm6P4lubWwiaSSOCO1tnCl3Z2ALxFj8zE8k4zXN3EJ8tT8wGflB6g1A84iUhZCSCRz/ADFAHrngHxn4y1XxRYxan4wnXTYj9pvnmtrSONYE5bc3lAgMdqZBBG8V2/ij46aFZB4fDFvNr1yDjzYz5Vqp95WHzdvuK31r5jeOC6uElnVJXjHyiT5sfQdM+9bEF0qkYU4HqM/5NAHV+KPHXijxKrjWdYazs2yBY6bugjYejODvb3ywHtXJ3TWsNl9ns4Y4Y1P3VUDPv75qaeaORU3YIXnGelZV7LHkAHIHQYzQBmSj5t3qeOacoAGT2578+1MZgXYngk9qmiUhF5yMdCP880ATIpLfdByenpTtVRf7E1IgHIt5CfT7pxU6DLBl64+8e1O1BS+g6thW2i0lJz2+Q0Afd1FFFAHjX7UeP+EQ8P5zj+2V/wDSW5r5pnO0nPHY19K/tSHHg/w+f+oyv/pLc18y3JJcn1PNAFWZuM1AoaaZY16tT5T8vB/+tV7QLfzLh5G6KMZ9KAN7SbFYYVBG3tx1P0rTEQAIAB/Ckt/ljIJ568jPStrQYY7i7AeMyEjKkdiP8/jQBkSWMwGNh3EHg8Gse8iDBlI5+lenz2ayKJlUNhDuJA6AYyM/rXB+IIFimBOfm+8PfFAHnuoxeW5I9eaphic881vanEHeRSMkj9a55QQcHqOKAJgeKeMsRjqfwqNenHFPGAD3FACrngg9DQRSE4PHSlB575oAMYBHUfSjdgZwDn17UnGfamseMnkfyoA9a+F/gLwL4t8KI+s+Lf7M8RvNKBbC6iQqgbauY5BlsgbsqR96urg/Z51zRdd0zVdA8Q6ffC0uobpFuYngJCOG6qXBPHsPpXzo+0ghwCD2PNemfAPVtE0DX5NV8ReKZNI02w5SwgnlzdSkfxRR5JQDk5HJwOcEUAfQvxN+D+l+Kp5NW0do9K8Qn5jOqZiuT6TIOp/2x8w98Yr521nT9U8P6o2leILOSxvxllRjuSVf70b9HX6dO4B4r3HUP2i/Cqb10jT9Y1Nh0ZYVhT85GDf+O1wfjj4rXXjbSn0648KaPHbN8yNeXEk8kb9nXYIyjDPUN+NAHI2kJlu7dByGcdDjPNdvqrrNfSTq0ezgANJtGAMYzXI+DbC5Uw/aJhdNApYzFNvToSOea6m9gVrFjsJjYDkHGcc89+c/pQBLo/zvKjkIJN6YHTkcV5PLCVYg5DBjwe3NetwB1/1e52jIKDuXJwf+AgZH1rzvxLbm31e8yMIzl09Cp5zQBxusf6psE4rHXOR05rb1gbYDwM1iKOntQBOnAqZcfX+tRJxgDFSLnHHFAE7Ed8dKXkcNnj14pgySQMAn1pw6YHPrn1oAGOPrTc889f1peQe3BoAywUDJJwB70AOjR5JNqAn6Vs2uhSzAeY3vhe1aGiWCxRktzxyR1+lb1kgHzAhccfTFAGEfDieXnc5wcAZwazbzSJYM+US+Oqkc16MkDyxjZGSuOdo61n3kKuCCOPTHT8aAPNw3J9fcdKerdscjp71qa9ZiKRpUxgHBA7isdSD0zzQBOpOcD1qZOSSelQKQelSxnLHHftQBdhIQDB3Hrj0qxHL2LYJqlHjAznANTRrwB68fSgC9HzzyferURyABwOlUoc4HJ54q5AOAcdDQB7J+zN/yHfFuf+fWw/8AQ7quD1BZBrniFkIUHWNRBP8A2+S9a739mj/kP+Ljjra2H/od1XmGt6otv4n8SQuQANZ1DBJ4/wCPqU0ATRPJbzpIDlCeV9BVu4gjuE8yA7WYnOBnP/16yTcsrnfuSTAbZ2AIz0+hH51o2Enmk+Wwxxux2oAoNbgvhm2uCQVIzuNYGs6cYyZY+QTyB/D/APWrtNQtgqPKclhzuHv3rMZUkZo3UvnjHUUAcUIWdwwODnJGKie2MZ3FWb1PrXbWnh+UXB8wFEkwFLjgCukt/CNqlszykO3qO3+NAHlEOlTXDEoOGwR2yK07XQFUky4HcHNdZdQCyR4kjG9Dx6Y7H86pyrPcTxoAST1GM0AZcdpDFEPlUdyxHpUEgBd8EqMYGelbk9jtUmQsEPcnuPas6aWyt0Yl97AZ2k96AM1raVl2+Xx6k4zToo7aHYZ5V652jnFZ2p6u0zERkjjoP6VhNcyNkE8DmgDqp9Rs0DsvPp3/ADqnLq1rgBBJk8HgVzjMQxLdaZg4+XjFAHUHXYTHs8snb1bP64pY9dgjQbF+fPU9veuW+8g9eg45xQFJHp6UAdTN4jjUHCbiw9BTE8Tt5RjSD7p4rmmTB5xn+dSQIN3Pc9KAN6fWZ50BkxwcjGBzVVtQdwSQGGT+Gar7Ds4IwM09YnZCo79aABLiUkHGB6g4/Kp4LuUbsFwoPb+dSRWEjhcLk+/vWzHoEqxZYFl9M8/jQBlm93x4AIIOetRhJrnARCVzx2zXRR6RDEA2xS2QME1Ygt1RvkTYCM5UcE/SgDJg0KeYHlV9sdK3dO8NQgo084LnqFP3TUsGZgBu2oBjAOCT6VdA2r+6CgjnJ5/zigDZ03w/paqpaPdtBI3nOa0fEOn6db+BPEzQW8Yb+zLnawH/AExb9ay7EyhyDIwb1Dcc1o+Ibjb4C8SRswYtptz1HOfKagD6aooooA8Z/amwPBugE8f8Tlf/AElua+Y7jgEnk+uetfTf7U3/ACJugf8AYZX/ANJbmvmK4JLcD2xQBTkbrjFbnhpR5ZOM7jnrWBN3yAe2a6TwxxbLg8E0AbROxjx97nnpxW1oMsRYLLMIsvkk569s4rGlG+PggHqG/pVa1neO7jAJUlsHnGc0AevMRDJAN6YkDckfdGchvzrzfxmqR3czK68sCAvAI9RXZXN1+8iVRvZIxGeevHP1rkvHUTtFazuqkn5CcckgfpigDhbgBpT3BXtXO3i7bgjHB5HvXUSRZVix+Y/hxXP6vERIhHXOKAKQbpnn1qQNxnPNRp04/Gpd3yAfwr0z2oAXqR34zTlx0yBTT3xnnrmg8dMc9/SgBS2Pxprd8cDHSkPBPWjAxz+FAETH+VRn0x74qZl9eaj4z/M0Aa/h7DBwe56d66qAbUbGemOOrVyWgn5mA45rqoMhRyfegD1HQ7CCawgNifOB5Jj559x7e9bkWg3DwqWgaUgHDAZ9evPc15/4R0XU7q4E9ncSWi5HzDkMfpn6V6XBN4n02IiN4r1U/hdeTnnr/wDXoAopo0hG14ZVG1h907ScEfhz+dcR8QrOOGGOSUNFMvyhXA3MTzjA7D3rtbvU/GNwheCw021C/Lln3H68jivKPFV9qN1qUn9rXLT3EXy8jhQfQUAcPrJxGenFZBTaAdynP905rU1tsLjgEnFZS4GeufSgCVcYGKlTr059ajHQeh9akU+nSgCVWwufzpQScH1puPlJHHpilwff04oAQtgH0q5o8Xm3nqF6VTkGCe9b/hmIbWlZSecjA60AdHAPLjyowMcfhWxodobqVmIHlIMketZe47DgoBjHIzXT+DfJY+VK5Vcbzjrx7+9AHSraIkW3btAXKqWwWz3z2Hoa5rXrdVV7jHl5cJsA29ua7ht0rPaxqv2iNVADHouRlT9OPxrkvH7+WsVu+FZCVUEHI78/496APPNcw1u42jL4HPauQX5W56DrXT6tKWdF3dASSPX+lc3PGUkIYgAnI5B60ASIfbp696mU54H4VBGOv9asKc5zyfcUAWIhzyeasIcN1IqvEeCR1PQ1YjBx1+tAFmE4yBkg8kYq5AR/ERyP/wBeKrRgggAmrkC/L1Vc+vOaAPYv2Z8/2/4vz/z7WH/od1XgvjnUPs3jzxQjAkf2zfY4/wCnmSvfP2as/wBv+Ls/8+th3/27qvA/Hmmmfx14mldjtOsX+PYfapBQBFp2pxSKkfm7WJz6dfWuosIrmQjyVfA53A+tcFHaxWwVuCc/dzyK6nQvFy2W2K7AltxwGHVR7UAer6RpJvLDMxJcYBxx9P8AGlm0FLYbwo6+npVLQNftriKOWxkG09Q2NxHvXZsq3NqrjG4rjco60AcnNKVtiioQnOGzUGk3knn/AGa4GQ3IY8Vuy2LxZC8n3OBXNavCFt96HMkfO0D7w9PbFAGrqOnQ3kZdsNJjqAPm9cVwmqX0FgT5C4k9M5571paf4k82X7LdARxg4R89D6H2p2o2FvfZe6RVyfvoOPzoA4O/1a6uy6k7VxyF4/GsWRgScZJ9+c11eq+HLi3iMtv++jyfmHX6VzFzE8TMHUoR1yODQBSYDPIz2+lVJM57YFXpFH3SvI5IFQSQkdh+NAFLaQcZ+vtT2wMYBPrUhiCEcH/GlIBYgHHpQBGEUZZ2xg9B1J9v8afGnBIGcc4NG3gEr+NWoLd2jwMkNz0oAriPcw/iq/Zaa5c7iMemeSKv2mmOoUsp5rf021ZHwEAYHaee/v8AhQBVtNFRogzMgIGdp4P0zVgWUcRjbBYZ+UAcGtlFQCRdobOMH2pkqqSm5ysYOQOn4fnQBBHaxRzKU4z95QMfjV8mMW67FYlc89xnpmiJlfcdoZSeHJ4xTQ+RIqAKCSfTFAEDgNHgq+4/LkDoaSKPypWChySNwy3Aqd2JGDJ5jZ52jkn60igIfmyTnIHvQA+EIoZCnQ9BzjNXYEDRFo1IkBI24xt96bbQnzHD8v0YgVoR2vyJhAc475z60ALBEgRQoLN94vnAqHxRvXwfryA7v9BuMnHbymrYtYwpBOWXoPY1R8Xps8I68ehbT7ngc4HlNQB9SUUUUAeL/tUY/wCEM0DPT+2V/wDSW5r5muSMH19RX01+1P8A8iboHGf+Jyv/AKS3NfMk+S3JyKAM+c84roPDR/0QZz1NYEw5OD371t+G2Iix/tHPFAHQEFhjLYPqOKdYxeZqtqpwR5i5yOlPycDGM+9T6TAWvY3P3FbrnHA/+vQB1ckwNzKQu3LkMxHKg+h7GqeuQre2F3boo+8ZI+c4dRyPxH4ZFWpPMkQp1eQhSSOpxnPTrxT4bZ3YyRhiwG4E4+YdCOueeD9aAPL2fKDPP4Vg6yFMWRz3BrvPE2jPas80IzGfmcAYK+/0zXE6mgMbZx0IoAwFbtUinP41Cp461Ip6UASggn+lSMxcKCTtHAyMcVCp496epz9aAEOOvaj9adjvxTSfUj2FADH4zUTHI561IcnnqKjPHSgDS0MhZG4HBrqrZwoDEg9CfSuQ0diJm4znHWuntmymT93v60Ae7+DEt/7NgZNuSv3d3JOOfx5rZu9UltZZUhVNyglRkndjt6V578Or4XcctqGCvCq/Tb3x79K6XUbdpZvLG4SSJtB5O3nIoA3vtbXKkS7V54ySDgjIJHoCK8S+JERi1xpl+VLlNyjPcHaw/l+desWFpK0ytj5HHmF+hEgwMAdgR1ryL4oXW7VBa5UvbO/zBcEqSOvryKAPONZfMgHByc1QQ+vWrGpH50Hrn8arx44yOPagCwjAqQRnPOamUDABFQRgcHpUi5x1oAmJGOc89BilQ7TnrUZc+vHrTol3nnpQBJeXInZSiKmBgAf5611OiRmO1QelcnEu+5RTyM8/Su3tF2xLt7jPTFAFyM5UEZI5zxmur+H9q00t1K3/AB7wAbyF689P0rkwzEhscjoa9C8Jx/ZPDIGQs17KXA9EHHPegDVsWY3EzcBndeC2MgHPX0JxXnnjTUjf+Ir6USZiVvLjwOAo4wP1+tdtAoQ3EysdsVtJ1XAzjg+3NeTyl2XK/MxGTigDM1CT77Z78fhWChyfx9K19ZbZCwrHiA2uSTwBgepJ/lQBYQcc9KsxDI9qhjHzdR7VOuePrQBYQZGT39KsRkAEA9TycVXjHSrCj+IfjQBaDc49cAf/AF6uQPjsT0AqlCo3kL+XpV22HQL6+tAHsn7NAA17xaB2tdP/APQ7qvC/HU7f8Jn4njycLrGodun+lSmvdf2av+Q/4tAIIFrp/I/37qvCvGNtLN468UtG2Aus35znGP8ASZKAOOuZpHOck+hPemKWbrxgZrRuYIoi569uveqcjMuNowtAGjo9/Pp0wlhbnrgHj6V7x8P/ABdFq0IhmAik2gbM8fUV87mVUHzPz+VX9J11rGYPBnzBgqaAPqmeBF+eQlgeBg8n8K4nxBGxaTyExgc45yO9c54P8dzahKLTUW4K8HPWu5YRzQbojuBGeBk596APJdRia0nDkDZJyMDj3FXdM1h4kaKcb4mGQM9BXReI9EUW7NCrbc7sA8A+1cSg8uYxgE8kemaAO8s5IbiINGwKsfug9fWszWtGMyu0cKNzzx1FYNrcPbkRnO3OVI5I9x6Vtw65cWwDT4ljIwB/ED7GgDl7jR1jJPlHbnnIx+FUpdMRclVZT6HvXo0eo6RqRMcp8jvgjB+uain8PPLEslnOk6kcqOtAHm8ujEgbc/yzVcaUhYlnyT2I5rttS0y4tVZniZFBAbA6f571ny2+3JkUbyB8u3GD/ntQBz8WnIq7sfKeORzWtb2kaRhDnI/yKfFCySEtzsPIPSp7ZyvMmG5wcd6AJreJQoZ9w6EnuD/ntVpYxtXggk7mxjg+9IsYUjap4zkZwCfWrUUcsvCKuGx7H60AVvNUB2VQMdOMAVXmmcSkFl5HAC4z6VdktHBZirAg8sR1H9Ky7iPy4nxIzLjAH9fpQBNFdIjbmAZtvH+OKk+2SSRgFVwW5xzj8ayVYLtYKQoPBz1q/GoZlQkBc9R39qAL4JERO/BJ649KdbksjY+45z8vOaVI0eMrGvyg9Ce1XtNgBL8qFHbGcDrQBc0u2xIA+QD0A5xWzBCvkt5vRW4HT/OaitYQzng8DGM9K1GiYgqQBI3QnoB/jQAy3VpDHhPmbPGO9Q+LrIJ4G8Stxxplz9M+U3P1resrbHlghsdBk9af49t1Hw68UdPl0q6I/wC/LUAe20UUUAeM/tS4/wCEO0DP/QZX/wBJbmvmS5+9hePWvpv9qYZ8HaAP+oyv/pLc18y3OOSPXrQBnznjoa0fD0oBdM4wcis6bI6nt61JpEnl3m3s3X3oA7WNsrwPfFdT4WmgnDQ4RLjaVXBxn0PPFcjBKCowQeOQB2qxCv2i4RGJVCeoHagD1ix0lmL7p4st0CsDnH40txHo+ko0up36wKBjIKhmH0GT/wDqrNg8KaekKpcNLG558xZSOcdf1qxZ+GtBtrkTSK1y6gMPNJbGfr9MUAcP418R2Op2/wBl0qK4WAOC00gwHx2A6gd+TXnt+MhvTpya+gfGeiJrHh6eO2SJJ4fnt0BADkc8/hxXgt+Mxklcex6g0AcefldlPBBpwNLdgLcuB0zTQcjtigCYHjnnmnhzyAAv4c/nUKnjmnAnqetAEg9f8ikY8+lNyQc5/SkcnaTySP8AOKAEJ5qzpelalrFy8GkWM17NHE07xw/M+1cZKr1Y89Bk+3Fe1+E9D+CWueFtIt9Q1h9L11bWMXk0lzLbZm2jef3oMX3s9K7z4e/Bmw8PeMtM8TeF/FY1Gxti4eGSNJPMV0ZeJY2A43Z+7zjtQB8waBGJAWXBy3r0rejX5RtXBB4r6e+J3wc0zxTLNquhtFpWvt8zyBf3F0fSVR3/ANsfN67ulfN+taRqmhavJpuvWT2F+oLbHOVlX+9G3R1+nTvg8UAdV8J8/wDCTFASA0Ld8V7NfWsbyZ2Y+QKD7dSfrXj/AMJYR/wlIZiMLEcj3z1xXt94MSopB24w2fTtQBUgtR9lQhNqksG75+XGfrXzP4+kEni3VsE/LLsHfgACvqiLa1kytwUJJx0Oe9fKnjZceKtZLKOLlxj0/GgDh785mGc1Eh5qfUFxcc8g1Av6UATg981IOnNQp096lHIGT0oAfjOfSnxzlBtzgHrUWcjg800nv36UAXdMw96mc5yTmu4gXhRg/Lj3rjNATddFj0wBXbWkYKnPCjkZ/wA80AaWi6c19exR4YL/ABtnHHcZ7V3zOhIZsRoAqqoOAoHAGfwqvYWccFqiRgRyNGMlxkvnoc+ntVs2T7G+VcOfm46LjPQ0AR3Mu3SNQyo3NA27Hb3/ACryxuExjJx+des3VuPLaOUBBIm0p2UbWH0PP8q8l1FWtmkhkOHjO0gdsUAczrsmWC8jnArNiwcHpVnWGUuFyxcE/TFVI+Dx+QoAuwcnaPpVlDhucYHWqsMgC5B5PAPoKlQjbjpz0/rQBbDDkjA9qsLJnqDj+dU0GcjOcfnVlOVXFAFpCc4Ax+NXIic4yc9uKoxnIxkZ/nV6HhgeM+3agD2b9mY513xdnr9lsP8A0O6ryDxZZQT+JvE7tKyyDWdQOCOD/pUvFev/ALMpzrnizB4+y6fj2+e6rwLx9JL/AMJx4oXzCqDWr/AHf/SZKAMfUFW3bIw2B+NYtxdyNnHAqWeZ8NkHpj/Cq4ZXHzflQBCWLdTUkRw4IPFPECkEowHt60scZDZI4oA0rSYxSq6sQRzxXr/gPxIJrZI58F4+SCeSPWvFwoP3eD71s6JdvbTq6HBU9BQB9HPHHPGbmPDRPyeK868UaJ9lu2uLdP3TnO0c4P1rovCmtb4BISGjb78YHI+n0rT1WKNockK8DknPce1AHlzKrRkBdxHQ5oG5epIAxtIOf/11sarpxtZwwU+UemKoSIuBjIHcY6elAGbdQujfeG77wP8ASpNO1O6s3fyZ3U4xgnjPvU7qSAGGSeMVU8kNNI0eBnGTjjNAHT2XipmiZL9FdO7AZrTN3pOpIrRCNJCOmdv+RXCEhQ6k4JHzAc59Kos5H+qyCPusPT1AoA7m901FhkGCiHuvIxWZBYbidrb+cYPcVnafrF7beXHFKTGRwH5HvXQ6RqFrfXAW6hEbngsh/nQA+20yaWPJTYo5JHb6V0el6IMoxBIAyTjtW9otpDJEpjdZVA+UE8/SuhgsVZNqjHPGKAOKurJPIdQisfQDFebawjR6jLG2ASO3T6V7dqWnMJW2px9OfrXGeJNAF9+8iOJehP0oA86hj3bd5DkH5s8jFaNrCflZeQR+VTDSLu2ch49w3cnGRxV2ygc5Xy5Ny/L8w6n6+lACxKoypO1QMZXoCO1bej2wZio4QjnsDVKxtZCdhhKgdwODXT6dZS7wwUBSMjNABawMhCjAUHlgOT7VqxWheM7myg6c1NDZsyHkADPy4x9auW1uUBQqyj1HX60ATWEGEXk9egrO+I0yr8PfE4Dfe0y6X6/umrYDhAC/HByQe1cp8RHaXwP4k7Y025OB0/1TZoA9+ooooA8Z/al58HaAMZ/4nK/+ktzXzNc5yfwr6Z/alGfB/h/r/wAhlen/AF63NfM9xk4I9fyoAzpBzwMn0xVeKTy5kf8A2qsSr2OPzqnL3yOTQB2VnIWiBJxx+tbGlXX2W9gm2B0VhmM8jFctpFwWgQ5BPTHvWqs2UAxj+lAHtsGpw6hZF1UHcp3bu3sR6cCsm5iuIJY5I9kqbuFXoVx39RjiuJ8Ka1JZ3SJIWkt5Dtb2Ht6Eda9omsbdbBWUF/usD7Hv+NAGTtlWw5yrIzOrZ5xjOBnrxnivAtem+0391KsYjWSRnCL0GT0FfTSWyS6fJnBBQgDHQ88/rXzVrVs1rqNzA/3o5GUn8aAOH1MFbn61AD2rQ1yIrIrcDBrOUjigCRSe/BqTPJ/lUXOMYp6n6fU0ALuxzn6UbqRuKT2IzQA1j19K9c+BvjTwT8PbW71rVEv7/wAQXWYVhtLX/j3iB/vOVUliMkgnAwB/FXkZPvTV6dPrQB9P337Rd3cp/wASPwuiKT8st9ec490RT/6FXC+OfHHiLxzpv2PXpNLhtdwdEtLIb4yP4lkkZ2U+4x1rjNICiBAw4GPzrUlOFPIwePpQB3PwctymriUM7bI2jMj9+gHQYzXr94xe9JRSYgMMTxyO59q88+GtubbRZLjK5IVRj+E8812yMXVnJBXbnr1PrQBoWPKT9TxggivmX4hxGLxfqwHI88kY9SBxX0lp04aVeSWeMLj064P6V8/fFqFYvGV8QAN4Rsj3HNAHl2pgiYe4quuCPerOqj98MdyaqKcd6ALCnA9akHtUC8g8VJntxz0oAczc9f0ppOMj1pW68U09M+tAG94aU4L46k/hXa6fE0wCRozM3YDrXJ+H0CwocZ9frXqXw8t45dQaRz8yDC8+3+RQB0vh231bTbOMz2EF9Eq9m2TIp/Rq6C2vtAvdp+1pZTKPmS4Pkvj02nj3yKlnuBZRRxnccAg55GPb/PrUgh02+Utd2KPIGK/OgbBAGevYZFAGXrF3pdtYyyrqlrL8pIjWRcvnqB+FeJ+ILz7TdSy4Kg8Adc12nxMs4LW4t5YLaGCPlMKu0k4znAFea6lNtjOeB6DpQBzV82+7YAcCiM/L7d6r72eVmbncc1ZQf/qoAnToP8Ksx4GM4/nmqqMcnNWEOc85NAFiM5HOTmp0YbcdzVZWx7+mKsKeeOo/nQBaRjwCMnFXIzgnJI71TtlLOvQdTzxVyNdpIJAPYGgD2n9mT/kOeLsf8+th/wCh3VeA/ECeMeOvFCnYzrrV/wAMM/8ALzJXv37MhB13xdjgfZdP/wDQrqvm/wCJQI+IXi0566zfHH/bxJQBj7A3Q5PoTURhzyoI7VWV2Vsj8qnNyzNyKAHqGBAUf/XrUs41O0DBbnNU7Ta/DMoJ67uhq68RVCwIUA4BHc0AOktVcHaMOe/anxwvEdp5P0psLso5IJyetaca4hIBBbIP0oA2/DOpyWckYyTlhnPYfjXqOm6hE1usdzj7PIMc/wAJ9a8ktLRsoU3epOM4/Cuj0DUPLlNtP908ZbOAPegDuLuzjQG3uTvhcZVv6iuS1Owks7gxSHkdCBwy9vxrubFf7QtFhbIeMfuz/eH+FUryx8+1MMqYkj4Gep/OgDiHtwAN2dmMggdM9qiFqGLBVyD05yQa25bWRW2lQCM/e7e1VdqxMvPJyQAOSPTFAHM3cLRyHkKABzjJ/GqaWxLDaMrnnaa6PUIFDBlAI6+/0rOtIDnu4B69BzQBGtv0VAMj747mtHRoB5hym4j170LA5PAGc4yOtbGkwIJEKjDg7QD/AEoA7DQ1KRgRfKCOfXHeuv065kSJQ4ySMgE9BWBpCKsG9gSvv6+4rSUSGXgspx27Y60Aa63STFlIKkVFc6fBNjzFG7pkVRjbDB9vPv2rRiusDc6jHfNAHNatpv2Y5C8dj2PtWZArqzp5YPow64Ndy5guINkg3If4sdKrLpKJMGjG5SOCRnigDAtbcDIcDk5AHJFaiBQQBnpjI71dNkU4PbkEdfpT1iDR7eAcdx0oAZaqQxzjGcA1b29CRjAxk9jTbWL2ww46dasOrBTjk9qAM6UNM4t0+93x6f4Vn+O7BYfhz4qZhub+ybrBPb9y9dFZW4Uc43E8nHJqj8RUz8NPFh9NIu+fX9y9AHqdFFFAHjP7Uv8AyJ/h/wD7DK/+ktzXzRdHk+/P1r6X/al/5E7w/j/oMr/6S3NfM1x0OfXHSgDOnJPAAGBj0qlcDeGXJAPAIOK7X4ea14d0DxY174w0D+29NNlJCtv9mhuNkrPEyvtlYAfKrjI559zXpp+JvweA5+GX/lFsP/jlAGZH8F7660Cy17wLfx6tpt5Cs6Wd4yxXCZHKCQDYzA8HITkGuLvraXSr/wCw6tZ3Wm3pH+ou4jGze654Ye6kivr/AOHd7peo+DdNvdA0htG0udGkt7JoI4diljzsjJUBvvcHndnvXJfEb4jeBIrS40nU44PEs3RtPtoluQG/2mPyIR7sCOwoA+crZfKlDDJxzgHrX0Bocwu/C9jJ/GIwPUZHBr5+uPLfW5rnTrT+yNJYZXTRcNc7D6+Y3I/3RwK9q8F3JPhYD7xikBUYx8poA6jSjndDkEEduOa8M+Kmli18TSSABVul3jjHI4P9K9gS48iZTuJTOVbpj2PpXK/F2wF9oi6jAo3QtuwByAeGzQB8/axb+ZbsepHp2rnBXZXSZUg4PpzxXJXUZinZQOM5FAAuMZp6kf4+9QqfapFOOlAEg6e2aax6D0oz19Kad2fSgBGOWJAHHaiJd0ir3JpCeDiptPXddxj360AdrpwYRg4BwOuParcEJd1UjcS3Azj9ahtuLXO35ffitvwxbifVIUfIQHDZ9O5/KgD1jRLVYdEtreMBXKmVgD1Pp/nrVhZG+x7ZTtct8pU9sZwccVVaQpbGTaUxsKqOuM4wPfH4U2SVogYkgLCMh13MByw7/iaANKxeZb62Z8lQ6ghcYzyD/nvXkPxnUf8ACYzEEfNCp4P869NieQShwpjZV79MjJ4HqSBivNvjDmTWrO4LD95bAfQg9KAPItUG2VWAzVEEbumPYVo6yuecd6zBQBYHIpwx0qNPepFx3oAdkAnHf9aAN3GMnNN3Auy5XcOSO9T2KGS5VfxOaAOp0hAI0yR7V6J8PJ1XWooXcgSEAccZH8s+tcJZR7V7Zx+ddb4Fi87xNpqnJxJn06DrQB69dWrlQ+6UDYO/AwT8v51XtbWQXAjVQYVifbkY5Zs/hx3rqruzMtqo/iyX49eg/Sq6WyraOr/dQ4LHnFAHjvxVuUZbdBtEkUpRfmJO3bzu9TkCvI9cuP8ARzwMk4rr/HOpnUdfvJBnykdkjHqBwW/GvPtXlLyqnIx1GaAKSHsOhq1FwearpwM4NWUypII+YHkUAWF547VKh4HHXpUAbAzx/hUgb/8AVigCwCM9cc8e9SqxwD6dB2qxp2k3F2NxHlpkfXmugh8NRsuNzdvmzQBgRyYxk8f5/OrsL5IOOeuT61ZvfD89vlo2LrjOMf1qnF+7wCBkHByO9AHuP7MRzrni7kE/ZrDJ/wCBXVfO3xGXPxB8WY6/2zfHP/bzJX0R+y//AMhvxd6/ZrDP/fV1XgvjuL/ivPFTkZB1m/7f9PMlAHGtGVXnp9KjVd7YHHtWo9pLKMKD6Z9aPsqQr8zfN9KAM4KUPBOasC6kGAWyBx+FOaH5znqemP51ELcsW4yB3oA07eWOUbWbHHpWrYzCAYkUMjH5Se1c/FCyqGwcA9q17GfLLG65UetAHUW0h3KVXdn+JK0rTY4USAq24/N/eP1rGspfLCvHkxY+Zc10lkgnjD2/7zHQ9/yoA7DRPN8tDFncpAVz3AroLi3Mwju1X2kXGcfSsbwozoyRSKzDofSu8tbFBu2jEUnJX3oA4jW9NWb/AEhejHDY/maxJLMmTATdjgcdjXpUumYaWMrlH6GsRtJkglaMElRxlhQBwF9YBWxIp44GO31qpaaf5czM74hY7OBn5T1/z7V313pRlBx0+mRWbHpn7zlBg8EY4A9KAMOLTwnqeeAfWtLTrJ0kRiMHOcAcf/rrctdMVlACISOo5/Cr1vYqg5UEDpx09qALOnw+VC5KFs/5zU0CHIZyDxgYq/Y27rC2M49+lKls3nBiBjpgdKAFs40JZpvlCjOOgqrJLBPuFu6tjgL6GrWqIUtCAD161zf2V4mLx7hITkY6GgDSXeqsSTgHge1a+lzZYB+QTVPTW8+IJMmJB+prVitShLBeD6f0oAtPGpBONwqF7XeBjA5q5bRnZtPBPenpEUDZXjNAFKKAhsnrUskOUwee9aEUStztwaWSDNAFGCI4B449qyviUn/Fs/Fp/wCoRd/+iXrpEgxj09KwviamPhj4uI/6A95/6JegD0OiiigDxn9qYgeDtAz/ANBlf/SW5r5nuGyeAfTmvpj9qYZ8HeH8df7ZX/0lua+Z7gHLAt0PH1oAzpeD24qpdbtp2Bd3QbulXJR7ZqrJ3w1AHW6v4/8AEfif7PYalqDQaQiCJNNsMwW6oBgKQDucAY++x6VpWlvCtqohSONAvAVcD8hXntsxS7iPfNdxZOWiAJGBznrQBYUbmLMM55OTXqngmRodBYlVw7Ko5J5IOSfpXlwQnknHOMDnFeseFlVNHjjdDgn5l6kDgfhnB/KgCZpRJL5bsI968HBJOOM8dc+tSx4ubR7C42ss8R+YHg57/wD1qqTRtE+Zm3SRHdGOmc5OPp2q1p6kqpweMyJxyD9fTqKAPDtZsHstQntpVIaJyuPTHFcjrlsVffkcGvbviBoQlYXkHJA2OG5Jx/nrXletW6tCTtxigDjx7ipFx+PpUbqUZlI5BpVOCeKAJPrQTn+tN3Z6Up9AaAEOe3WrWkruvBn0qmT71c0hv9JJA7flQB2kRwhC5PHQevpXqfhjSBDo0FxZr5s06jMmOAO4H+PevJrQhiAx5IwT712/hjxJqWlKlrZqJ4lclI2GSpPXB9D6UAemx2krqI3U4b5WDA5OP5Gqt5BN5m9kLRsRuG3HB46DvzSad42niQf25pUyRt1nhGQv4c/lkVqLrnh6aFrlLuIr/GpYr3zjbkUAY7Iy3BDsmSQoZeTxkA/njj2rlfiPYNPpn2gqGKLvDHgg8ZA9R3rspvGOg2OWt7WS4QNu/dw5BPtgfhXB+O/HMOs2D2Vpp8toG+VvMxwvXGOozigDxnVo/wB2xxjHrWMmBjjmuj14AIWXBzwfrXNrjPSgC9p9rNf31rZWgDXFzMkEQPQu7BV/UivWNc/Z+8c6buNnBp+qxgcfZbnY+PcSBRn6E14/ExV1dCVZGDKwOCCOQQR0IrtdD+J/jfRtosPE+pFAeFupBcjHpiUNgfSgD0b4RfCk6z/wkWg+PPD2oafI0cU9lfGIo8LqWVvLlwVbO5crkjjkdK4/xx8NNb+Heol9SUXWkOwWHU4UxGfRZBz5bfXg9ielfTnwj8QeItS8Dx6348l061Fwd9sVjMB8nHDyFmIy3UYA4we/EviD4o/D62gmtNS8QaXeRyKY5LeD/TNwI5VljDZ+hFAHyrafNHkHkHPTvXonwksnuPEIl6CCPJI7Z7VyPiyXw6Nchf4f2uqtp0shMtrdxCOKEf3omdt+P9hlx6EdK9c+Elg1vYvcHgyNnn+7QB3VzOIh5USjeetV/EV0ll4au5zlVjhdv0pj7jPvU4BOPx9Kw/itcC1+H16OhmRYl9eWH/16APm+5JK8/e689cnrXMah+9uSRkEe1dHe5CnPQdq5aVy0rkE5zQAIvXOcipo8BehB/kKiUnB46d6euMcnmgCfOGyv61ueHNP+0yrM/wBxT8oxkE+tY1pE1xcpEv8AF1Pt616DpVssECqvAIHUUAadrCiR5HC45x29hWtp8RmIVAS3oP8AGsyJiq9+nT3rvfB2mq9l5kxQKrCTJ6cd/pQBzl7aujFJEwT0wOP/ANVcTr9okExkUHa3p2Oa9h8XwRQ2yEqPMJB245Ueh/wryjxa+I4lGMF8Z9qAPSv2W8f2z4vwMYt7D/0K6r5g+Kl7dR/E/wAYxx3M6RrrV7hVkIA/fv2r6f8A2W/+Qx4uwc4trD/0K6r5c+K0LN8UfGLAjH9s3v8A6PegDmxqN8AQLy5A9BK3+NNa+u2PzXU5+shpot2PdaPsz+q0AL9tus5+0zZ9fMNH2y6/5+Zv+/hpRZyHuv50ospP7yfmaAE+3Xf/AD9T/wDfw0C/vB0u7gfSQ/4077BL/eT8zSjT5T/Eg/E/4UAC6pqC/dvrofSZv8amh17V4P8AUarfx/7lw4/kai/s6X+8n5n/AAo/s6b+8n5n/CgC6nivxFGcx6/qyn1F5IP61ZXx14tUYXxTrwHtqE3/AMVWUNMmP8Uf5n/CnDS5z/HH+Z/woA1D478XHr4q14/XUZv/AIqmP428Vucv4m1xj6m/lP8A7NWcNKnP8cX5n/ClGkzn+KP8z/hQBePjPxQeviTWj/2/S/8AxVN/4TDxLnP/AAkWs59ftsv/AMVVP+yJ/wC/F+Z/wpRpFwTjfF+Z/wAKALg8ZeJx08R60PpfS/8AxVKPGnigHjxJrf8A4Hy//FVUOi3P96L8z/hS/wBh3OM74fzP+FAF0eOfFgHHijXR/wBxCb/4ql/4Tnxb/wBDRrv/AIMJv/iqonQ7kfxw+vU/4Uf2Jcf89IfzP+FAF1vHHixvveJ9dP11CX/4qmf8Jn4o/wChk1r/AMD5f/iqrroF0y7hJBj/AHj/AIU7/hHrsjiSD1+8f8KAJ18a+KlOV8Ta2D6i/l/+KqQePPF46eKtf/8ABjN/8VVRfD12x4kg/M/4U8+GrwLkyW//AH0f8KALX/CfeMf+hs8Qf+DKb/4qj/hP/GP/AENniD/wZTf/ABVVR4avCcCS3/76P+FOHhi9LYEtv/30f8KALI+IHjIdPFviH/wZTf8AxVH/AAsHxn/0N3iH/wAGU3/xVRx+ENQkxiW2H1Zv8KlXwVqLHHn2Yz6u3/xNACf8LB8Z/wDQ3eIf/BlN/wDFVHdeOvFt3azW114p16e3mQxyxSahMySKRgqwLYII4INXl+H+qtjFxY8/7bf/ABNNuvAOqW1jc3T3Fi0dvG8rhXfJCjJx8vtQB+ktFFFAHjP7Uv8AyJ3h/wD7DK/+ktzXzTc98nsRzX0t+1J/yJ/h/nH/ABOV/wDSW5r5rlTJ5zigDMmzxnHNUpBwx7VoyAZzVSXrQBTB2uhz0I6V3WkOCgHXjOTxXCyj8+1dXoMweJe+F70AdjpFoLy8ihXceNxC9eO4FenWEbW8EcYJDkHkfxN14rynS7yWzvYbmDHmxncM859j7V6RZePLUKu3TZA7AhwPmLH2I7fhQBtpZiVQQ2OBycduMj29qs2GkSebiIfu3zyzHj29ap2/iouA76Pd7c5BC5GfyqC61XUNVc21vHJZwMcM7t+8f6UAbGspo9lZzi+v4guCWC84/AdDXzjqkas0wQkxlyVYjkjJxmvcrvwlaXdufMR5J8bgZJCcfh0rx7X7OWyvZrZ0KmMkAN1AoA801OLybphgjPWqwbkknr3rZ8QRfdfGDnpWMooAcDgY7Up//VSdaU9KAI3xnpVrSji6/CqzdQOT7Vb0kf6YM8fjQB2dihJGBxx+NekfDrRRd3sUrjIzkDH8NcBppyCuOcZr2f4RywBnj6SKgbJOc/SgDrP7HSBAkO1gSTtPc/5/lWDqPh/TDfbgiLIfmCqgwSfQ9hXWasd6qyybCcqCTjORjr2I5/OsDURIL2MvII42YnzD/CMBT+VAEUdhAjIIeWAA+Xnbz3/A1438S7P+zvFUtspziGNzznkgnFe6wWTQjcM4XIwW6HgEn0FeRfG2AHxRbXWflntFDLn7rKSMH6jBoA8q1T5rdweeOtc0o/Wun1Y4tpOecHP1rmF6jjigBwqQhWQq2fmGMg0wU/tQBNI0mo3MbXssty4OA88jSED6tmupsLcBU2rgDjj0rntJi8yYsfuiuus1AGduRxzQBfsIZJ7pIY1OXIBxk8V9EeHIf7O0qJMLuCgHjoPf615N8ObISak88qHZENxH9K9SEzyRPtfEjEnaePQY+gz+JoA0fvx4iXZztGGzg5/SuN+ON6qeHNPgU5aacNj2RSf8K6K1lxLgFgADkA5+bHP61wHx1lKT6LaZwUt2kYe5wM/zoA8e1OTEJzxgYP1rlAxyfc10Wsvttnx6cVzseCRk4H50ATIfl68d6kA9P/1VHH+ualUZOBznpigDovC9qCzTMMZOK7S3+VR0DHp3xWDocXk22BnIGOnTNbcYBHJ4x2FAFyNRjAGRn16V6r4Q2ro8M867IpQ6KhbPy5wSPrjrXl+nW8l3cQwxKWlmcRgAcnJr2SWOOG5t7K2jVhbqscYPQHu2P6H0oA5Tx/ceU9rbI6PwzEkYKgnge1eSeLZQ9zEg525PNdx4x1BLjxHfnJ8tG8tB6BeP8a841yUvebieWYnH04oA9l/ZYJOseLye9vYf+hXVfMnxS/5Kd4wz/wBBq9/9HvX0z+yr/wAhfxf/ANe9h/6FdV80/E8E/E7xh/2Gr3n/ALbvQBzCjBFPA3e1AXvj8alRefSgBFUgZ7etOCnPNPCfL15qWOMseeAOtAEagkcCpAp7ipfKC9ORTwrM/wA2Sx655oAhC4PSlAGcnrUwHUYA96UJnOBg0ARBfb9adjHqO9TAKAMEHIyKAq+ooAYRkknJNOVQOTS4yOKcq8Yz19KAEVcnkE1LGgHHzfjTlTB6fT2p20Z9R6igACg9SQcHGaa2Ooycj8qstFl8pzgdO5x6VC6gjIU+pIoAYffOR+tN45POaeVyuT0oIAGMYzQAsZx6/QVbjCkHJcgegH5VVU4BOO/apkYkYxweozQBJlFbOXx36VKPJ2FT5+7v93FV8fKwHzY9albBhBHDd/rQA9TAf+fkEe6VLE1uHOPtPB7lfy6VTBC4FODEjIzj1oA2YngRgSbjnnDFev5VNHcwB/mW5556rx+lZAYg87SB0xzke1WYccZ5PUelAG5b3EBXAFwMgEEuuP5Ua7NEPD2prtfcbSXncOpQ81mwSqMjnHsKTW5GOiagvUfZZP8A0E0AfetFFFAHjX7Uf/IoeH+n/IZXr/163NfNl0c/yz619J/tRjPhDw+Bn/kMr/6S3NfNk/UjPXjigChMMYz/ADqpKPWrkgxkADFVZOOnNAFKXqa2PD0pAK5xg4ANZUvQ1No0uy6Knvz1oA9AtCMZOOccd66fwhALjW4ICxBfI46nv+Fcrp77gDwM9SPQe1dn8PjHH4q04SEhXfaOfYnmgD0eONrLcrRFiuAVB46YGKqXF8sLqVj2xE7GcKTt443fie3vXT3MKTXEjBuMZwTwvGP/AK9cxqqpDcRSISY5sHaegKjH+NAGro7yZ82QAKvL85B47E9vf8K8t+MWmraa0tzH9y4Tp9OvFeo6ZP59sCoBkQDJBPI9P6VxPxihZdOt87THFJsjPfHv+NAHgusxFoJMc9+lcsOK7W9UMZNuMfd4rjp02TOuMYNACDkcUpOeQPwoXrjgCmyyJGAJHVM9NxxmgBDznGKu6KM3y8Z+lZjzwMCDLER7sK+k9N+CmkeLvC2meKPh/qf9nteQhzY3Raa3WQcOiyffXDBhk7+lAHnFrlCmDyR+lehfDnVfsmtRwkqUuPlPqeK5LxD4d1zwnL/xU2k3FlCCFF2P3tu3/bVeB9G2n2p+h3HlajZ3EZUqsincORgn1+nNAH0Xcrm0chQ7bg2PxrmtRklXUDEwLIr/AC9xXV6cpa2Td8zHBBB7+tVZbdHuS/lk/Pj86AHWcLSRqXIMixhePU9T9a8M+M0ufEqwckwRAnj1Jx+lfQcUKwrKUYnJ6n6V84/Fd9/i/Uf9kInXkYH/ANegDzXVmItZOvP8q54Guh1jm1YHqK54UAPB4yMUu7PWkAGeRT4xudOxJoA3NFi/d8qTzk+1ddpdhPdzxQ2ybnPbtWFo0QVQckHHT1r1f4XvZrNdQ3LxxTShfJaTGCOR+hwaAOm8O6d/ZOmQ2cbF5m5lOej56Z9BVrLiWRlAlkBVIwxwRk+/Q4yea2ZdJnhhjlVvOG3AI757+/8ASs8W86yN5asS8mWLc+2fp9RQAsU4tvLAjJjaQ5bHIHOGP1wBXmXxkvHuvFhB4WG1iUA98jJr06RGYRh8L/C2PlJGOfwyAP8A9deTfEyJm1t7k/8ALSNVOBgZA7CgDzXW5N0JBJPNY6LkZzx3rT1rOEBxkGqES/LgUAKgyO9W7QBpEXPVh0qIAYFWbBQbuLGCM0Ad5p6EQqcHGO/NaMUY2HnkjkdhVLThhFyueOCR0rpfDVrHd6vBFcbAnLkH+LHb60AdB4GsxaqdUmU71BW3B+nLepx0rttOkaOdZJiuMGUg9SQDnn8KrW1mJYj5SFQwB2FsFFBxjH5fiau3NtLFpskhUb/LdAB6EEAc9TQB4jfuZ55biQ/NK5kbr/Ec1x+sn/SwOTxXaXgWNdpHKgdenHauG1Fy2oOTyBgUAe2/spf8hbxh6+RYf+hXVfOPxMTPxJ8Xnt/bV7/6UPX0f+ymc6t4v7/6PYdv9q6r53+I65+JHi44/wCYze/+lElAHK+X9eakCnHSplQkHinpHnqCMGgCFVq1bp8mTzSbMjPb1qTBVAPSgBhw5z0Apwxjg9KcUPAA56inrGVyTx+NAERwPmyOv400sfx6VKIieDgmntAQOOcd8UAQ846j6UJknkVZ8vAI7HGfenJGuMkHb0/+v/8AWoAhjTccYyR1q0sTKBkDnvViOFSEWNR935mGeT/9atNLBmhHykHGOBzQBihD6cD0p4X5u/vntWp/Zcu/lCqHktjOKpSxlWPykYyBkYoArY3fd+8OtNBYcrlW9qlCYBwOT1qNj8wB/E0ANJ56Z4phAwBuGOpFBx2pm48DH5mgBxHABxnr17U+M/WoCeAc/nU0RycbgPY/zoAeGxnHSpCxKkYUZ6VCVwxHv1FSqAUA75oAYj/MTj3605H4HUnPQU3aCMD5voKMNjke1AFuNgX7genpVkSEDCtjPHNU4k4+tWtoL8cfSgCa2kO7CgkdOvNP1cP/AGJfZBwbeQg9j8p5p8MBMoC9Seh9as6jbY8P6o2BkW0vX/cNAH3fRRRQB43+1F/yKHh//sMr1/69bmvmq4x1P5V9K/tQ/wDIo+Hv+wyv/pLc182z9MkdfSgCjKM5PHHSqknAxkGrkhwevrmqsgGBmgCnL1xjnFV0bZKhB+6RzVqQe/vxVVl60AdtpM5eJe/HQV0WmXsttdRSxsFkiIZT6EVyHh2QywoO+MdfSumiUgK4zgY/CgD3zwpqiapaRyja7AAlPQ98in63YbVIQkLuLj6mvOfhpfm11oQmQ7ZBkA9Ce9ew6jEJIFcc4z+dAGH4ah2NhkA9ePXvXNfGq08zw+sgBBilVj9Dwa7ewjRHDD5ayPiTZ/bvDN5CoHmNGSPw5/pQB8y3I59+c4rlNWTZeE9mGa6+6XBZiNrHgj0rnNei+RXAIwccigDH/kK7P4T+PH+HfimbWU0xdSMtlJaGFrkwY3PG+7dsbP8Aq8Yx361xYHGaUDPU0AfR/wDw1JP/ANCXH/4Nz/8AGK938K+J/wC0vBFh4i163g0NLmEXDxzXQZIUJ+QtIwUcrtPIGM4r8+JFO07GGexIzXTS6/q/inVo5fEOoT6gYwDGkpAii7fJGMIg/wB0CgD6i8V/HTQ4UltfDNlLr8zAqZT+5tffLsMuP91SD614PdBr3XbjVXhs9PeX/lz02LyLYf7W3Jy3q3HrioYyo4PPTqO/+FWI2YNnAzxgetAH0x4ccz6NaOxG4xqc++KkZj57sD/F0qp4OYvoVqWXkxg4NW5mw/XPXjH60AWwwNsSMYPNfM/xQBj8WX+4/M+GHvxX0pEM2ZI6HkV83fFlj/wmF8jfwBAPyzQB5zqrZtWLHr6Vz49ulb2rE/ZjgDArBUe9ADvzq1YxmSUHBwKqdK29GjCgdOeaAOk0mPcoU446e/tXo3h7w3JcRCaXdtA+6vXIGa43wtB5uoRLjcVwckcDnvX0VpMEMdlHhsKgLf73HX3xkUAczpkepae+NNnIZfvW0+Xifpkev49q008VaWJQNTsriO5RtxTyCwDDjIcdRVy4iMdwuxSQxyrDocjr7fh9asyPAYc+QN+Mkrxk9196AOe1Hxj4atZszR3AdRgL5OT68DNeQeONbj1fUDPbIY7cD5UPB/Hv0rs/i5a/ZXtyzrlzkJ/F9T9a8nv2Kqc0Ac5rbZmQdqgjHyqcU3VXAlLOeFUk17Dc/ATXW8JafrGgajY6xLNbrNNaRuoIYjJEUgJSQDpzt6dT0oA8lUHaMjvWhpYzcjIPHrWz4M8HT+JPHVr4W1E3mlXcvnb98RSSFlhd1LIwzt3KufUZwe9QnRtQ0DxBfaVrUHkahaPtkQHII/hdT3VhyD/UGgDp9NG6MZGeM8ng13Hhfw9e3jRXdu/lBGDKzLnce4964rTsYGeAOPavZvAhA0SDdkg5we/vgeuaANuK8itLcHXFjWHqLlFO1Wz/ABL1HPfpV3VDAui3MltcR3EbRlh84JI9j3q3p0scjMG2tj727nt1/wA9q4v4l29pBYrLaxiFiwBEWUVgT3A4/CgDyrVZQWkZBhcnv/nNeeXB8y9lOCMucV2esT7Ymf7qgH8q4uJt7k8ctmgD3f8AZTGNW8X8HPkWGc/711XgfxAjDfEHxcf+o1ffj/pEle//ALK//IX8X4Of9HsP/QrqvC/Hg/4rrxXk4B1m/I+v2mSgDlhDt5YYHp1oEZxkHOe1XGiYrjbwOopsVvIzE449fSgCv5eMFeasJASBxknke9XrPTLi4bFvE8hOMACuy0fwDqNwFedRGncd8UAcFHAWJ2ZJHGBT1sJN67xs9f8AGvYLX4dvEjDCjvx1NYN/4Pu4WO9Qx6YzjntQBwL2ojUYyy56+tJHECSoB3A9DW3e6bPG5UxEBepPYZ61QELB/unbu4PvQBSeLB6bQP1p8MRJJbgCrRhaYkMvQ8cVZtotspA5GcE46UASaVa5nCbO4zkHFdzpltFb27G7VI4zh3YnNZWhwtGf3qqc4/D8K0vDEtlo+tS3XjPQj4qtS++J1lAECj0t2Ijk+pOaANbR4JfEqta+GNEuNXTdg3CARwKf9qZsL+C7j7U7xl8L5NC0aC517UozqV3OoisdNXbGoHzOzyONzjA2/KE5dete++DfG/hjxLGtvoOoQCeNQDYuvkzRgDp5TAHA9QMcdax/i1qnhrS10t/FXhE+IlkMiwN9jtpxAcKSMzOuCw54znYc9KAPnk6LYAkKh24/jHU1TbSLZlOIY2fBbZjv257V6gfFPwz2lv8AhU+QOpGlaaf/AGrXnls0Z+2vZ2BsbSS9uZra12InkxPO7omEJUAKyjAJA6CgDPfSbEqP3SKQBuVRnmoU0OxlDKIgCBkcda1Hy53CJ8DOPQ0y3aMFgwUsOQBnNAGVN4bsfvRozEjPHaoV8M25IG/A3HOOcGug2ttKo+FzyBzxViLZI+AwyuFIHXjpigDnrnwcmwPDMWG7ABHWoJPCrpEfLYnBwcriu3s2EoMmD5eOpHHpV0QCSNThgQcfQUAeWz+H72I42ggdxUMmk3CMd0LY6qduM161Lao6xiRQqk/eHU/hTZLGNvmjCkDoG6nNAHkv2Uofm4YcYIxUyQfMG4Oev1r0W+0SIgZhBHU896pL4WDlShK+7Dg+1AHNWdmNzuQ6jHAJ/Wrms2jf8IxqzsCSLOY7vbyzW6NNntjtZTgcbm9qPEVuY/COtk8sbCfJx/0zagD67ooooA8Z/alyPB/h/Bwf7ZXr/wBetzXzfJyTmvpD9qQZ8H+Hx/1GV/8ASW5r5uk46HPrQBUYZOO5qBwvPOAOh9amc9ueTUD9/wCEfyoArOvJzj8qqSDnrVuU5Peqso65GaANjwtLtldT1ByDXZqd0Yx6c5rz7RX8u+ABxkce9d/anfFuzlscYoA0tIufst1bzIxzHIGHcHmvouyk+16cp43Yz7GvmuIhuSOCOcete9eAL1rrQ7PzOpjwfbFAF4KVkwvAzkeuKm1WJZ7B1PQrgn0NNulKXOOhJx+FTK3mRGM9CM8UAfLOu232XU72Dbt8qZkA649PrXNaxEGs3xyccV6V8VdN+w+KpXVdsd0nmLgfxDg/0rgLhN6FcY47fSgDjc+tOHQnqKR12yMp6g4pRnAGTg0AGODxWhoR2349x/WqGataW+29jPrQB3URxtGeepOOtWoRulQHON44+prPtTuwehGOlXYP9euD/Gp6e9AH014WTy9MhUqqhVGFHQDtT5mzISB+I9Kj0EeXpcTMcfuwCfQ460pVjLwCPWgDQtiDCyjIxxXzP8X8J43vhk8oh5HtX0tbNuTd2PFfM3xiJ/4Tm/HTEcfXtwaAPO9Vb/Rjgjk4Iz1rE+lXtSfJIByM1RH60AOjXdIo9a6PT15HFY+nw+Y4JFdBYx4I5BJ6UAdHotwYJ0kVSdp+bHHH1r3/AMPXUn2SFoyNm3cSpx2J/n+dfPVpwx29V7ivoP4fos3hawlkUNvh+Yevb+lAGpczQHETgKrokgPb6+34VPJEArlE3SGPBUnC/e+96e9U7y1le4RjgHA7duw/KtuwjP2SNV+UbetAHj/xouEkuLZF2nYSqnPOAO4rx6+cc57ds133xRukl8WXkMWRHbDyhjucAmvOL44Ruv40Ac/dtunY/hXS+BvGfiDwfIZvD2py2ybt0ls/7y3k/wB6M8fiMH3rlnYmRi3JzU9rK8Usc0cjRSxOsiMuOGByOCCOvrQB9zfDfU7nxlomn+IPEXhqLTNTiLC1kbDsyFcGRCQGRWyflP15GDWb8Z/h4PGGlrqGlLHH4jsUP2dz8ouE6mBz6H+En7rc9Cc/N2kfFj4grcrHF4qu2QY3ebbW8mQO2Wjzz65rt9M+KPj4oC2s2Ew6Zm05Tzn/AGGWgDmdLbfEcJJE6MY5YnXa0bqcMjDswIwR7V7d8NbRj4bV5B8srl1B6bRnFeUSLrniXxe+qXi6RHLdIIrmOyt5IvOI4SQhnf5xwCeMjA7A171axRaZptpZxcBFUcD0GKAGQW5Fy0iguxfG88Hb6CvMfirrSPc/2bCwcwuGmcnIBx930r12R0SxnuH4SJWZuccAZP8AKvl7WLt7me5uJG3PPIznJ9ef5YoAwNfvGfER5Zu/YD2rOt1AIFQ3UxmunbsvHJqzbckcYxQB7t+yuMax4v8Ae3sP/QrquDu/DH9peLfEtzIpdW1q/wBq+p+1yj+ld7+yz/yGPF/r9nsP/QrqrGkxKw1nzQqxtrWp5Pc/6bNigDkrD4eRHDzoi5PAPJ+tbNp4M0a1kOYlkYH+JePpXUGeCKNTJOcfdwF6j61VW+0yF2ZpJpWQkAluKAHQWtjpyKlraRDIGSAMn2q2sF5LGrJGiKeSTgDj1qk2vW0Y3RIg2/MG9qx9a8QSylhHMuwgEMG6+1AHVPc2duimWZXdTkBelY2o3VpMxZGQ9jxXF3GqMhKCQZB6MetUp7t95cyhQ3AYdj6GgDQ1mGzmc7Wzk5wTx71nSaLayu20HGQS2RzVDfO75bDNxhgeD9R6Vcj88HdIwjBbBAHH4D0oAbJ4fgwc5Ibr7DrxWfceHguSjEk84XrXQ28k65BYOuOn+FXkXzYXR1VicEZXkUAcmXa1jRdxQdJMCpINbgC4JDqeMEdR6Vu3lgXjCkAgnJyM49qyrzQYXQ4UjnqOMD6UAZ95Lpt+y7ohlDlH6MjdirDkH3FW77xR4hutE/suXVRqdmkqSImogySxFTyUmHzZK7l+ffwx6Vl32kzwN+4BaPOffn/PSqZieM/NvUg8n+poA6CK6jQ5blcEcHFSrcRsqj5gg9DXNhHYNlcADGc/lxSxl4wAM4A3cmgDpPOhyC5JHT5eBSoYHBcOq85yf61zy3cqqokOQwx68/4U15wGOMnjufyoA6NpLYxnaSxA5PYGk2oAFMvVuTn+tc21xtAJySOgz0zU/wBo2kkEcHqQePpQB1kCxmNg0rCMj7m/t347VqW1spRRFJlepJODjFeewXcgBLSZz39ali1SVEykr47DPBoA9EuISDDiTLNnGO+B2FQFrjIBjBHUNjr9feuMt9euxcQNlCibg2W5JI44/wAK6G28SRmMFxtPHI5xQBvWsHnsm9XBx1XgVuWFqpwGRWPXnriszSNQtbkZaUBs4HPBrdhh2OpKkq3Icc49qAJU0iGQ5KfN6dqxfHmgQx+A/EcwHKaZdN+UTEfrXUW77WbkEE8Dr+VUviA3m/DjxTnjGlXZ5/64t2oA9kooooA8d/adgkufCnh6KEAyHWQQCcdLS5P9K+Y7jIdkcMrjghuor6z+OMfm2fhRD31k/wDpFd14F400QPmaLiVc8/3h6GgDz+Q/r6VEwycc/nT2LBiCCD0x6VCxOcdRQA09DkDpj1x71Wfqfap5DwcD8BUDqSOFJoAZbv5dzGw4G6vQdNcNCmXwoH5mvOiD/wDXrufD0gltU7kDI56UAbCkibPYHrXsXwknMmkNESSYZcfgeRXkQILHPH07V6B8JLoJqd1bElVdRIvuRxigD1XUiFlJxklapW8hR0OGwTn/AD71a1P5nXIzhQc1mXOVZSDwO4PTP9KAOF+N1kH0uzvEUERTAbvZh6/WvFJUJkZQTkHPFfS3iix/tvwdfWoA85UbbgdxyD+lfOMoKlCeD1OO3/16AOG1RDHfzLx1z+dQKcDNa3iaHbeo4H3l/lWUMDqKAEPHep7QlLuPcCCCODxioTn6U+E4lUnPWgDsrWTKZ745rUtmxICASQynGfcVg2TjaP7xroNJXzbmGNVJzIgwR7igD6csWEWlRkcjYDxVZZdzLJjJPHHp71buF8vTEjA52jJNZCXIBWMZAJ6kfzoA3LY7FPByTz6DNfNHxhH/ABW15k5+RP5GvpWykWS3cKSzAjd/Svm34z/J44vR/wBM4/5GgDyq9OST71XRS5wMVYu+pNQQnD8DnBoA2LAAIMZJHAFbdlxgkZIyax7TCov0rZsMMAcYXpQBp2ufMXOcelfRvw3hA8IafGxAOwlsemSa+drJDJLsQZZuBX094UhFroNsjDhYxx+FAFi7PmOERfkUVfbENgCegXOKpOPmBBwfaoPFN0bfwzdyscbYXf8AIE0AfL/iO8a81e/uSQWluHfg8deP6Vyuq3GyNip47A81r3TkorNjcea5vVzkDJ6mgDNB3Hmn4x7UxRipo0LsqKSSxxQBv+GLbc28jINdxZK0cYyc8cErWLoNqERMrgAdq9I8KaDPfusjqVt0wWPTPpigDo/AGlR2sZvbmPcyjKg9z7e/Nd/LJ5m12ILN1wcn6CsWCFIYBBbArGhUgYPH9CauWg3EMu4oyllBHPX36Y70AQ+O737F4A1AowDSqsCt6s5AP6Zr5v1uVYoZCMDP6Yr2r4wXa/2Xpdkhzukedx6gDaP1JrwbxLIfKYA5DcZoAwITluecnNaVvzgZ6nis+Ecep9K0bXjGOoP5UAe7/ssjGseLh/072H/oV1WbFePHqGsogYmPW9SxxkA/bZjWp+y2c6z4ux0+z2H/AKFdVyl3qbWura/HFGzONZ1L5gOP+PybrQBZvry5lV40kILHv/F7fWqXnzFQuxmVDyFGDx603+2JCMG3CDryMkmrNhcRTsBIAo+tAEE42KPOYliM5U96oSxr9oDL5m5fm2nocjqK6r7JDcZO4O24YCnPApkmjb2JTO5OQcY/DPegDjGjkbJVS3X7x5wfSp0gG4uqZJHG49fpW42nuzupVk29Cw5OO1Rrp8oYCXdvZugA60ARWdiGmVzkM6gn0JrRe2cKN2ChOM1NaBod0YGxG556Z7YrVRCGxKpV8YHTHPegDFjtNjEOC2ORjr+FW4YRywYhx/s4x+FbRijlj8p0GQOq9fXGfypJ4Y5EJ+8x+6c4z6j+VAGS8RZmYIeeW46j6VCtrG0nyr8xHAb+laTRfMDGhLY+bsce/rUZZzKPkBHYqOaAM9rQbgSqkD7xI6mqV/o0EkbllKngEqMe9dI8WYt4yNx4GMZqv5bryrc9WI6ZP+FAHDT6HKqsYudvQD1rNNm8Q2urKMYJxmvTWtleJSGBGMnjt7VXmsVuAVkQZxgZHX/PrQB5o8AxjkY5OB2qCWIFt3GWODj09q7m/wBHTDtGAjY27c4PFYMtgkCyBvlY9yP5UAYiwMqbwMZ6nHAqMQ7VHdC3Y/drWSBQHUsePvA9TUbxReaUx8zfMDjjj1oAzwDKp2/d3YP+FNkgVmbAYMcY7YrRjRQ7ZXB3EHC806WIEq64LDgj1B/nQBnw2Ye4jJyXVTgnsD7VbjiY4wAcHkdgD3qxFb7pRIzFGAAGauR26gnPI9CvQe9AEds0kcifM3HIIrp9H8S3EMiIzGWMnDK1Ym1WRlwV4wcYB/CpreE7uA/B9MgUAeraLNFqSh4yQc8jHSrHxCtlT4aeLCueNIu//RL1z/h9Htwm35ecjHG4/wCeldJ43n8/4WeLTKoVxo930/64PQB6pRRRQB518Zhuj8Ij11lv/SG7ry7XrcyqxIGe2PSvUfjLjZ4QyOP7Zb/0hu64HUV4foTjnnr+NAHifivTzbXHnIPlb72OxrnHPp1r1LxRZCaGQFflI6fhXl1wjRTNG33l4oAack4FRSbsnsT6GnHnrTCDjA7+tAELjC+ldB4UuNoeMjJ6Dtj3rCZfQ1oeHX2agFJADjgk4oA7xOoDN1Aye1dV8PpDB4pseyyEwnHTkcfqBXKWrgjcMgkZwfaui8KOE1vTXzkrcp7Y55oA931M7U3dDjH1FYt9KsU/JYxdIyvGQR/jWzrDEFVBGNuP8K56+IzGcEna38XGR39qALmjybJMNnZJweOh7ZrwLx5pR0nxPqFoF2w+Z5sWeMq3PH45r260kVFciQEqwGF9+cfgRXG/GfTkubTTNZgUHnyJeOm7lc/8CBH40AeH+IbZp7HeBlozu98Vy+K9AMW7cjD7wPLd64/UrI2108Z6A5H0oAzjSr99fqKVkbn0p0MbNIoA696AOjsTgJg8+ldj4Nia48Q6VbgD57lOD3wc/wBK5SwhIwAMkdcDGDXo3whsWu/G1ozD5LeN5yfTAwD+ZoA9u1qVwiRrwNo3Zrm/MLOzhjwflOc57En2q7r90DMygEHbt3np+VYaSblVUJ2tES/sByyk9hxQB2Hh+QMHTkcAnn+XtXgvx7tTF41Z26SW6EHpnBIr27QJ1F1Hs+6w2gHryOg9q8w/aDtkfxDprH+O1ZSfo/8A9egDwG7Byc+tVlzkc1p6lbSQysrD6H2rPiUlh6UAadoWO0Meh/WugshtQHnJ9OM1g2fJBxW/bDaFA5J7Ht9aAOq8EWP2zXrdCCVGSR7D1r6TgXytNVV4zgAV4T8JrUy6yXHRV6/U17tc/u4oewAJ+lACO26VQOf61z/xauxa+C9S+bDND5a89SxAxW9ZANOjZBBIA47+teffH29MOgwW4I/f3Cjp2UZoA8DvT8xGcAdvSub1JiZR7VuXT/McfUiueu23Tt7dqAIBnr2rR0eIyXiYxwe/aqI7Guj8OWgBLyAf/WoA7XSLfKqB+de6+FjYy6HYQW8kccqRqSDzl+/Hf+deR+FdON/cxQpx3JHb2r2bQNJhsosW8CkOuSrLnd2zzzmgC02lyLE+ZBhgAJN2R6f5PvVtofJdncAuent9KkWcabE7pazyQKAHhjXcVx/Eo9Paq7eJ/D00fzXwgkwTsnRkI+oI4oA8h+Kd15viAxIcR20KxKo6Z6k/ma8g8RyeZKoHHJB/CvUfHdzFqOt3l1bcwu2FyOoAxn9K8l1l914QMY6kZ70AV4evXrWpaLnBP5VmwnHPP4Vq2edwwAfx5oA9z/ZcGNZ8Xf8AXtYf+hXVc9La79S12RQpf+2tRI554vZvyrov2Xs/214vyefs1h/6HdVWtYA8uskAEtrOp8Dr/wAfs9AHPyWTYAbG3dgEDkVGLUxqwC5L5zxz710UkZIZEjbAOOagktzKE428Z/CgDN06yvJBN9iG4QRedJkjhB39+1bFhrIwiXQ2nIA9DVJoJFJfdtLAg7TgEf1FMaFAcnLkfKOen+NAHXx+RcgRlQwPXFVjpav91GODx7n/AArG0i7mtXCv8sJGe/H+FdfYSJKokQZ46Z7UAY02nL8rMgyvGM8YpSdwRGI3KfvEc49hXRTQCRgT2I6dKqS2wdyxB3LxkdMd6AM6RVSIlhuPQduKqTeYh4GR6Z5x2rUltSyEOG8teemOf61SniVDkbw2OeetAEKoGd/MO4k84PSp5LYsB5RVTj5Txyaz9sm4hUXbu+Y45q+jqYwMMccYI6UAIVJj/eAOW+UknAyP5VFLDsj3KqFc5VWz+daaOHIUMMY5wMg/T/69Mnhctt2oyDk4POewHpjrQBQ2FWYDhD0HfP8ASoznBBAU9ix6n0zVq4QFQyIxY8YBqvGuNqbWXGccdSf60AOmthNAqyIA3qvOaxtV0lpYn4O4ev8ACK9BstHcWqu4HmMMEeoqveWDRq25c8EYx+dAHkF7YzW7DK7eMbgM/hWa8WxskYctwMZ4r03U7RZIAuACFwAepP0rl9S0ZlWV1bsMFRkfSgDkZMjjlefvev0qxaqxO5iPmPP09anuNNuY32yqw5zlemcU5IXVSsylSDjlenuKAHxoFDkqfmycseaeHDLjH3eBgcVOkfmD5EIYnA3d+a0NO0qa4ZRHFI5zx8tAGckJkKOd5YdsdP8AGul0PTC2Hl4Bxx9Pat7SvCUoKvOm053AdR0rrrTTIYEjEg3sBn8aAM7R9O3MrMoVR0OO1J8RSsfw28VooIH9k3YGe/7l63yVwAuAegANc38RXL/DzxSq9tIu84/64tQB69RRRQB5x8aMCLwjkZ/4nJ/9IruuHv8Ap83Ge2P513Pxm/1fhHqf+Jy3T/rxu64i7XIIXBB7CgDl9WgyGA/yK8r8UWflXAlUHBODXrt+hZWwO+PwrhPE9oZo3xyGGeeDn+tAHA+w5NIRz6GlZcEj04oIIOAaAI2HGaksTtvYz3zilK569qSDi4jPU5HSgD0Ow+aLA44yM10Xh5M6rZheCblCMcg/MK5rS3LQ5fIA5+prr/BULXHiOxBX5BN5hyOgHNAHtGuMPtCgHAUZNYd2wkZ4mUE53DL46961r/LK0jAlnGz6DmsuaLdEN+DJGmQG7lc9vSgClEhiiOJkDmVMpwNxBPQ+/pVi50231PSb7Srshbe53JnOdj9Qw/ED8qkRIpJG8sZUFZAcfdBIPX16jNWlZFYq+1gHYjI6A84/Xg0AfPd5plxp97PZ3sbJdQOUdPf29iORWFrFoJoydpEqcjI619B+MPDqa7bLPCEGpwpiORjt81R0Rj047HtXjWq2csMkizRmORG2upHIPpQB560GDyOasWcCiQEjOO+K1Li0BkJXkGkghZeAPcHFAF2zjJYgEHHtxXsfwWsFtrHVdYkG1WK2sbH2+Z+Prj8q8t0iymuHiht03yyyCKONR1YngV9AWthDoWiafpMbbxbp+8YdHkblm9+eKAMq+DSvceYM7ZCOvBGOn69aqWJEbszr8pHl7Qc7c9j71dDiS5VX+VMjJK8Nlcjj69cUyJVMU7Py29Xx3GSBgDFAFy0ylwmw/KrbwT6Djg1y3x4tWnttIvcfdd484/vAH+YrsEjWKU7gdjk9s4IGTn36e1UvHmn/ANs+EJ4EwbuLE8YxjLKMke3BoA+dtRtlmtyp+8oyPauW8gpIy9ga7SYAYOTjPeucvIdlyxHKk5FADLNcYGOhxWvArMOMZHvWfAmVBx36Vq2oyRuXjr0oA9d+BtrvubucgkKFUfU816vqUw81kzn+Hr+dcf8ACK0+xeGEuGGGkJk6evAzW3dv558tCVJPQ8e9AGzprF7nccYY8Ee1eOftDXedU0u03ZCrJMcepIX+hr1/QHEqIwOGzyv54xXgfxyuRJ45mTORDAin6nJoA80unBHzHOBWBJzIx962Ls4BPAzWPtJ6CgCazh86ZQOldppMW0qADhfbr7j1rC0e3CoCQSx611+m24wrAZz36/WgDsvBL+VqMEY2hJfkORzk96910908hIcqrnCkev0/I14v4GtDda1BHGWJALZx0x2r2H7O1srFgBjGwA9T3oA1YHIJAA4PI64ri/ibHC+mNLIFMi52ED5gfr6da7G0BaFCRkjjHrz1rzT4pXwVIrMFvNL5CdNqDufqaAPL9SnKoxzjBxxzXnF8Q9/Mw6ZxXZ65eIkcjhhwOnv71xKZJy/JJyfrQBNBH09a2LOPBzn3FZ9uMYxz64rUt8jgYz/nvQB7b+zEu3W/Fox/y62H/od1U2jxDOquTwdZ1Pgf9f09QfswnOt+LsjpbWA/8fuq2fDFm9xDqpjHP9s6mCT0/wCP+egClcWwYK+0A9jjkc+lVjZySsu1MN1OPT0ruF0yNVUMm7H5VMlqqDCoAOO1AHATaddbFCRnbxw4pj6RdLbyFYCTkY9fyr0GW3EjL1C5556VA9uu44wD796APO1sZ4OJIywbHy9h6GrmlyzWs7AsTHwCCOp9a7RoFLcLju2ehqCbTY5SN6DJ/DFADbWQTw5XPHIIOc05ot2eec5GOKILQ2h/dszJ93aT0qwFzjPDj1H+c0AVyoKkEgKTzVC9sh5QIU7euPWt2ODO7OVUgdelPSFQhUrgdwaAPP5EKXMgweMggnAqaAiQsAepweOB+NdbqGmREqyRLtPBwM1mNpMX3VLBR/CRzmgDOXCOOCAV5HTFXFACZyCAPvYqaPTSp2l8+hq5Dp8QQZZmPpnNAGa4aZwqIXJGVx0H0rW0zSCZRLPjZwQvqR3q9bW8aINiEc4B9K0YQQAPujsKAJUUYAHAHpTJrYPEwYZqZVJ2jBBz2qwkTlORigDgtasFj2y4OM4J9K5+4tpF2mJdxPZeOlem6jYxPEfOcKP5VztzJptmchnkweidKAOVsdMMjlpY15PAIwB9K1otBgJ/eQr07jIBqdtdto22panAOdzdKq3Wu3DFwpVecAAcD0oA2bfTLGFB+5QkdMCpzPFASIoo1GcZA6VzkGoSljl2IHJIHrUslyGOWJAxznvQBs3F2ztt3jAPOOMUPelWXLEjgH/9VYL3JaQbBypwferUIkm3bgQSeB6/40AaoLyuPLIOeRgdCah8f232f4X+LCQN50e73f8Afh61tGtzDHvl++eQPSq3xKTHwx8XOxHOj3n/AKJegD0WiiigDhvihbJeXng2CQZV9YkHXv8A2feY/WvO7+F4ZXimU7lyDxwa9G+Jef7Q8FYzn+2X6df+PC8qPUdNt9QjaOZAH6rKo+ZWoA8luU2jnhcc9zXMa5ACj8c889a7fVrN7W4kiZQGjODjIBHqPauZ1ONjG5UYB59uaAPItQh8q8kXAAzkVX2gVteJbcRXSsoODxWSB2xQAzHynApI12upx3FSY4603jcuTQB32hruiBOOBXp3w5095NRkuCjKkEZA7/Mehrzjw1hokIIyTgHqB7V7f8MolbSNQXlWEygkdcFaAN8xkoNwbAByCep75+tZz2/zIpJyuQG/X8e361rLECCPm/dnDLk/4VLaWB3ebP0A4w2MDn9Md6AMW1so3YE5kIbOMnG32/GpvsNyLYARZOeygk5Jq9fataacmIhHgc+g+n1rEPiyQsNoZhk8pHkfyoAmuLe5VF3BkwxHzLnPHYenGea8w+J+nRw+I5JE4M8SSlc/dYcH8OK9DufGVsit9qSUsASAiMCP6V5x4ouxquofaQjRoF2hGwSR68UAef3cKgjH8WeM81CkOCAeGbC8jpW5cRATnCE8Hn0NQm3Ksq8hxzwKAPRPgxpUL395qEkYeS0jVIfZmzlvrjp9c12+rxFp90TESZAUE46Cue+CdxDs1S0diLnak65/iTocfQ/zrrLm1M0zsowWO3cpwzc8Dnp17daAOfjsMBZVIZUBzhuh54/nzVy3smCMRvILhsE4PAJ6/U10NnpkEeWm3SHdu+8QMe/bp2q4kmmqCjGAY4xu3Y9s0Acy9oQjODsZiFQg8rgjIzUkiF4HRdp+XJYnoc5GD+f4V0EkWlzxgq0ab+hDFTWdqGlBXZoWBQtgdsDGCMj6CgD558d6Yun65cRRxlY3Pmr2wG5x7Vx1zEG9B+FeqfEyBP7ZihyWkWMq358VwE9r09en40AY8MY5HBGeladhavcXEUKIWkkYKNvJOfSnRWZ3jAGV5/wrvfhZoJvfEAvJP+PezG92IwM9hQB6xbW403QrLTo8B1QA+3GKqSh5klVsFwoDYPBxwasXbGe9JVBlfmAPoKrxoWgl3Ejec7l7exoA2fDTlrqRs5AwGz1BC9fxr5z+Lcxm8f6yxPCyBMfRRX0noMAVwE2sVTG4dzgcmvl3x7L5/jPW3bPN3IOewBx0/CgDjLxvlJAx9Kq26bnxzx1FXLxflPBpbCEAgjqaANrTIido429cdfxrqrJMFQOuM/4Vj6LFznb09en1rpbO2YyZAPHzHAxx/wDXoA9N+EVh5t5e3W0ARBYwR6nk/wBK9Rkt1dgCKxfAGkrpXhu3UrtllHnSeuT2/LFdGvL0AV7uWKw0+WeTAjiQs30HNfN+vajNfXNxeTvulmcsefyH4CvZPi3qQttASwjb9/euFK5/5Zjqf5CvB9VuWjVl3Hj1A/KgDjfEE4eZR1OckZ4rMt16Ajg06eTzLqQn+8QPapYgCw9KALMCg5yOa0oE6cH5u1UoEJI21owDAHJ2/wA6APaf2aABr/i7HH+i6fx/wO6rsvAyD+ytSODzrOq/+l89cZ+zMc674t/69dP/APQ7qu38CgnR9Q4P/IZ1X8f+JhcUAbTgKvT3qNlywJXvVsoxYcZFM8snbkZB60AVJI1bGemcD61GYscYwfSrzocDA4ppjbgADPc0AUJISWzxTcbUxtz6HNaIiOeOmKPJGelAGU8W8DIbkYye9WreIKixyDIHQ96uCDaMDNK0XA9j1oAga2wpA5FM8jb1HWtOJQQeKSWAbTgcelAGbHHyf7uMVUudPLSBo8jHYda2RFyMjinLCxIxjAoA59rOfeDt3bfbjFWorEsASvLcGtryA3WpUhVOcUAUoLAKOcj6VZWCKIAsMketTM4U1WmvIY/9awA9TQBIzkAbFAqs80mfmbjpUsM8dwh8og1QnDCbOOeuM0AUNfkxbsoz0POelcPNIVIHLEdmPOK7nXQBZs7gc8HFckLU5YNtCkcexoAqQhWRgygNjoD90+tRtGB8rBdw5IIxkVYS0ZTnO4kEAjj8KsJblFVnAIHUnrigCid0agoMhT+h7e9TxgOcuBvYYypzinm2cS7iA6Ht3+v1q3BanPyDcvHQ0AR21sNrbQMHge5ra0i0Esod1wEHI7fhRBamQr5arxx0robe1WGJIlXk/eNAD7aPfJ/siuS+L+pKvw+8TwLwp0u6X6/umrsL6QW1uVUdOSRXkHxbvGk8GeIM4GbCYDPP8Bz0/wA/hQB9B0UUUAcJ8Ur6x0y78GXerXlvZWUesv5k9xKsSJmwuwMsxAHJA+prJn8deD43yvizw8ynjI1KAnH/AH1XqNFAHgHjDxf4VnuoXt/Emiyny8OY7+Ijrx0b61xt54i8PlONb0ps/wB28j/+Kr6xooA+EPFep6XKoaDUrGQg/wAFwrf1rmhqFp1+1W//AH8H+NfopRQB+dRv7M5/0q3/AO/g/wAaVL+z3rm6twAf+ei/41+ilFAHxd4b1nRkjVZtY06Lpy9zGMfrXpHhnx94f0h5f+J9o7QzKA6fbowQR0I+b8K+iaKAPHF+Kng9UVhrmnNIB90XsIz/AMCLVm3fxN0m/kEUev8Ah6CMnIBv4wF9yS3P+eK91ooA8Us/EXgoBXu/Ffh+ebuX1GHaPoN1bEfjXwWnC+K/DoHtqUI/9mr1OigDyufxf4HuIzHL4q8OMhHIbUYCD/49Xnvi3UPCFtKk+leJtCeKRsNFHfxOUOOMYbIWvpaigD49m1zQQpxrOlsQOP8ASozn9ap/21om/cdY00AdMXSc+/Wvs6igD5G0jxXpWm3kd3Z6/p0M8TZR1uY8j14J5B7g9a7KP4t6coJlv/DzuRjcLxQD+G7ivoeigD53Pj6x1gDz/FOg2cHZft0WfwUsMfjV621fwewH2jxppLMOp/tWFc/gGr3qigDxAeIPB8a/6N410iMkfxanA4P4Fv1rM1L4h2GnxlYfE3h66t84Bhvoww+q7j+Yr6CooA+O9Q8QaLd3cs8msaYXc5/4+0P9axLnVtIK4GqafjPa4Q/1r7fooA+JbPUNIuJo4f7W0uMyNjfJdRqqj1OW4r13RfEvg/SNOgsLTxLoYDMHnkOoQ5cgdzu6177RQB4EfGvhlj5q+JNFDt8uTfxAgZyRgNVxPGXhSVOfFOioWG4KdRi7HGD83pn3r3GigDyrTPHfg5JYyfFfh9Qq7edRhHT/AIF3r538ZX2i3mt6hcQaxpz+ZPIwZbpG3fMcHOa+3aKAPzuvbqyPC3tqfpKp/rUlld2QI3XtqPrMo/rX6G0UAfDml6tpMcY36pYKPe4TP867jwZqfhifU4P7Q8QaNBApDt5t9GoOD05avquigDzz/hYPgwfKvi3w6AB21KHH/oVSxfEHwWDz4v8ADv8A4M4f/iq76igD5x+J3jjw7qWtKtpr+kzQwx7d6XkbKxznjB6V5druuaRKjhNSsnBH8Nwjf1r7fooA/OoX1nuJ+12/X/noKsxahYjOL22H1lX/ABr9DKKAPgO21PTs/wDH/arkd5lH9a0YNV0sFR/aViOMc3CAD9a+66KAPAP2YLm3u9c8XvaTwzxi2sFLROHGd11xkd+ldF4T8X+GdLttUs9U8R6NZXces6pvguL6KORM385GVZgRkEH6EV67RQBwH/Cf+Cu/i/w7n/sJwf8AxVJ/wn3gr/ob/Dv/AIM4f/iq9AooA8/Pj7wUf+Zv8O/+DOD/AOKo/wCE98Ff9Df4dz/2E4P/AIqvQKKAPPj498FHgeL/AA6P+4nB/wDFUv8AwnvgoYx4v8Of+DOD/wCKr0CigDz4+PvBf/Q3+HP/AAZwf/FUp8feC+v/AAl/hz/wZwf/ABVegUUAefp8QPBan/kb/Dv/AIM4P/iqm/4WD4KPXxh4c/8ABnB/8VXdUUAcH/wsDwVn/kcPDn/gzg/+Kpw+IPgn/ob/AA5/4M4P/iq7qigDhx8QvBOP+Rv8Of8Agzg/+KpjfELwUf8Amb/Dv/gzg/8Aiq7uigDzuf4g+DAvHi7w8T7alD/8VWNceOPCE0oL+KtAPXgajDj/ANCr12igDyyy8deD4ZAf+Er8PBT1H9pQj/2ar0njzwWxz/wl/h3P/YSg/wDiq9FooA8t1Lxv4NntmRfFnh73/wCJlD/8VWOvjDwiJG3eKdACn01CEj6fer2qigDxBvFvhEFv+Kq0Jh2/4mEPHv8AepV8XeE1Db/E+gNj7oGown/2avbqKAPFY/Fng8oQ3irQN3bOoRf/ABVSw+LfB0bEr4q8PgZ/6CMPI/76r2WigDy6w8a+DEcySeLfDwIHA/tOH/4qtFPiD4LUs58XeHT6D+04f/iq9AooA8l1nx94TkGyPxXoDg5JxqMJ/wDZq8w+IXiLQL7wprUFn4h0iSRrSbaq3sZZz5TYUAHkk4GK+qaKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Detail view of the hands shows subperiosteal resorption in the phalanges (arrows).",
"    <br/>",
"    (B) Detail views of both distal clavicles show subchondral resorption bilaterally (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daffner RH. Clinical Radiology, The Essentials, 3rd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17380=[""].join("\n");
var outline_f16_62_17380=null;
var title_f16_62_17381="MRI of triangular fibrocartilage complex tear";
var content_f16_62_17381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    MRI of triangular fibrocartilage complex tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI following arthrography shows a tear in the triangular fibrocartilage complex (TFCC) of the right wrist. The T1 fat suppressed sequence (A) confirms the presence of the tear (white arrow) with leakage of contrast into the distal radioulnar joint (yellow arrow head). Similar findings are seen in the STIR sequence (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17381=[""].join("\n");
var outline_f16_62_17381=null;
var title_f16_62_17382="Ant superior iliac spine";
var content_f16_62_17382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Anterior superior iliac spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Artist's drawing of the pelvis (right anterior view), showing the position of the anterior superior iliac spine, a bony prominence easily felt in most patients at the anterior-most portion of the iliac crest (C). The bone marrow needle should be inserted in the position marked by the asterisk (*).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17382=[""].join("\n");
var outline_f16_62_17382=null;
var title_f16_62_17383="Amantadine: Pediatric drug information";
var content_f16_62_17383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amantadine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"    see \"Amantadine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/53/3925?source=see_link\">",
"    see \"Amantadine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Amantadine;",
"     </li>",
"     <li>",
"      Mylan-Amantadine;",
"     </li>",
"     <li>",
"      PHL-Amantadine;",
"     </li>",
"     <li>",
"      PMS-Amantadine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1044970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-Parkinson's Agent (Dopamine Agonist)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Adamantane",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1044963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"      see \"Amantadine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder (ADHD):",
"     </b>",
"     Limited data available: Oral: Children &ge;5 years and Adolescents: Initial: 50 mg/",
"     <b>",
"      day",
"     </b>",
"     ; titrate up at 4-7 day intervals in 50 mg increments to effect; reported range: 50-150 mg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses 1-3 times daily (morning, noon, and 4 PM); maximum daily dose (weight-dependent): &lt;30 kg: 100 mg/",
"     <b>",
"      day",
"     </b>",
"     ; &ge;30 kg: 150 mg/",
"     <b>",
"      day",
"     </b>",
"     (Donfrancecso, 2007; King, 2001; Mohammadi, 2010); dosing based on two small open-label trials (n=24, n=20; age range: 5-14 years) which suggested improvements in symptoms and ADHD outcome scores; a comparison trial with methylphenidate (n=40) did not detect differences in efficacy between the treatment groups (Mohammadi, 2010); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Autism (hyperactivity, irritability):",
"     </b>",
"     Limited data available: Oral: Children &ge;5 years and Adolescents: Initial: 2.5 mg/kg/dose once daily for 1 week, then increase to 2.5 mg/kg/dose twice daily; maximum daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     ; dosing based on short-term (4-week) double-blind, placebo-controlled trial of 39 pediatric patients (treatment group, n=19) which showed improvement in clinician-rated behavioral and hyperactivity ratings (King, 2001a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Influenza A treatment/prophylaxis:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A. Please refer to the current ACIP recommendations. The following is based on the manufacturer's labeling and ACIP recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Influenza A treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1-9 years: 5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 2 divided doses (manufacturer's labeling: 4.4-8.8 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ); maximum daily dose: 150 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;10 years and &lt;40 kg: 5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 2 divided doses (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;10 years and &ge;40 kg: 100 mg twice daily (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initiate within 24-48 hours after onset of symptoms; continue for 24-48 hours after symptom resolution (duration of therapy is generally 3-5 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Influenza A prophylaxis:",
"     </i>",
"     Refer to \"Influenza A treatment\" dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Continue prophylaxis throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed. For ages &lt;9 years receiving influenza vaccine for the first time, amantadine prophylaxis should continue for 6 weeks (4 weeks after the first dose and 2 weeks after the second dose).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Multiple-sclerosis associated lassitude (fatigue):",
"     </b>",
"     Limited data available (Pohl, 2007): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;10 years or weight &lt;40 kg:  2.5 mg/kg/dose twice daily; maximum daily dose: 150 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;10 years and weight &ge;40 kg: 100 mg twice daily, may titrate dose to clinical response; maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Traumatic brain injury (TBI):",
"     </b>",
"     Limited data available: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents &lt;16 years: 4-6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 2 divided doses; maximum daily dose (age or weight dependent): If &lt;10 years or &lt;40 kg: 150 mg/",
"     <b>",
"      day",
"     </b>",
"     ; if &ge;10 years or &ge;40 kg: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     (Beers, 2005; McMahon, 2009). While total daily dose similar in trials, the reported dosing approaches and efficacy results are variable (eg, timing of therapy initiation, duration of study, outcome measures) (Williams, 2007). In an open-label, case-controlled trial of 27 pediatric patients with TBI within the last 24 months prior to enrollment (n=17 amantadine treatment, n=10 controls), patients received 5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     for entire study period of 12 weeks; results showed improvement in behavior (parental report) and a subset analysis suggested therapy more effective on cognition for those with more recent injury (Beers, 2005). In a double-blind, placebo-controlled crossover trial of seven pediatric patients (mean age: 12.7 years) with TBI within last 12 weeks prior to enrollment, therapy was initiated at 4 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     up to 300 mg/",
"     <b>",
"      day",
"     </b>",
"     for 1 week, and increased to 6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     up to 400 mg/",
"     <b>",
"      day",
"     </b>",
"     for Weeks 2 and 3 of the study duration; improved consciousness observed during treatment period of study (McMahon, 2009; Vargus-Adams, 2010).  Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;16 years: Initial: 100 mg twice daily for 14 days; on Week 3 increase to 150 mg twice daily; may further increase to 200 mg twice daily on Week 4 if needed; dosing based on a multicenter, double-blind, placebo-controlled trial of 184 patients (age range: 16-65 years; treatment group, n= 87) which showed 4 weeks of amantadine therapy initiated at 4-16 weeks postinjury increased the rate of functional recovery (Giacino, 2012). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Drug-induced extrapyramidal symptoms:",
"     </b>",
"     Oral: 100 mg twice daily; may increase to 300 mg/day in divided doses, if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     Oral: Usual dose: 100 mg twice daily as monotherapy; may increase to 400 mg/day in divided doses, if needed, with close monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with a serious concomitant illness or those receiving high doses of other antiparkinson drugs should be started at 100 mg/day; may increase to 100 mg twice daily, if needed, after one to several weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Influenza A treatment/prophylaxis:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A. Please refer to the current ACIP recommendations. The following is based on the manufacturer's labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Influenza A treatment:",
"     </i>",
"     200 mg once daily",
"     <b>",
"      or",
"     </b>",
"     100 mg twice daily (may be preferred to reduce CNS effects)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initiate within 24-48 hours after onset of symptoms; continue for 24-48 hours after symptom resolution (duration of therapy is generally 3-5 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Influenza A prophylaxis:",
"     </i>",
"     200 mg once daily",
"     <b>",
"      or",
"     </b>",
"     100 mg twice daily (may be preferred to reduce CNS effects)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Continue prophylaxis throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Administer 200 mg on day 1, then 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-29 mL/minute: Administer 200 mg on day 1, then 100 mg on alternate days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Administer 200 mg every 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer 200 mg every 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis: No supplemental dose is needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous arteriovenous or venous-venous hemofiltration: No supplemental dose is needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral, as hydrochloride: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 50 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 50 mg/5 mL (10 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15574778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken without regard to food. For regimens with multiple daily dosing, timing of doses may vary based upon patient tolerance (eg, if insomnia develops,  administer evening dose several hours before bedtime) and use [for ADHD, administer morning and noon; if thrice daily dosing, last dose should be given around 4 PM (Mohammadi, 2010)].",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F12935454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets and syrup at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1044972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of influenza A viral infection (FDA approved in ages &ge;1 year and adults);",
"     <b>",
"      Note:",
"     </b>",
"     Due to high resistance rates, amantadine is no longer recommended by the CDC for the treatment or prophylaxis of influenza A (CDC, 2011); symptomatic and adjunct treatment of parkinsonism; treatment of drug-induced extrapyramidal reactions (FDA approved in adults); has also been used for attention-deficit/hyperactivity disorder (ADHD), autism, fatigue associated with multiple sclerosis, and in post-traumatic brain injury for behavior and cognition",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amantadine may be confused with ranitidine, rimantadine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Symmetrel may be confused with Synthroid&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F132720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delirium, depression, dizziness, dream abnormality, fatigue, hallucinations, headache, insomnia, irritability, lightheadedness, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Livedo reticularis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dry nose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggressive behavior, agranulocytosis, alkaline phosphatase increased, allergic reaction, ALT increased, AST increased, amnesia, anaphylaxis, arrhythmia, bilirubin increased, BUN increased, cardiac arrest, CHF, coma, CPK increased, creatinine increased, delusions, diaphoresis, dysphagia, dyspnea, eczematoid dermatitis, euphoria, GGT increased, heart failure, hyperkinesis, LDH increased, leukopenia, mania, neutropenia, neuroleptic malignant syndrome (NMS; associated with dosage reduction or abrupt withdrawal of amantadine), oculogyric episodes, paresthesia, photosensitivity, psychosis, pulmonary edema, rash, respiratory failure (acute), seizures, suicidal ideation, suicide, urinary retention, withdrawal reactions (may include delirium, hallucinations, and psychosis), visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reported with dopamine agonists: Impulsive/compulsive behaviors (eg, pathological gambling, hypersexuality, binge eating)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1044975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amantadine hydrochloride or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1044962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage reduction recommended. Use with caution in patients with hepatic impairment; rarely, elevations in transaminases have been reported. Use with caution in patients with heart failure, peripheral edema, or orthostatic hypotension; dosage reduction may be required. Use with caution in patients with a history of recurrent and eczematoid dermatitis. Use with caution in patients with a history of seizure disorder or with concurrent CNS stimulant use; may increase seizure activity or EEG disturbances in patients with pre-existing seizure disorder .Avoid in untreated angle closure glaucoma.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1044961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Deaths due to amantadine overdose have been reported with the lowest lethal dose being 1 gram. Drug overdose has resulted in cardiac (ie, arrhythmia, tachycardia, hypertension), respiratory, renal, or central nervous system toxicity. Due to increased resistance, the ACIP has recommended that rimantadine and amantadine no longer be used for the treatment or prophylaxis of influenza A in the United States until susceptibility has been re-established; consult current guidelines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use has been associated with neuroleptic malignant syndrome (associated with dose reduction or abrupt discontinuation). Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions, and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases. Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed. There have been reports of suicidal ideation/attempt in patients with and without a history of psychiatric illness. May exacerbate mental problems in patients with a history of mental illness; use with caution in patients with uncontrolled psychosis or severe psychoneurosis. May cause a withdrawal syndrome of agitation, anxiety, delirium, delusions, depression, hallucinations, paranoia, parkinsonian crisis, slurred speech, or stupor; gradually taper dose avoid abrupt discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use oral solution containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: Amantadine may enhance the anticholinergic effect of Glycopyrrolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F132660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies and in case reports in humans.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Influenza infection may be more severe in pregnant women. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Oseltamivir and zanamivir are currently recommended for the treatment or prophylaxis influenza in pregnant women and women up to 2 weeks postpartum. Antiviral agents are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (consult current CDC guidelines).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to influenza vaccine, or who have taken an antiviral medication during pregnancy to the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1044969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function; mental status, monitor for signs of neurotoxicity; periodic skin exam for melanoma, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1044960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As an antiviral, blocks the uncoating of influenza A virus preventing penetration of virus into host and inhibits M",
"     <sub>",
"      2",
"     </sub>",
"     protein in the assembly of progeny virions; antiparkinsonian activity may be due to its blocking the reuptake of dopamine into presynaptic neurons and causing direct stimulation of postsynaptic receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1044974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Normal: 1.5-6.1 L/kg; Renal failure: 5.1 &plusmn; 0.2 L/kg; in saliva, tear film, and nasal secretions; in animals, tissue (especially lung) concentrations higher than serum concentrations; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Normal renal function: ~67%; Hemodialysis: ~59%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not appreciable; small amounts of an acetyl metabolite identified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 86% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Normal renal function: 16 &plusmn; 6 hours (9-31 hours); Healthy, older (&ge;60 years) males: 29 hours (range: 20-41 hours); End-stage renal disease: 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (80% to 90% unchanged) by glomerular filtration and tubular secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Negligible amounts removed",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1044967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/53/3925?source=see_link\">",
"      see \"Amantadine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness, blurred vision, and impair ability to perform activities requiring mental alertness or physical coordination; rise slowly from sitting or lying position. Do not abruptly discontinue therapy, may precipitate a parkinsonian crisis; avoid alcohol; may cause dry mouth. Notify physician of mood/mental changes, swelling of extremities, difficulty urinating, dizziness, lightheadedness, shortness of breath, and/or if intense urges occur.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatr",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aoki FY and Sitar DS, &ldquo;Clinical Pharmacokinetics of Amantadine Hydrochloride,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1988, 14(1):35-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/3280212/pubmed\" id=\"3280212\" target=\"_blank\">",
"        3280212",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beers SR, Skold A, Dixon CE, et al, \"Neurobehavioral Effects of Amantadine After Pediatric Traumatic Brain Injury: A Preliminary Report,\"",
"      <i>",
"       J Head Trauma Rehabil",
"      </i>",
"      , 2005, 20(5):450-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/16170253/pubmed\" id=\"16170253\" target=\"_blank\">",
"        16170253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Influenza Division, National Center for Immunization and Respiratory Diseases. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza --- Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2011, 60(1):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/21248682/pubmed\" id=\"21248682\" target=\"_blank\">",
"        21248682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Interim Guidance: Considerations Regarding 2009 Novel H1N1 Flu Virus in Intrapartum and Postpartum Hospital Settings,\"  Available at",
"      <a href=\"file://www.cdc.gov/h1n1flu/guidance/obstetric.htm\" target=\"_blank\">",
"       file://www.cdc.gov/h1n1flu/guidance/obstetric.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/12755288/pubmed\" id=\"12755288\" target=\"_blank\">",
"        12755288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\" MMWR Recomm Rep, 2008, 56 (early release):1-60. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e717a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e717a1.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chitnis T, Krupp L, Yeh A, et al, \"Pediatric Multiple Sclerosis,\"",
"      <i>",
"       Neurol Clin",
"      </i>",
"      , 2011, 29(2):481-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/21439455/pubmed\" id=\"21439455\" target=\"_blank\">",
"        21439455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donfrancesco R, Calderoni D, and Vitiello B, \"Open-Label Amantadine in Children With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2007, 17(5):657-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/17979585/pubmed\" id=\"17979585\" target=\"_blank\">",
"        17979585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giacino JT, Whyte J, Bagiella E, et al, \"Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(9):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/22375973/pubmed\" id=\"22375973\" target=\"_blank\">",
"        22375973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green LB, Hornyak JE, and Hurvitz EA, \"Amantadine in Pediatric Patients With Traumatic Brain Injury: A Retrospective, Case-Controlled Study,\"",
"      <i>",
"       Am J Phys Med Rehabil",
"      </i>",
"      , 2004, 83(12):893-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/15624567/pubmed\" id=\"15624567\" target=\"_blank\">",
"        15624567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King BH, Wright DM, Handen BL, et al, \"Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001a, 40(6):658-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/11392343/pubmed\" id=\"11392343\" target=\"_blank\">",
"        11392343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King BH, Wright DM, Snape M, et al, \"Case Series: Amantadine Open-Label Treatment of Impulsive and Aggressive Behavior in Hospitalized Children With Developmental Disabilities,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 40(6):654-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/11392342/pubmed\" id=\"11392342\" target=\"_blank\">",
"        11392342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMahon MA, Vargus-Adams JN, Michaud LJ, et al, \"Effects of Amantadine in Children With Impaired Consciousness Caused by Acquired Brain Injury: A Pilot Study,\"",
"      <i>",
"       Am J Phys Med Rehabil",
"      </i>",
"      , 2009, 88(7):525-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/19404190/pubmed\" id=\"19404190\" target=\"_blank\">",
"        19404190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohammadi MR, Kazemi MR, Zia E, et al, \"Amantadine Versus Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Trial,\"",
"      <i>",
"       Hum Psychopharmacol",
"      </i>",
"      , 2010, 25(7-8):560-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/21312290/pubmed\" id=\"21312290\" target=\"_blank\">",
"        21312290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patrick PD, Blackman JA, Mabry JL, et al, \"Dopamine Agonist Therapy in Low-Response Children Following Traumatic Brain Injury,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2006, 21(10):879-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/17005105/pubmed\" id=\"17005105\" target=\"_blank\">",
"        17005105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pohl D, Waubant E, Banwell B, et al, \"Treatment of Pediatric Multiple Sclerosis and Variants,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2007, 68(16 Suppl 2):54-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/17438239/pubmed\" id=\"17438239\" target=\"_blank\">",
"        17438239",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strong DK, Eisenstat DD, Bryson SM, et al, &ldquo;Amantadine Neurotoxicity in a Pediatric Patient With Renal Insufficiency,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(11):1175-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/1763530/pubmed\" id=\"1763530\" target=\"_blank\">",
"        1763530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson AJ, Toosy AT, and Ciccarelli O, \"Pharmacological Management of Symptoms in Multiple Sclerosis: Current Approaches and Future Directions,\"",
"      <i>",
"       Lancet Neurol",
"      </i>",
"      , 2010, 9(12):1182-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/21087742/pubmed\" id=\"21087742\" target=\"_blank\">",
"        21087742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vargus-Adams JN, McMahon MA, Michaud LJ, et al, \"Pharmacokinetics of Amantadine in Children With Impaired Consciousness Due to Acquired Brain Injury: Preliminary Findings Using a Sparse-Sampling Technique,\"",
"      <i>",
"       PMR",
"      </i>",
"      , 2010, 2(1):37-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/20129511/pubmed\" id=\"20129511\" target=\"_blank\">",
"        20129511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams SE, \"Amantadine Treatment Following Traumatic Brain Injury in Children,\"",
"      <i>",
"       Brain Inj",
"      </i>",
"      , 2007, 21(9):885-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/62/17383/abstract-text/17729042/pubmed\" id=\"17729042\" target=\"_blank\">",
"        17729042",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13387 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17383=[""].join("\n");
var outline_f16_62_17383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132677\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044970\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044963\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132650\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132635\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15574778\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12935454\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044972\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132723\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132720\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044975\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044962\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044961\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298728\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132644\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132646\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132660\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044969\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044960\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044974\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044967\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13387\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13387|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=related_link\">",
"      Amantadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/53/3925?source=related_link\">",
"      Amantadine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_62_17384="The surgical patient taking glucocorticoids";
var content_f16_62_17384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The surgical patient taking glucocorticoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Amir H Hamrahian, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Sanziana Roman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Stacey Milan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17384/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/62/17384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic glucocorticoid therapy can suppress the hypothalamic-pituitary-adrenal (HPA) axis and, during times of stress such as surgery, the adrenal glands may not respond appropriately. Protocols for \"stress dose\" steroids followed reports in the 1950s of possible surgery-associated adrenal insufficiency due to sudden preoperative withdrawal of glucocorticoids. However, numerous studies have questioned both the need for and the doses of supplemental perioperative glucocorticoid.",
"   </p>",
"   <p>",
"    The management of the surgical patient on chronic glucocorticoid therapy is reviewed here. Perioperative glucocorticoid regimens for patients taking replacement glucocorticoid for primary adrenal insufficiency are addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177132320\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of stress doses of glucocorticoids, such as 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    for several days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], had become a common perioperative practice for patients on glucocorticoid therapy, based upon early case reports of intraoperative adrenal crisis after abrupt withdrawal of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], and the observation that glucocorticoids have a permissive effect on vascular tone and blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a number of reports, including two randomized studies, have questioned the need for supplemental perioperative stress dose glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/1,7-12\">",
"     1,7-12",
"    </a>",
"    ]. The current approach is to determine perioperative glucocorticoid coverage based upon the patient&rsquo;s history of glucocorticoid intake, as well as the type and duration of surgery planned [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/2,13-15\">",
"     2,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to suppression of the hypothalamic-pituitary-adrenal (HPA) axis, chronic glucocorticoid therapy may cause a number of other problems in the perioperative period:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired wound healing [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased friability of skin, superficial blood vessels, and other tissues (eg, mild pressure may cause hematoma or skin ulceration, removing adhesive tape may tear the skin, and sutures may tear the gut wall)",
"     </li>",
"     <li>",
"      Increased risk of fracture, infections, gastrointestinal hemorrhage, or ulcer [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One important reason to avoid supraphysiologic administration of glucocorticoids perioperatively, unless absolutely necessary, is that they have acute side effects that can influence surgical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/7,19\">",
"     7,19",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperglycemia",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Fluid retention",
"     </li>",
"     <li>",
"      Increased risk of infection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An anesthetic agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    , should be avoided in patients at risk for adrenal suppression and adrenal crisis. This is a commonly used anesthetic induction agent known to have properties of inhibiting steroid synthesis and precipitating acute adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/20\">",
"     20",
"    </a>",
"    ]. While etomidate has many benefits in specific clinical settings, it is best avoided in patients with possible HPA suppression. If it is used, patients need to receive glucocorticoid coverage perioperatively or be closely monitored for any clinical features suggestive of adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with possible HPA suppression, the presence of unexplained nausea, vomiting, hypotension, orthostasis, change in mental status, hyponatremia, or hyperkalemia should prompt checking a random cortisol and, depending on the urgency of the situation, may require empiric therapy with additional corticosteroids. Additionally, postoperative stressors, such as infection, myocardial infarction, bleeding, or other complications may also prompt the administration of additional glucocorticoids.",
"   </p>",
"   <p>",
"    Patients who are taking glucocorticoids should be monitored carefully for infection postoperatively because glucocorticoids may suppress the fever response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CORTISOL SECRETION DURING STRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute physical or psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, resulting in increased plasma corticotropin (ACTH) and serum cortisol concentrations. Stress exerts its effects by stimulating the hypothalamus to release ACTH secretagogues, with corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) being the most important [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery is one of the most potent activators of the HPA axis. The degree of activation of the HPA axis depends on both the type of surgery performed and the anesthetic agents used during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Plasma ACTH concentrations increase at the time of incision and during surgery, but the greatest ACTH and cortisol secretion occurs during reversal of anesthesia, extubation, and in the immediate postoperative recovery period, primarily in response to pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The response is mediated by afferent nerve impulses, since it can be abolished by interrupting the neural connections from the operative site, such as by sectioning the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/28\">",
"     28",
"    </a>",
"    ], epidural anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/29\">",
"     29",
"    </a>",
"    ], or local anesthesia. The plasma ACTH and serum cortisol responses to surgery can also be reduced by opiate drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/27,30\">",
"     27,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is considerable variation in the increase in cortisol secretion among individuals undergoing surgery; this variability is in part due to concomitant medication use, age, and concurrent illness. However, in general, cortisol secretion is proportional to the degree of surgical stress. The normal basal secretion of cortisol from the adrenal gland is approximately 8 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and increases to approximately 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of cortisol during a minor surgery or illness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/13\">",
"     13",
"    </a>",
"    ]. Small, transient cortisol responses are seen with minor stress (eg, inguinal hernia repair), returning to baseline within 24 hours after uncomplicated surgery. Patients exposed to greater surgical stress (eg, subtotal colectomy) have been shown to have greater cortisol responses (75 to 100",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    normalizing by postoperative day five [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/24,31\">",
"     24,31",
"    </a>",
"    ]. The cortisol secretion rate can reach 200 to 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with severe stress (such as major trauma), but secretion rates greater than 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in the 24 hours after surgery are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECT OF EXOGENOUS GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous glucocorticoids exert negative feedback control on the hypothalamic-pituitary-adrenal (HPA) axis by suppressing corticotropin-releasing hormone (CRH) secretion and, consequently, ACTH secretion. This leads to adrenal atrophy and loss of cortisol secretory capability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/32\">",
"     32",
"    </a>",
"    ]. The time course for recovery of the HPA axis after stopping glucocorticoid therapy following a prolonged treatment course is variable and depends upon a variety of factors including the dose, time of day, and duration of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients whose glucocorticoid history is uncertain, biochemical evaluation of HPA may be considered prior to surgery or a short course of glucocorticoid therapy can be given perioperatively (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Evaluation of HPA axis suppression'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179742\">",
"    <span class=\"h2\">",
"     Nonsuppressed HPA axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    doses of less than 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given in the morning do not suppress the HPA axis. The equivalent morning doses of other glucocorticoids (eg, 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , 0.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , or 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ) will have a similar effect (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that the following groups of patients do not need additional perioperative glucocorticoid coverage because they are",
"    <strong>",
"     not",
"    </strong>",
"    considered to have suppression of their hypothalamic-pituitary-adrenal axis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient who has been taking any dose of glucocorticoid for less than three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who have received",
"      <strong>",
"       morning",
"      </strong>",
"      doses of",
"      <strong>",
"       less",
"      </strong>",
"      than 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent, for any length of time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients being treated with",
"      <strong>",
"       less",
"      </strong>",
"      than 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent every other day [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients can be safely maintained on their normal daily dose of glucocorticoids in the perioperative period. Furthermore, these patients do not require testing for HPA axis suppression, as the testing does not accurately predict development of adrenal crisis postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Monitoring of these patients for any evidence of hemodynamic instability perioperatively should be sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179792\">",
"    <span class=\"h2\">",
"     Suppressed HPA axis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, patients who should be assumed to have functional suppression of hypothalamic-pituitary-adrenal function include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient who is currently taking more than 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent (eg, 16",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , or 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      ) for more than three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Any patient on glucocorticoids who has clinical Cushing's syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest that these patients be treated with supplemental glucocorticoids in the perioperative period in accordance with the magnitude of the stress (",
"    <a class=\"graphic graphic_table graphicRef69479 \" href=\"UTD.htm?5/17/5403\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179806\">",
"    <span class=\"h2\">",
"     Intermediate patients (HPA suppression unknown)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients currently taking doses of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or higher of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or its equivalent) have considerable variability in HPA axis suppression that does not correlate well with age, sex, dose, or duration of therapy. This variability is probably due to differences in rates of glucocorticoid metabolism (",
"    <a class=\"graphic graphic_figure graphicRef59504 \" href=\"UTD.htm?5/27/5566\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additionally, doses lower than the equivalent of 5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    daily taken in the evening may disrupt the normal diurnal variation and the way the patient responds to surgical stress [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/37,46\">",
"     37,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that all patients in this intermediate category undergo preoperative evaluation of their HPA axis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Evaluation of HPA axis suppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73207804\">",
"    <span class=\"h3\">",
"     Glucocorticoid use in past year",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient who has discontinued glucocorticoids in the year prior to surgery presents another problem. Early studies found that profound suppression of the HPA axis could take up to one year to recover fully [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This led some to recommend the administration of glucocorticoids to any patient who had been on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses of more than 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for more than one week in the 6 to 12 months prior to surgery, but this is clearly unwarranted.",
"   </p>",
"   <p>",
"    For patients who are currently off glucocorticoids, but used them in the past year, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who received regimens that would not be expected to suppress the HPA axis do not require testing (see",
"      <a class=\"local\" href=\"#H3179742\">",
"       'Nonsuppressed HPA axis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      All other patients who received regimens of either longer duration or higher doses of glucocorticoids that could have potentially suppressed the HPA axis (eg, the suppressed or intermediate &ldquo;unknown&rdquo; HPA suppression categories) should undergo preoperative assessment of their HPA axis beginning with a morning serum cortisol (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation of HPA axis suppression'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Inhaled and topical glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic use of inhaled or high potency topical glucocorticoids has potential to cause HPA axis suppression, although this rarely manifests as overt adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/47\">",
"     47",
"    </a>",
"    ]. In general, we suggest not providing additional perioperative glucocorticoid treatment in these patients unless they appear Cushingoid or exhibit signs or symptoms of adrenal insufficiency perioperatively.",
"   </p>",
"   <p>",
"    The effect of inhaled and topical glucocorticoids on the HPA axis is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 21 studies of urinary cortisol excretion and 13 studies of morning serum cortisol concentrations in patients taking inhaled glucocorticoids found evidence of HPA axis suppression that was most common with inhaled glucocorticoid doses greater than 0.8",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      but was often absent even at higher doses [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/48\">",
"       48",
"      </a>",
"      ]. HPA axis suppression was seen with lower daily doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      (0.75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link&amp;anchor=H13#H13\">",
"       \"Major side effects of inhaled glucocorticoids\", section on 'Adrenal suppression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The inhaled agent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/45/33488?source=see_link\">",
"       ciclesonide",
"      </a>",
"      , is hydrolyzed to its active metabolite, desisobutyryl-CIC (des-CIC), in the lungs, limiting systemic availability. A meta-analysis of four studies using doses of 160 to 640",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      did not show evidence for suppression of morning or 24-hour urinary cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical corticosteroids, particularly class I agents (the strongest), can cause significant hypothalamic-pituitary-axis (HPA) suppression using as little as 2",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      for two or more weeks. Factors that predispose to HPA suppression include use of high potency corticosteroids, chronic use, application to highly permeable areas, treatment of large areas, occlusion, poor skin integrity, liver failure, and young age. Routine use of even mild corticosteroids in young children can cause HPA axis suppression. Systemic absorption is increased when there is an altered skin barrier, which is common in the conditions for which these medications are prescribed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H18#H18\">",
"       \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Systemic'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3965855\">",
"    <span class=\"h3\">",
"     Intra-articular and spinal glucocorticoid injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic absorption occurs after intra-articular glucocorticoid [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/50-53\">",
"     50-53",
"    </a>",
"    ], and hypothalamic-pituitary-adrenal (HPA) axis suppression has been described after both intra-articular and spinal injections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Several factors, including the dose, interval, and the number of glucocorticoid injections, have an impact on the severity of HPA axis suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/50,56\">",
"     50,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the risk of perioperative adrenal crisis is likely to be low in patients with a history of previous glucocorticoid injections, we suggest HPA axis evaluation in those who have received three or more intra-articular or spinal glucocorticoid injections within three months prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/55\">",
"     55",
"    </a>",
"    ], or those who appear Cushingoid on exam [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION OF HPA AXIS SUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, patients taking 5 to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent for more than three weeks and those taking glucocorticoids in the evening may or may not have suppression of the hypothalamic-pituitary-adrenal (HPA) axis. The patient who has discontinued potentially suppressive doses of glucocorticoids in the year prior to surgery presents another problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H884513\">",
"    <span class=\"h2\">",
"     Morning serum cortisol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of morning (prior to 8 AM) serum cortisol has been described as a good screening method for evaluation of secondary adrenal insufficiency, with a good correlation with maximum cortisol achieved during insulin-induced hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients on chronic glucocorticoid therapy, an early morning cortisol &lt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (138",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      24-hour off glucocorticoid replacement dose is highly suggestive of an impaired HPA axis with the need for additional glucocorticoid intake perioperatively (",
"      <a class=\"graphic graphic_table graphicRef69479 \" href=\"UTD.htm?5/17/5403\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with an early morning cortisol level &gt;10",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (275",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      likely do",
"      <strong>",
"       not",
"      </strong>",
"      have a significant impairment of the HPA axis and may be continued on their current glucocorticoid replacement dose on the day of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. Such patients do not need additional perioperative glucocorticoid therapy.",
"     </li>",
"     <li>",
"      In patients with an early morning cortisol level between 5 to 10",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (138 to 275",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      we suggest further evaluation with an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      or empiric additional perioperative glucocorticoid therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H884520\">",
"    <span class=\"h2\">",
"     ACTH stimulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest measurement of serum cortisol at 30 minutes after 250 mcg ACTH stimulation for preoperative evaluation of the hypothalamic-pituitary (HPA) axis. A cortisol level &gt;18",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (497",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    30 minutes after 250 mcg ACTH stimulation predicts an adequate adrenal reserve during surgery with no need for glucocorticoid coverage perioperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/44,61,62\">",
"     44,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with an inadequate response should receive additional glucocorticoid coverage (",
"    <a class=\"graphic graphic_table graphicRef69479 \" href=\"UTD.htm?5/17/5403\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    may be normal in patients with acute (within two to four weeks) ACTH deficiency, as might occur soon after pituitary surgery and, therefore, cannot be relied upon as an indicator of a normal HPA axis in such circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/63\">",
"     63",
"    </a>",
"    ]. An insulin tolerance test or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation test may be done to evaluate HPA axis in such patients. However these tests are not practical in most clinical settings and, therefore, we suggest empiric replacement with glucocorticoids in patients with suspected acute ACTH deficiency due to recent pituitary surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    A normal cortisol response during the ACTH stimulation test confirms adequate cortisol reserve during surgery and a lack of need for glucocorticoid coverage perioperatively. However, a normal clinical response to surgical stress has been reported in three studies of patients with an inadequate response to high-dose ACTH stimulation test while being maintained on their usual daily glucocorticoid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17384/abstract/1,8,44\">",
"     1,8,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of stress doses of glucocorticoids has become a common perioperative practice for patients on glucocorticoid therapy. However, available data suggest that these doses are excessive and unnecessary in most patients. The current approach is to determine glucocorticoid coverage based upon the patient&rsquo;s history of glucocorticoid intake, as well as the type and duration of surgery.",
"   </p>",
"   <p>",
"    We suggest the following approach for perioperative glucocorticoid coverage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsuppressed HPA axis &ndash; For patients who have been taking exogenous glucocorticoids of any dose for less than three weeks, or morning",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (&lt;5 mg daily or its equivalent) for any duration, or less than 10 mg of prednisone or its equivalent every other day, we suggest continuing the same glucocorticoid regimen perioperatively (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients are unlikely to have a suppressed hypothalamic-pituitary-adrenal (HPA) axis, and neither preoperative evaluation of the HPA axis nor supraphysiologic doses of glucocorticoids are needed. (See",
"      <a class=\"local\" href=\"#H3179742\">",
"       'Nonsuppressed HPA axis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suppressed HPA axis &ndash; For patients who are currently taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &gt;20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three weeks or more, and in patients with a Cushingoid appearance, we suggest additional perioperative glucocorticoid coverage, because HPA axis suppression should be assumed to be present (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our recommendations for specific glucocorticoid regimens are based upon the type and anticipated duration of surgery (",
"      <a class=\"graphic graphic_table graphicRef69479 \" href=\"UTD.htm?5/17/5403\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Intermediate HPA suppression &ndash; For all other patients, the degree of HPA axis suppression is unknown, and biochemical evaluation of the HPA axis should be performed. (See",
"      <a class=\"local\" href=\"#H3179806\">",
"       'Intermediate patients (HPA suppression unknown)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Although the risk of perioperative adrenal crisis is likely to be low in patients with a history of previous glucocorticoid injections, we also suggest HPA axis evaluation in those who have received three or more intra-articular or spinal glucocorticoid injections within three months prior to surgery. (See",
"      <a class=\"local\" href=\"#H3965855\">",
"       'Intra-articular and spinal glucocorticoid injections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first step in the evaluation of the HPA axis is a morning (8 AM) serum cortisol (24-hour off glucocorticoid replacement dose).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the 8 AM cortisol is &lt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (138",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      the patient is likely to have a suppressed HPA axis and we therefore suggest additional glucocorticoid intake perioperatively (",
"      <a class=\"graphic graphic_table graphicRef69479 \" href=\"UTD.htm?5/17/5403\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the 8 AM cortisol is &gt;10",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (275",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      the patient likely does",
"      <strong>",
"       not",
"      </strong>",
"      have a significant impairment of the HPA axis and the patient may be continued on his current glucocorticoid replacement dose on the day of surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If 8 AM cortisol level is between 5 to 10",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (138 to 275",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      we suggest further evaluation with an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      (if time permits) or empiric additional glucocorticoid therapy (",
"      <a class=\"graphic graphic_table graphicRef69479 \" href=\"UTD.htm?5/17/5403\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who undergo a standard 250 mcg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      , if serum cortisol is &lt;18 (497",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      in response to ACTH, we suggest perioperative glucocorticoid coverage (",
"      <a class=\"graphic graphic_table graphicRef69479 \" href=\"UTD.htm?5/17/5403\">",
"       table 2",
"      </a>",
"      ). For those with a serum cortisol response &gt;18 (497",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      no coverage is needed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212862\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to acknowledge Dr. Gail Welsh, Dr. Ellen Manzullo, and Dr. Lynnette Nieman, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/1\">",
"      Bromberg JS, Alfrey EJ, Barker CF, et al. Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation 1991; 51:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/2\">",
"      Salem M, Tainsh RE Jr, Bromberg J, et al. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 1994; 219:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/3\">",
"      Shaw M, Mandell BF. Perioperative management of selected problems in patients with rheumatic diseases. Rheum Dis Clin North Am 1999; 25:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/4\">",
"      FRASER CG, PREUSS FS, BIGFORD WD. Adrenal atrophy and irreversible shock associated with cortisone therapy. J Am Med Assoc 1952; 149:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/5\">",
"      LEWIS L, ROBINSON RF, YEE J, et al. Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment. Ann Intern Med 1953; 39:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/6\">",
"      Axelrod L. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet 1983; 1:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/7\">",
"      Mathis AS, Shah NK, Mulgaonkar S. Stress dose steroids in renal transplant patients undergoing lymphocele surgery. Transplant Proc 2004; 36:3042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/8\">",
"      Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery 1997; 121:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/9\">",
"      Shapiro R, Carroll PB, Tzakis AG, et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/10\">",
"      Bromberg JS, Baliga P, Cofer JB, et al. Stress steroids are not required for patients receiving a renal allograft and undergoing operation. J Am Coll Surg 1995; 180:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/11\">",
"      Friedman RJ, Schiff CF, Bromberg JS. Use of supplemental steroids in patients having orthopaedic operations. J Bone Joint Surg Am 1995; 77:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/12\">",
"      Thomason JM, Girdler NM, Kendall-Taylor P, et al. An investigation into the need for supplementary steroids in organ transplant patients undergoing gingival surgery. A double-blind, split-mouth, cross-over study. J Clin Periodontol 1999; 26:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/13\">",
"      Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997; 337:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/14\">",
"      Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/15\">",
"      de Lange DW, Kars M. Perioperative glucocorticosteroid supplementation is not supported by evidence. Eur J Intern Med 2008; 19:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/16\">",
"      Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/17\">",
"      Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/18\">",
"      BOLLET AJ, BLACK R, BUNIM JJ. Major undesirable side-effects resulting from prednisolone and prednisone. J Am Med Assoc 1955; 158:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/19\">",
"      Schiff RL, Welsh GA. Perioperative evaluation and management of the patient with endocrine dysfunction. Med Clin North Am 2003; 87:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/20\">",
"      Wagner RL, White PF, Kan PB, et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984; 310:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/21\">",
"      Murray H, Marik PE. Etomidate for endotracheal intubation in sepsis: acknowledging the good while accepting the bad. Chest 2005; 127:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/22\">",
"      Antoni FA. Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr Rev 1986; 7:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/23\">",
"      Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 1994; 15:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/24\">",
"      Chernow B, Alexander HR, Smallridge RC, et al. Hormonal responses to graded surgical stress. Arch Intern Med 1987; 147:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/25\">",
"      Jabbour SA. Steroids and the surgical patient. Med Clin North Am 2001; 85:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/26\">",
"      Udelsman R, Norton JA, Jelenich SE, et al. Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol Metab 1987; 64:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/27\">",
"      Raff H, Norton AJ, Flemma RJ, Findling JW. Inhibition of the adrenocorticotropin response to surgery in humans: interaction between dexamethasone and fentanyl. J Clin Endocrinol Metab 1987; 65:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/28\">",
"      REDGATE ES. Spinal cord and ACTH release in adrenalectomized rats following electrical stimulation. Endocrinology 1962; 70:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/29\">",
"      Brandt M, Kehlet H, Binder C, et al. Effect of epidural analgesia on the glycoregulatory endocrine response to surgery. Clin Endocrinol (Oxf) 1976; 5:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/30\">",
"      George JM, Reier CE, Lanese RR, Rower M. Morphine anesthesia blocks cortisol and growth hormone response to surgical stress in humans. J Clin Endocrinol Metab 1974; 38:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/31\">",
"      Yong SL, Marik P, Esposito M, Coulthard P. Supplemental perioperative steroids for surgical patients with adrenal insufficiency. Cochrane Database Syst Rev 2009; :CD005367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/32\">",
"      Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976; 55:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/33\">",
"      Livanou T, Ferriman D, James VH. Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy. Lancet 1967; 2:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/34\">",
"      GRABER AL, NEY RL, NICHOLSON WE, et al. NATURAL HISTORY OF PITUITARY-ADRENAL RECOVERY FOLLOWING LONG-TERM SUPPRESSION WITH CORTICOSTEROIDS. J Clin Endocrinol Metab 1965; 25:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/35\">",
"      Westerhof L, Van Ditmars MJ, Der Kinderen PJ, et al. Recovery of adrenocortical function during long-term treatment with corticosteroids. Br Med J 1972; 2:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/36\">",
"      Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/37\">",
"      Axelrod L. Perioperative management of patients treated with glucocorticoids. Endocrinol Metab Clin North Am 2003; 32:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/38\">",
"      LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993; 95:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/39\">",
"      HARTER JG, REDDY WJ, THORN GW. STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN. N Engl J Med 1963; 269:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/40\">",
"      Fauci AS. Alternate-day corticosteroid therapy. Am J Med 1978; 64:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/41\">",
"      Ackerman GL, Nolsn CM. Adrenocortical responsiveness after alternate-day corticosteroid therapy. N Engl J Med 1968; 278:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/42\">",
"      Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg 2008; 143:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/43\">",
"      Kehlet H, Binder C. Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients. Br J Anaesth 1973; 45:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/44\">",
"      Kehlet H, Binder C. Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients. Br Med J 1973; 2:147.",
"     </a>",
"    </li>",
"    <li>",
"     Christy NP. Corticosteroid withdrawal. In: Current Therapy in Endocrinology and Metabolism, 3rd Ed, Bardin CW (Ed), BC Decker, New York 1988. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/46\">",
"      NICHOLS T, NUGENT CA, TYLER FH. DIURNAL VARIATION IN SUPPRESSION OF ADRENAL FUNCTION BY GLUCOCORTICOIDS. J Clin Endocrinol Metab 1965; 25:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/47\">",
"      Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/48\">",
"      Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/49\">",
"      Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/50\">",
"      Reeback JS, Chakraborty J, English J, et al. Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis. Ann Rheum Dis 1980; 39:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/51\">",
"      OKA M. Absorption of acetates of hydrocortisone, delta 1-hydrocortisone and cortisone from the joint cavity into the circulation. J Clin Endocrinol Metab 1958; 18:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/52\">",
"      YOUNG HH, WARD LE, HENDERSON ED. The use of hydrocortisone acetate (compound F acetate) in the treatment of some common orthopaedic conditions. J Bone Joint Surg Am 1954; 36-A:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/53\">",
"      Lansang MC, Farmer T, Kennedy L. Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections. Endocr Pract 2009; 15:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/54\">",
"      Duclos M, Guinot M, Colsy M, et al. High risk of adrenal insufficiency after a single articular steroid injection in athletes. Med Sci Sports Exerc 2007; 39:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/55\">",
"      Kay J, Findling JW, Raff H. Epidural triamcinolone suppresses the pituitary-adrenal axis in human subjects. Anesth Analg 1994; 79:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/56\">",
"      Armstrong RD, English J, Gibson T, et al. Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate. Ann Rheum Dis 1981; 40:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/57\">",
"      H&auml;gg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf) 1987; 26:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/58\">",
"      Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab 2003; 88:4193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/59\">",
"      Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test. Horm Metab Res 2009; 41:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/60\">",
"      Endert E, Ouwehand A, Fliers E, et al. Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency. Neth J Med 2005; 63:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/61\">",
"      Dekkers OM, Timmermans JM, Smit JW, et al. Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency. Eur J Endocrinol 2011; 164:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/62\">",
"      Dickstein G, Saiegh L. Low-dose and high-dose adrenocorticotropin testing: indications and shortcomings. Curr Opin Endocrinol Diabetes Obes 2008; 15:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17384/abstract/63\">",
"      Borst GC, Michenfelder HJ, O'Brian JT. Discordant cortisol response to exogenous ACTH and insulin-induced hypoglycemia in patients with pituitary disease. N Engl J Med 1982; 306:1462.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 146 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17384=[""].join("\n");
var outline_f16_62_17384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177132320\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CORTISOL SECRETION DURING STRESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECT OF EXOGENOUS GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3179742\">",
"      Nonsuppressed HPA axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3179792\">",
"      Suppressed HPA axis patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3179806\">",
"      Intermediate patients (HPA suppression unknown)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H73207804\">",
"      - Glucocorticoid use in past year",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Inhaled and topical glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3965855\">",
"      - Intra-articular and spinal glucocorticoid injections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION OF HPA AXIS SUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H884513\">",
"      Morning serum cortisol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H884520\">",
"      ACTH stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1212862\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/146|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/27/5566\" title=\"figure 1\">",
"      Prednisone metabolism toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 1\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/17/5403\" title=\"table 2\">",
"      Corticosteroid coverage surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_62_17385="Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis";
var content_f16_62_17385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17385/contributors\">",
"     Richard Lewis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17385/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17385/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/62/17385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an entity that describes a group of related neuropathies, all having chronicity, demyelination, inflammation, and immune-mediation in common.",
"   </p>",
"   <p>",
"    In the classic form of CIDP, motor involvement is greater than sensory, and neurologic deficits are fairly symmetric. Weakness is present in both proximal and distal muscles. Most patients have globally diminished or absent reflexes. Cranial nerve and bulbar involvement occur in a minority. The clinical course of CIDP is slowly progressive in a majority of patients, but a relapsing-remitting course is noted in at least one-third.",
"   </p>",
"   <p>",
"    Of major importance, CIDP generally responds to immunomodulatory treatment with glucocorticoids, intravenous immune globulin, or plasma exchange.",
"   </p>",
"   <p>",
"    The treatment and prognosis of CIDP will be reviewed here. Other aspects of CIDP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstays of treatment for CIDP are intravenous immune globulin (IVIG), glucocorticoids, and plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These treatments appear to be equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment choice is influenced by patient preference, side effects, treatment cost, duration, ease of administration, and availability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/5\">",
"     5",
"    </a>",
"    ]. Advantages and disadvantages of standard therapies for CIDP include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IVIG and plasma exchange may lead to a more rapid improvement in CIDP than glucocorticoid therapy, but are less likely than glucocorticoids to produce a remission",
"     </li>",
"     <li>",
"      IVIG is expensive, and its supply is sometimes limited",
"     </li>",
"     <li>",
"      Glucocorticoids are inexpensive, but chronic use is limited by common and clinically important side effects",
"     </li>",
"     <li>",
"      Plasma exchange is expensive, invasive, and available only at specialized centers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized controlled trials and systematic reviews have established that intravenous immune globulin (IVIG) is effective for the short term treatment of CIDP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/2,5,7-11\">",
"     2,5,7-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review and meta-analysis published in 2009 identified five trials with a total of 235 subjects that compared IVIG with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, the review identified one trial [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/3\">",
"       3",
"      </a>",
"      ] that compared IVIG with plasma exchange, and another [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/4\">",
"       4",
"      </a>",
"      ] that compared IVIG with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      . The following observations were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The rate of disability improvement within one month after treatment was significantly higher with IVIG than with placebo (relative risk [RR] 2.4, 95% CI 1.72-3.36). To obtain improvement in one patient, the number needed to treat (NNT) was 3. Overall, IVIG improved disability for at least two to six weeks.",
"     </li>",
"     <li>",
"      The benefit of IVIG was similar to that of plasma exchange and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial included in the meta-analysis was the double-blind multicenter ICE study, in which 117 patients with CIDP were randomly assigned to treatment with either IVIG or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/11\">",
"       11",
"      </a>",
"      ]. IVIG was given as a loading dose of 2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      over two to four days, followed by a maintenance dosing of 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      every three weeks for up to 24 weeks in the first treatment period. The following results were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The proportion of patients showing clinically meaningful improvement in disability maintained to week 24, the primary outcome measure, was significantly greater with IVIG treatment than with placebo (54 versus 21 percent), with an absolute difference of 33.5 percent (95% CI 15.4-51.7).",
"     </li>",
"     <li>",
"      During a 24 week extension phase, 57 patients who were first-period IVIG responders were randomly reassigned to IVIG or placebo. Patients who continued to receive IVIG had a significantly longer time to relapse than those reassigned to placebo during this phase, and the relapse rate was significantly lower for patients treated with IVIG (13 versus 45 percent, hazard ratio 0.19, 95% CI 0.05-0.70).",
"      <br/>",
"      <br/>",
"      Thus, the ICE study confirmed evidence from earlier trials that IVIG is effective for the treatment of CIDP. In addition, the ICE results suggested that the benefit of IVIG extends to as long as 48 weeks with maintenance treatments of 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      every three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/11\">",
"       11",
"      </a>",
"      ]. As a result of these findings, the IVIG formulation used in this trial became the first FDA-approved treatment for CIDP. However, it should be understood that there is no known difference in effectiveness between different IVIG preparations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent randomized trial of 45 adults with CIDP compared IVIG (0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    daily) with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (0.5 g daily), each given for four consecutive days every month for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/12\">",
"     12",
"    </a>",
"    ]. Discontinuation of therapy due to lack of effectiveness or intolerance during the six months of therapy, the primary outcome, was lower for the IVIG than the methylprednisolone group (3 of 24 [13 percent] versus 11 of 21 [52 percent], relative risk 0.54, 95% CI 0.34-0.87). However, during the six months after stopping therapy, the proportion of patients who deteriorated and required further therapy was greater for patients who responded to IVIG than for those who responded to methylprednisolone (8 of 21 [38 percent] versus 0 of 10 [0 percent]). The strength of these findings is limited by small patient numbers.",
"   </p>",
"   <p>",
"    While IVIG therapy can usually control CIDP, most patients require repeated expensive treatments every two to six weeks for many years, since IVIG monotherapy does not usually lead to remission. This point is illustrated by a 20-year review of 95 patients treated with IVIG for CIDP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/13\">",
"     13",
"    </a>",
"    ]. More than 75 percent of the patients improved, but of those who improved, over 85 percent required repeated treatment, while fewer than 15 percent were able to discontinue treatment at a mean of 3.5 years and median of 2.1 years. Severity at onset and residual deficit were negative predictors of discontinuation. However, the placebo effect in the ICE trial, as well as in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    trial, suggests that the number of patients who remain stable after discontinuation of IVIg may be significantly greater than 15 percent.",
"   </p>",
"   <p>",
"    IVIG should be used cautiously in patients with severe kidney disease because of its association with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/6\">",
"     6",
"    </a>",
"    ]. Only formulations without sucrose and with low osmolality should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Dose and side effects of IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of IVIG is 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    infused over two to five days (eg, 0.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day for five days). Observation should determine if the treatment is effective. Benefit may not be apparent after the first course of IVIG treatment, and some experts advocate repeating infusion of IVIG (1",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    three weeks after the initial treatment before determining efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients with CIDP require repeat IVIG maintenance dosing every two to six weeks. For patients who respond well to initial treatment and remain clinically stable, the maintenance dose can be tapered to 1.0",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    or as low as 0.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per dose, given over one to two days. The taper dose and frequency of IVIG should be adjusted so that the patient does not deteriorate between doses.",
"   </p>",
"   <p>",
"    Side effects of IVIG include headache, nausea, fever, aseptic meningitis, rash, acute renal failure (mostly related to sucrose containing products), and rarely hyperviscosity. IgA deficiency can lead to anaphylaxis in patients treated with IVIG.",
"   </p>",
"   <p>",
"    Hematologic side effects (eg, hemolysis, neutropenia) of IVIG are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H22#H22\">",
"     \"Intravenous immune globulin: Adverse effects\", section on 'Hematologic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonhematologic side effects of IVIG (eg, anaphylaxis, renal toxicity, aseptic meningitis) as well as the risk of thrombosis are discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of glucocorticoids for CIDP was first reported in the 1950s [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/14\">",
"     14",
"    </a>",
"    ], but no large controlled trials have been performed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small trial, 14 patients with CIDP and no prior treatment completed a three-month regimen of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , beginning with a dose of 120 mg every other day during the first week, followed by a slow taper off prednisone by the end of 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/15\">",
"       15",
"      </a>",
"      ]. Patients who received prednisone had a clinically meaningful improvement compared with 14 patients assigned to placebo. This was the only trial comparing glucocorticoids with no treatment that was eligible for inclusion in a systematic review, which concluded that it provided very low quality evidence of a beneficial effect of oral glucocorticoids for CIDP [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multicenter cross-over trial of 32 patients with CIDP, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (60 mg daily for two weeks, tapered down to 10 mg daily over one month) was compared with IVIG (2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      administered over one to two days) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/4\">",
"       4",
"      </a>",
"      ]. Both treatments were associated with a significant improvement in disability, and there was no significant difference between the two treatment groups.",
"     </li>",
"     <li>",
"      Substantial data from retrospective series suggest that oral glucocorticoids are beneficial for CIDP [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/17-21\">",
"       17-21",
"      </a>",
"      ]. The maximum benefit of glucocorticoid therapy in these studies was seen after one to six months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/6\">",
"       6",
"      </a>",
"      ]. However, relapses were common, particularly when tapering the dose [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical experience suggests that glucocorticoid therapy is more likely to produce a clinical remission than either IVIG or plasma exchange.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing of glucocorticoids is not agreed upon. There are several equally reasonable ways to start and then taper the dose. Regimens including daily and alternate day oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , weekly pulse oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , and weekly or monthly pulse intravenous methylprednisolone. How fast to taper and when to taper depend on a variety of factors.",
"   </p>",
"   <p>",
"    Chronic glucocorticoid use is limited by common and clinically important side effects that include weight gain, cushingoid appearance, easy bruising and skin fragility, cataracts, aseptic necrosis of the femoral or humeral heads, hypertension, diabetes, and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, glucocorticoid therapy is generally contraindicated in patients with peptic ulcer disease, brittle diabetes, refractory hypertension, severe osteoporosis, and systemic fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether to use daily, alternate-day, or pulsed oral glucocorticoids is determined by the individual nature of the patient's medical health and the severity and pattern of CIDP.",
"   </p>",
"   <p>",
"    In the PREDICT study, 40 patients with newly diagnosed, naive CIDP were randomly assigned to treatment with either high-dose pulsed oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (40 mg daily for four days followed by placebo for 24 days, repeated for six cycles) or daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (starting with 60 mg daily for five weeks and tapering to alternate day doses and then to zero over the following 27 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/22\">",
"     22",
"    </a>",
"    ]. For the primary endpoint, the remission rate at 12 months, there was no significant difference between the pulsed high-dose dexamethasone and standard prednisolone treatment groups (10 of 24 [42 percent] versus 6 of 16 [38 percent], odds ratio 1.19, 95% CI 0.3-4.4). While this study did not show an advantage for pulsed dexamethasone, it does provide an alternative regimen for giving glucocorticoids that may be useful for some patients. Some practitioners believe that weight gain and cushingoid side effects are less with pulsed glucocorticoid treatment, while sleep and psychologic effects may be greater.",
"   </p>",
"   <p>",
"    Although less well-studied, retrospective evidence suggests that weekly pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (500 mg once a week) is also an effective option for long-term treatment of CIDP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternate-day glucocorticoid therapy may reduce the incidence of side effects, but some experts believe it is less effective than a daily dosing regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/6\">",
"     6",
"    </a>",
"    ]. Daily dosing may be preferred for younger patients and those patients with little in the way of side effects. In addition, daily dosing may be preferred in patients with diabetes, so that there is a more even daily effect on blood sugars.",
"   </p>",
"   <p>",
"    One suggested oral regimen is to start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily (usually around 50 to 80 mg daily; no more than 100 mg). The dose is then titrated according to clinical response. Patients who have a good response can begin dose tapering after one to three months.",
"   </p>",
"   <p>",
"    Glucocorticoid tapering can be done in many ways and should be individualized as a daily or every other day regimen. The dose can be tapered by 5 to 10 mg every two to four weeks in clinically stable patients.",
"   </p>",
"   <p>",
"    As an example, with the every other day regimen, the taper from 80 mg daily would begin with 80 mg alternating with 60 mg, then a month later to 80 mg alternating with 40 mg, and eventually to 80 mg alternating with 0 mg. Tapering of the high-dose day would then commence. We suggest slowing down the rate of the taper once a dose of 30 mg every other day (or 15 mg daily) is reached. It is usually necessary to go back up to a higher dose by at least 10 to 20 mg if symptoms recur during the taper.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intravenous",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with oral glucocorticoid therapy, there is no standard regimen for pulse IV glucocorticoids. One suggested regimen is an initial dose of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for three days, followed by 1000 mg one day a week [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/24\">",
"     24",
"    </a>",
"    ]. Tapering is accomplished by slowly decreasing the frequency of dosing to once every 2 to 12 weeks",
"   </p>",
"   <p>",
"    Limited observational data suggest that IV and oral glucocorticoid regimens are equally effective, but that IV therapy is associated with less weight gain and fewer cushingoid features, but possibly more restlessness and sleep problems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small randomized clinical trials have found that plasma exchange is effective for the short term treatment of CIDP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. These trials were the only ones identified as eligible in a systematic review and meta-analysis of plasma exchange for the treatment of CIDP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the meta-analysis, the following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was significantly more improvement (using an impairment scale score) during or after plasma exchange than after sham exchange",
"     </li>",
"     <li>",
"      Overall, about two-thirds of patients initially improved with plasma exchange",
"     </li>",
"     <li>",
"      In one of the included trials, relapses of CIDP occurred in 8 of 12 patients (67 percent) who initially responded to plasma exchange, and in seven of these patients, the relapse occurred within a week or two after stopping plasma exchange [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of observational studies have also found that plasma exchange is effective for CIDP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/28-34\">",
"     28-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like IVIG, treatment with plasma exchange alone is unlikely to lead to remission, and plasma exchange has the added concerns of an invasive procedure that requires repeated venous access and (often) indwelling catheters that are susceptible to clotting and infection. In addition, plasma exchange is available only at specialized centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Regimens and side effects of plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with CIDP and severe disability, we suggest plasma exchange beginning with four to six exchanges over 8 to 10 days. The plasma exchange schedule after that depends on clinical response, but can usually be decreased to one exchange every three to four weeks. However, if symptoms occur between treatments, the schedule would be modified to eliminate the interval changes. The implementation of therapeutic plasma exchange, including techniques and regimens, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main complications of plasma exchange are hypotension, sepsis, and problems with intravenous access. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other immune modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;New CIDP therapies are needed that are more effective, more specific, more cost effective, and less toxic than currently available treatments (ie, IVIG, glucocorticoids, and plasma exchange).",
"   </p>",
"   <p>",
"    A number of immunosuppressive agents have been reported to be beneficial for CIDP in observational studies, but none have been rigorously studied in randomized controlled trials with enough power to provide convincing evidence of effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The list of immune modulator drugs that have been used to treat CIDP includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/20,21,36-38\">",
"       20,21,36-38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/21,39-43\">",
"       21,39-43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/44-47\">",
"       44-47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interferon alpha-2a [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       Interferon beta-1a",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/53-55\">",
"       53-55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/56-58\">",
"       56-58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/59-63\">",
"       59-63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/64\">",
"       64",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While many of these agents remain promising, evidence from larger clinical trials is needed to determine whether they are effective for CIDP. Of note, a small randomized placebo-controlled trial in patients with CIDP requiring intravenous immune globulin or glucocorticoids found no significant benefit for oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (15 mg weekly) on any of the primary or secondary outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/57\">",
"     57",
"    </a>",
"    ]. However, there was a remarkably high placebo effect suggesting that the design of the trial may have contributed to the inability to find benefit from the drug. Thus, the role of methotrexate in CIDP remains unproven.",
"   </p>",
"   <p>",
"    Historically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have probably been the most commonly used drugs for CIDP from this list.",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/21,39,40,42,43\">",
"     21,39,40,42,43",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/41\">",
"     41",
"    </a>",
"    ] studies have found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may be effective for CIDP, and a systematic review concluded that the available observational studies suggest that cyclophosphamide treatment is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/35\">",
"     35",
"    </a>",
"    ]. These studies included intravenous pulse regimens and oral daily regimens of cyclophosphamide for patients who failed other therapies. Some of the responses were quite remarkable and sustained [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of this,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has been advocated, despite its potential toxicity, for patients with severe disease refractory to other treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/43\">",
"     43",
"    </a>",
"    ], and high-dose cyclophosphamide therapy has used in attempt to reset the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Both moderate (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    monthly for six months) and very high-dose (eg, 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered over one hour intravenously for four days) cyclophosphamide regimens may induce a remission of the disease. However, cyclophosphamide treatment is associated with potentially life-threatening side effects and should therefore be carefully considered and performed only at specialized centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choosing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some patients with CIDP who have such mild disease with minimal impact on function and quality of life that treatment is not required. However, most patients are significantly impaired by the disorder, and for these patients we recommend initial immune modulating treatment using either IVIG, glucocorticoids, or plasma exchange.",
"   </p>",
"   <p>",
"    The initial choice among these equally effective therapies is influenced by disease severity, concurrent illness, venous access, treatment side effects, availability, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with severe and fulminant CIDP, we suggest treatment with a rapid immune modulating therapy such as IVIG or plasma exchange rather than glucocorticoids. We prefer initial treatment with IVIG if available because it is usually easier to administer than plasma exchange.",
"     </li>",
"     <li>",
"      For patients with more insidious CIDP, where the goal is to achieve remission, we suggest initial therapy with glucocorticoids or an alternative immunosuppressive drug without IVIG or plasma exchange. A glucocorticoid course of up to 12 weeks on the starting dose may be required to decide whether there is a treatment response [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/1\">",
"       1",
"      </a>",
"      ]. Alternative immunosuppressive agents are employed when glucocorticoids are contraindicated or considered too risky; choices include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . As already noted, the effectiveness of these drugs for CIDP is not established.",
"     </li>",
"     <li>",
"      For patients who fail to respond to the initial mode of therapy, a different therapy should be substituted. The criteria for treatment effect vary per patient. Some patients may not improve, but the treatment may still be considered effective if the disease stabilizes without developing progressive deficits. Some abnormalities, due to severe axonal loss, may be fixed deficits and will not respond to highly effective treatments. It is important for the clinician and patient to be clear on what is likely to respond. &nbsp;In addition, patients and clinicians need to understand that there may be improvements in energy and well being that do not necessarily point to an effect on the disease itself.",
"      <br/>",
"      <br/>",
"      As an example of treatment substitution, failure to respond to IVIG might trigger intervention with plasma exchange",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunosuppression with glucocorticoids. The potential yield of this approach is illustrated by a series of patients with CIDP that included 26 who did not respond to initial therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/34\">",
"       34",
"      </a>",
"      ]. Of these, benefit from an alternative treatment was observed in nine (35 percent). For 11 patients who required a third alternative treatment, benefit was observed in three (17 percent).",
"     </li>",
"     <li>",
"      A small portion of patients (&lt;20 percent) who respond to the initial therapy may need no further treatment. However, most patients will relapse sooner or later, and those who respond to IVIG or plasma exchange may require repeated treatment at intervals that typically range from two to six weeks. Similarly, relapses are common with glucocorticoid therapy, particularly when tapering the dose. Thus, for patients with CIDP who relapse after responding to initial therapy, we suggest repeating the initially successful treatment modality. For patients on glucocorticoid therapy who relapse, stopping the taper and increasing the dose is suggested. The timing and dose of ongoing intermittent treatments should be titrated to avoid relapses.",
"     </li>",
"     <li>",
"      For patients initially treated with IVIG who continue to require high doses for many months, we suggest adding glucocorticoid therapy or an alternative immunosuppressant. Similarly, we suggest adding glucocorticoid therapy for patients initially treated with plasma exchange who require frequent treatments over many months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suggested doses of IVIG, plasma exchange, and glucocorticoids are discussed in the appropriate sections above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Intravenous immune globulin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Glucocorticoids'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Plasma exchange'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of CIDP in pregnancy is similar to that outlined above.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids are frequently used in pregnancy and are safe for the fetus.",
"     </li>",
"     <li>",
"      Plasmapheresis is also considered safe for use in pregnancy, although not without potential complications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Regimens and side effects of plasma exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous immune globulin is generally safe but is associated with potential side effects that might be a particular concern during pregnancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dose and side effects of IVIG'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice among these therapeutic options should be coordinated with the obstetrician. The risks and benefits of these treatments appear to be finely balanced, and the decision is influenced by local availability, clinical expertise, and patient preferences.",
"   </p>",
"   <p>",
"    Other immunosuppressants drugs discussed above are NOT recommended for use in pregnancy, particularly early in pregnancy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Other immune modulators'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe CIDP who are refractory to treatment with IVIG, glucocorticoids, and plasma exchange, and are also refractory to glucocorticoids combined with IVIG or plasma exchange, alternative immunosuppressant treatment options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . The choice among these is dependent on a number of factors that include the expertise of the treating center and clinician, side effect profiles of the alternative treatments, disease severity, age and sex of patient, and concurrent medical problems.",
"   </p>",
"   <p>",
"    Among these choices, our preferred alternative treatment for patients with no contraindications is oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (7.5 to 15 mg once a week). Patients treated with methotrexate should receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    1 mg daily, or folinic acid 2.5 mg weekly, to prevent hematologic and other side effects. It is unclear whether a response to methotrexate occurs within three or four months or takes longer. We suggest at least a four month trial, if the clinical condition allows.",
"   </p>",
"   <p>",
"    For patients with moderately severe disease who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , our preferred alternative treatment is a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Keeping plasma trough levels between 100 and 150",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    may help ensure a therapeutic response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Improvement with cyclosporine therapy may occur within three months. However, the side effect profile for cyclosporine is greater than for methotrexate.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is used as a steroid sparing medication or reserved for patients with mild disease; a therapeutic response may take over six months. An alternative is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and clinical improvement with this agent may also take a long time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately two-thirds of patients with CIDP will initially respond to any single standard therapy (IVIG, glucocorticoid, and plasma exchange), while about 10 to 15 percent of patients are resistant to all of these. However, data are limited regarding the long-term prognosis of CIDP.",
"   </p>",
"   <p>",
"    One of few studies examining long-term outcome reviewed 38 Japanese patients with CIDP who had at least five years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/67\">",
"     67",
"    </a>",
"    ]. These patients had been treated with various regimens, including glucocorticoids (89 percent), IVIG (45 percent), and plasma exchange (34 percent).",
"   </p>",
"   <p>",
"    The following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17385/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete remission, defined as lasting more than two years with normal nerve conduction studies, was noted in 10 patients (26 percent)",
"     </li>",
"     <li>",
"      Partial remission, defined as able to walk, was noted in 23 (61 percent). In this group, there were 13 patients who had stopped immune modulating treatments, and 10 patients who required intermittent or continuous therapy, mainly glucocorticoids",
"     </li>",
"     <li>",
"      Severe disability (unable to walk) or relapses related to tapering of medication were present in five (13 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with CIDP who have clinically significant disability, we recommend immune modulating treatment using either intravenous immune globulin (IVIG), glucocorticoids, or plasma exchange (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Plasma exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe and fulminant CIDP, we suggest treatment with a rapid immune modulating therapy such as IVIG or plasma exchange rather than glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We prefer initial treatment with IVIG if available because it is usually easier to administer than plasma exchange. For patients with more insidious CIDP, where the goal is to achieve remission, we suggest initial therapy with glucocorticoids with or without IVIG or plasma exchange (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail to respond to the initial mode of therapy, we would substitute and alternative treatment. As an example, failure to respond to IVIG triggers intervention with plasma exchange or glucocorticoids. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with CIDP who respond to initial IVIG or plasmapheresis therapy will relapse when the therapy is discontinued and will require treatment. For such patients, we retreat and suggest repeating the initially successful treatment modality (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients on glucocorticoid therapy who relapse, stopping the taper",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increasing the dose is reasonable. The timing and dose of ongoing intermittent treatments should be titrated to avoid relapses. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CIDP initially treated with IVIG who require high dose therapy for many months, we suggest adding glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Similarly, we suggest adding glucocorticoid therapy for patients initially treated with plasma exchange who require frequent treatments over many months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe CIDP who are refractory to treatment with IVIG, glucocorticoids, and plasma exchange, and are also refractory to glucocorticoids combined with IVIG or plasma exchange, or have unacceptable side effects with these regimens, we suggest treatment with an alternative immunosuppressant (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . The choice among these agents must be individualized. Patients should be informed that the benefit of these therapies for CIDP is unproven, and that these treatments are associated with a risk of serious side effects. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other immune modulators'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the long-term prognosis of CIDP is generally favorable, data are limited, and up to 15 percent of patients are severely disabled despite treatment. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/1\">",
"      Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010; 17:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/2\">",
"      Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/3\">",
"      Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/4\">",
"      Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/5\">",
"      Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009; :CD001797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/6\">",
"      Ropper AH. Current treatments for CIDP. Neurology 2003; 60:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/7\">",
"      Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/8\">",
"      Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996; 243:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/9\">",
"      Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119 ( Pt 4):1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/10\">",
"      Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/11\">",
"      Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/12\">",
"      Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/13\">",
"      van Doorn PA, Dippel DWJ, van Burken MMG, et al. Longterm IV Immunoglobulin treatment in CIDP. J Periph Nerv Syst 2003; 8 Suppl 1:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/14\">",
"      AUSTIN JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958; 81:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/15\">",
"      Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/16\">",
"      Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2012; 8:CD002062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/17\">",
"      DeVivo DC, Engel WK. Remarkable recovery of a steroid-responsive recurrent polyneuropathy. J Neurol Neurosurg Psychiatry 1970; 33:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/18\">",
"      Oh SJ. Subacute demyelinating polyneuropathy responding to corticosteroid treatment. Arch Neurol 1978; 35:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/19\">",
"      Wertman E, Argov Z, Abrmasky O. Chronic inflammatory demyelinating polyradiculoneuropathy: features and prognostic factors with corticosteroid therapy. Eur Neurol 1988; 28:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/20\">",
"      Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/21\">",
"      McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110 ( Pt 6):1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/22\">",
"      van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/23\">",
"      Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008; 65:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/24\">",
"      Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005; 62:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/25\">",
"      Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/26\">",
"      Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119 ( Pt 4):1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/27\">",
"      Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2012; 9:CD003906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/28\">",
"      Levy RL, Newkirk R, Ochoa J. Treating chronic relapsing Guillain-Barr&eacute; syndrome by plasma exchange. Lancet 1979; 2:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/29\">",
"      Server AC, Lefkowith J, Braine H, McKhann GM. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979; 6:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/30\">",
"      Gross ML, Thomas PK. The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J Neurol Sci 1981; 52:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/31\">",
"      Toyka KV, Augspach R, Wieth&ouml;lter H, et al. Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic humoral factor. Muscle Nerve 1982; 5:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/32\">",
"      Pollard JD, McLeod JG, Gatenby P, Kronenberg H. Prediction of response to plasma exchange in chronic relapsing polyneuropathy. A clinico-pathological correlation. J Neurol Sci 1983; 58:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/33\">",
"      Pollard JD. A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies. Muscle Nerve 1987; 10:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/34\">",
"      Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/35\">",
"      Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2010; :CD003280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/36\">",
"      Dyck PJ, O'Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/37\">",
"      Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995; 118 ( Pt 2):359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/38\">",
"      Monaco S, Turri E, Zanusso G, Maistrello B. Treatment of inflammatory and paraproteinemic neuropathies. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/39\">",
"      Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976; 27:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/40\">",
"      Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 51:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/41\">",
"      Bouchard C, Lacroix C, Plant&eacute; V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999; 52:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/42\">",
"      Brannagan TH 3rd, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002; 58:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/43\">",
"      Gladstone DE, Prestrud AA, Brannagan TH 3rd. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005; 10:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/44\">",
"      Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1990; 53:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/45\">",
"      Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998; 21:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/46\">",
"      Matsuda M, Hoshi K, Gono T, et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004; 224:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/47\">",
"      Odaka M, Tatsumoto M, Susuki K, et al. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 2005; 76:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/48\">",
"      Chin RL, Sherman WH, Sander HW, et al. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003; 210:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/49\">",
"      Gorson KC, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998; 50:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/50\">",
"      Pavesi G, Cattaneo L, Marbini A, et al. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002; 249:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/51\">",
"      Hughes RA, Gorson KC, Cros D, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/52\">",
"      Hadden RD, Sharrack B, Bensa S, et al. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/53\">",
"      Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002; 9:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/54\">",
"      Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004; 63:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/55\">",
"      Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry 2010; 81:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/56\">",
"      Fialho D, Chan YC, Allen DC, et al. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry 2006; 77:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/57\">",
"      RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/58\">",
"      D&iacute;az-Manera J, Rojas-Garc&iacute;a R, Gallardo E, Illa I. Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient. Muscle Nerve 2009; 39:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/59\">",
"      Knecht H, Baumberger M, Tob&ograve;n A, Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004; 63:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/60\">",
"      Briani C, Zara G, Zambello R, et al. Rituximab-responsive CIDP. Eur J Neurol 2004; 11:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/61\">",
"      Gono T, Matsuda M, Shimojima Y, et al. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. J Clin Neurosci 2006; 13:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/62\">",
"      Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/63\">",
"      M&uuml;nch C, Anagnostou P, Meyer R, Haas J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 2007; 256:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/64\">",
"      Ahlm&eacute;n J, Andersen O, Hallgren G, Peilot B. Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998; 30:4194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/65\">",
"      Lewis RA, Lisak RP. \"Rebooting\" the immune system with cyclophosphamide: taking risks for a \"cure\"? Ann Neurol 2003; 53:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/66\">",
"      Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 2008; 1132:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17385/abstract/67\">",
"      Kuwabara S, Misawa S, Mori M, et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 2006; 77:66.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5265 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17385=[""].join("\n");
var outline_f16_62_17385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Dose and side effects of IVIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Oral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intravenous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Regimens and side effects of plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other immune modulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choosing therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_62_17386="Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis";
var content_f16_62_17386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17386/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17386/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17386/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17386/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17386/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17386/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17386/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/62/17386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/62/17386/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/62/17386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H182265351\">",
"    <span class=\"h1\">",
"     NEW TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2011, the Boards of Directors of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener&rsquo;s granulomatosis be changed to granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This change reflects a plan to gradually shift from honorific eponyms to a disease-descriptive or etiology-based nomenclature. The parenthetic reference to Wegener&rsquo;s will be phased out after several years as the new name becomes more widely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (Wegener&rsquo;s), which can be abbreviated as GPA, microscopic polyangiitis (MPA), the Churg-Strauss syndrome (CSS) and renal limited vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. All are associated with antineutrophil cytoplasmic antibodies (ANCA) and have similar features on renal histology (eg, a focal necrotizing, often crescentic, pauci-immune glomerulonephritis).",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of GPA, MPA, and renal limited vasculitis are reviewed here. Churg-Strauss syndrome has a different presentation and prognosis compared with the other ANCA vasculitides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=see_link\">",
"     \"Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to antineutrophil cytoplasmic antibodies, the pathogenesis of ANCA vasculitides, and the vasculitides in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698510\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been several attempts to standardize the classification and diagnostic criteria for small vessel vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. However, as will be described, the classification algorithms have important limitations. (See",
"    <a class=\"local\" href=\"#H271324763\">",
"     'Limitations of classification algorithms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698517\">",
"    <span class=\"h2\">",
"     ACR criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Rheumatology (ACR) 1990 criteria were only aimed at defining classification criteria for granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, prior to the broader separation of microscopic polyangiitis (MPA) from GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, the ACR criteria included any abnormal chest finding, including infiltrates, any abnormal urinary sediment, and nasal or oral inflammation. The ACR criteria have less value in separating MPA from GPA.",
"   </p>",
"   <p>",
"    The ACR proposed the following clinical criteria to facilitate standardization of patients enrolled in studies of GPA and to help distinguish these patients from those with other forms of vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasal or oral inflammation (painful or painless oral ulcers or purulent or bloody nasal discharge)",
"     </li>",
"     <li>",
"      Abnormal chest radiograph showing nodules, fixed infiltrates, or cavities",
"     </li>",
"     <li>",
"      Abnormal urinary sediment (microscopic hematuria with or without red cell casts)",
"     </li>",
"     <li>",
"      Granulomatous inflammation on biopsy of an artery or perivascular area",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of two or more of these four criteria yielded a sensitivity of 88 percent and a specificity of 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/6\">",
"     6",
"    </a>",
"    ]. Since the ACR did not establish specific criteria for MPA, these criteria did",
"    <strong>",
"     not",
"    </strong>",
"    discriminate GPA from either MPA or non-vasculitic diseases that can mimic GPA. (See",
"    <a class=\"local\" href=\"#H11699683\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698524\">",
"    <span class=\"h2\">",
"     Chapel Hill Consensus Conference (CHCC) criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CHCC provided definitions of disease, but not classification criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/4\">",
"     4",
"    </a>",
"    ]. These definitions have gained wide acceptance in defining vasculitides by pathology, including the size of affected vessels and the organ systems involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GPA, MPA, and Churg-Strauss syndrome (CSS) were distinguished from other systemic small vessel vasculitides by the absence of immune deposits.",
"     </li>",
"     <li>",
"      MPA was distinguished from GPA and CSS by the absence of granuloma formation and the presence of a necrotizing vasculitis.",
"     </li>",
"     <li>",
"      The potential value of ANCA serology was noted but not included as a criterion for diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698531\">",
"    <span class=\"h2\">",
"     European Medicines Agency algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Medicines Agency (EMA) algorithm combined in a step-wise manner the criteria for CSS followed by the ACR criteria and CHCC definitions for GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/7\">",
"     7",
"    </a>",
"    ]. The diagnosis of MPA was made only after CSS and GPA were excluded. Using this algorithm, fixed infiltrates that are present on chest x-ray for over one month result in a classification of GPA even though fixed infiltrates are most likely to be caused by pulmonary capillaritis on pathologic examination.",
"   </p>",
"   <p>",
"    It was suggested that the following surrogate markers might permit the diagnosis of GPA to be made in the",
"    <strong>",
"     absence",
"    </strong>",
"    of a biopsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower airways: x-ray evidence of fixed pulmonary infiltrates, nodules, or cavitations for more than one month, or bronchial stenosis",
"     </li>",
"     <li>",
"      Upper airways: bloody nasal discharge and crusting for more than one month or nasal ulceration; chronic sinusitis, otitis media or mastoiditis for more than three months; retro-orbital mass on inflammation; subglottic stenosis; saddle nose",
"      <span class=\"nowrap\">",
"       deformity/destructive",
"      </span>",
"      sinonasal disease",
"     </li>",
"     <li>",
"      Glomerulonephritis: hematuria associated with red cell casts or &gt;10 dysmorphic red cells; or 2+ hematuria or 2+ proteinuria on dipstick",
"     </li>",
"     <li>",
"      ANCA was included as a diagnostic criterion. A positive ANCA in a patient with surrogate markers for GPA allowed a diagnosis of GPA without a biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of this algorithm permitted the classification of patients with a correlation between observers of 91.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/7\">",
"     7",
"    </a>",
"    ] and resulted in fewer unclassified patients than either the ACR criteria or CHCC definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/8\">",
"     8",
"    </a>",
"    ]. However, most patients who have MPA would be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271324763\">",
"    <span class=\"h2\">",
"     Limitations of classification algorithms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Chapel Hill Consensus Conference (CHCC) provided definitions for GPA, MPA, and the CSS so that each disorder could be distinguished from the others [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/4\">",
"     4",
"    </a>",
"    ]. Using this approach, patients were diagnosed with MPA if there was no pathological evidence for GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/9\">",
"     9",
"    </a>",
"    ]. In clinical practice, patients are classified as having GPA if they have destruction in their upper respiratory tract",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nodules in cavities in the lower respiratory tract,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have granulomatosis on biopsy of any organ. Thus, patients who have nasal disease and necrotizing vasculitis on biopsy, but no evidence of granulomatosis, would be classified as having MPA.",
"   </p>",
"   <p>",
"    None of the algorithms reliably distinguishes between GPA and MPA in all patients. The defining pathological difference between GPA and MPA is the presence of granulomatous changes on biopsy, which may be missed due to sampling error. As described below, there is significant overlap in the signs and symptoms and in the ANCA serologies between GPA and MPA. (See",
"    <a class=\"local\" href=\"#H11698538\">",
"     'Clinical presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The inability to establish a specific diagnosis may be important clinically since the extrarenal manifestations, such as lesions of the upper airway, may require different therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/10\">",
"     10",
"    </a>",
"    ] and the rate of relapse is different [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/5\">",
"     5",
"    </a>",
"    ]. A critical analysis of the definition of GPA or MPA did not predict long-term outcome or relapse propensity in a cohort of patients followed in the southeastern United States. [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/5\">",
"     5",
"    </a>",
"    ]. In the absence of clearly accepted criteria for allocation of patients into specific disease categories, the use of the terms GPA and MPA will remain controversial, and may differ on the basis of geography and specialty [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative approach to classification is based upon ANCA serology. The rationale for an ANCA-based classification is based upon the dual premises that patients who have proteinase 3 or myeloperoxidase ANCA have more closely associated disease findings and that respective ANCA subtypes have better predictive value with respect to long-term outcome and relapse propensity than do either the terms GPA or CSS. Patients who are ANCA-negative can have either a GPA or MPA phenotype. However, immunosuppressive therapy is the same for patients with GPA or MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H4#H4\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A proposal has been made to obviate the problems with the ACR criteria, the CHCC definitions, and the EMA algorithm by using the terms proteinase 3 ANCA disease, myeloperoxidase ANCA disease, and seronegative ANCA disease. With this approach, no diagnostic criteria are needed other than serological findings. The fact that proteinase 3 ANCA and myeloperoxidase ANCA have more prognostic significance than the terms MPA and GPA with respect to response to therapy, propensity for relapse, and patient outcome support this proposed change in classification [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. In addition, genetic variants that are associated with ANCA disease are more specifically linked with the antigen (proteinase 3 versus myeloperoxidase) rather than with the clinical phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698538\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener&rsquo;s) or microscopic polyangiitis (GPA or MPA) mostly occurs in older adults, although it has been reported at all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Both genders are equally affected and the disease is far more common among white individuals; in a study of patients identified through the Glomerular Disease Collaborative Network, 89 percent of patients were white compared to the 2:1 ratio in the renal biopsy population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically present with constitutional symptoms including fever, migratory arthralgias, malaise, anorexia and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. Prodromal symptoms may last for weeks to months without evidence of specific organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698545\">",
"    <span class=\"h2\">",
"     Ear, nose, and throat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ear, nose, and throat (ENT) manifestations occur in patients with either GPA or MPA. However, they are much more common in patients with GPA (estimated frequency 90 percent versus 35 percent in MPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/15,16,18\">",
"     15,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other ENT manifestations include nasal crusting, sinusitis, otitis media, persistent rhinorrhea,",
"    <span class=\"nowrap\">",
"     purulent/bloody",
"    </span>",
"    nasal discharge, oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nasal ulcers, and polychondritis. Patients may also describe earache, both conductive and sensorineural hearing loss, or otorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with GPA more typically have evidence of bony and cartilage destruction resulting in saddle nose deformity (",
"    <a class=\"graphic graphic_picture graphicRef80564 \" href=\"UTD.htm?8/27/8638\">",
"     picture 1",
"    </a>",
"    ), upper airway and orbital masses (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80970 \" href=\"UTD.htm?34/31/35327\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77000 \" href=\"UTD.htm?17/55/18288\">",
"     image 2",
"    </a>",
"    ), cranial nerve entrapment and subglottic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"     \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698552\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with either GPA or MPA may present with involvement of airways or pulmonary parenchyma causing hoarseness, cough, dyspnea, stridor, wheezing, hemoptysis or pleuritic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/16,20-22\">",
"     16,20-22",
"    </a>",
"    ]. These symptoms may be accompanied by signs of tracheal or subglottic stenosis, pulmonary consolidation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural effusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"     \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients may develop pulmonary fibrosis and pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/20\">",
"     20",
"    </a>",
"    ]. A detailed discussion of this issue can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"     \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chest x-ray findings are variable. Common manifestations include nodules, patchy or diffuse opacities and fleeting pulmonary infiltrates, and hilar adenopathy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67766 \" href=\"UTD.htm?25/20/25926\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55999 \" href=\"UTD.htm?42/15/43249\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link&amp;anchor=H90822068#H90822068\">",
"     \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although parenchymal lung nodules are a well recognized manifestation, ANCA vasculitis occasionally presents with tumor-like masses outside the lung. Among twenty such reported cases, the most common extrathoracic locations were the breast and kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/24\">",
"     24",
"    </a>",
"    ]. Failure to consider vasculitis in the differential diagnosis in such cases may lead to unnecessary surgery, including nephrectomy. Sometimes a diagnosis of sarcoidosis or pulmonary tuberculosis will be made mistakenly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698559\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement is common in GPA and MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/16,18,25\">",
"     16,18,25",
"    </a>",
"    ]. In studies from the National Institutes of Health in the United States, evident glomerulonephritis was present in only 18 percent of patients at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/18\">",
"     18",
"    </a>",
"    ], but glomerulonephritis subsequently developed in 77 to 85 percent of patients, usually within the first two years of disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/18,25\">",
"     18,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934555\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of the glomerulonephritis are similar to those in other causes of glomerulonephritis, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic hematuria, which may remit and relapse, in association with normal renal function. The diagnosis of ANCA-positive glomerulonephritis may be delayed in such patients in favor of a clinical diagnosis of thin basement membrane disease or IgA nephropathy. However, the risk of progression to end-stage renal disease is considerably higher in ANCA-positive disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H460669045#H460669045\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Patients with a nephritic pattern'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute kidney injury with hematuria and cellular casts",
"     </li>",
"     <li>",
"      A variable degree of proteinuria that is usually subnephrotic [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/18,22\">",
"       18,22",
"      </a>",
"      ]. Proteinuria above 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      may be more common in patients who present later in the course of disease (and therefore have more glomerulosclerosis at the time of presentation), have a second concurrent glomerular disease, or have an atypical histologic pattern characterized by glomerular immune complex deposition [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H934547\">",
"       'Concurrent glomerular disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Rapidly progressive glomerulonephritis is common in this group of diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934033\">",
"    <span class=\"h3\">",
"     Histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of the renal biopsy findings in GPA and MPA generally parallel the severity of the clinical presentation, ranging from mild focal and segmental glomerulonephritis in patients with asymptomatic hematuria and normal or near-normal renal function to a diffuse necrotizing and crescentic glomerulonephritis with patients with acute kidney injury (",
"    <a class=\"graphic graphic_picture graphicRef53506 \" href=\"UTD.htm?6/12/6345\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with GPA, but not MPA, may have granulomatous changes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/4,22\">",
"     4,22",
"    </a>",
"    ], although granulomas are rarely found in renal biopsy specimens even among patients with well-documented GPA. Arteritis is occasionally seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16241149\">",
"    <span class=\"h4\">",
"     Pauci-immune glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, the glomerulonephritis is associated with few or no immune deposits in the glomeruli (pauci-immune glomerulonephritis) on immunofluorescence and electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/4\">",
"     4",
"    </a>",
"    ]. Almost all patients with pauci-immune crescentic glomerulonephritis are ANCA-positive (96 percent in two series) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The glomerular involvement is often accompanied by mononuclear tubulointerstitial infiltrates. (See",
"    <a class=\"local\" href=\"#H3403468\">",
"     'ANCA-negative pauci-immune crescentic glomerulonephritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16241014\">",
"    <span class=\"h4\">",
"     Histologic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients have pauci-immune glomerulonephritis, some patients with ANCA-positive vasculitides have atypical pathology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some individuals present with interstitial nephritis associated with vasculitis in the vasa recta, without glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/30\">",
"       30",
"      </a>",
"      ]. Such patients may subsequently develop the classic pauci-immune necrotizing glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Other patients present with necrotizing glomerulonephritis and subsequently develop interstitial nephritis that may be drug-induced [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with small and medium sized vessel vasculitis may develop renal artery disease with aneurysms or renal artery stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/34-36\">",
"       34-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with ANCA-positive glomerulonephritis occasionally have glomerular immune complex deposition on immunofluorescence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      electron microscopy, which has been associated with more severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377577\">",
"    <span class=\"h4\">",
"     Histopathologic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic analysis of biopsy tissue by",
"    <strong>",
"     light microscopy",
"    </strong>",
"    contributes to the ability to predict renal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. A classification system of renal lesions has been developed and its predictive capability was tested in a validation study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/39\">",
"     39",
"    </a>",
"    ]. The classification identifies four categories of glomerular lesions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Focal",
"      </strong>",
"       At least 50 percent of glomeruli are normal (ie, without vasculitic lesions or global sclerosis) although there may be subtle ischemic changes or a minimum number of inflammatory cells (fewer than four neutrophils, lymphocytes or monocytes).",
"     </li>",
"     <li>",
"      <strong>",
"       Crescentic",
"      </strong>",
"       At least 50 percent of glomeruli have cellular crescents that are either cellular or fibrotic.",
"     </li>",
"     <li>",
"      <strong>",
"       Sclerotic",
"      </strong>",
"       At least 50 percent of glomeruli are globally sclerotic (def than 80 percent of glomerulus sclerosed)",
"     </li>",
"     <li>",
"      <strong>",
"       Mixed",
"      </strong>",
"       Less than 50 percent of glomeruli are normal; less than 50 percent are crescentic; and less than 50 percent are globally sclerotic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To determine the prognostic value of this classification, a validation study was performed on biopsies from 100 European patients with at least one year of follow-up. Of these, 35 patients reached end-stage renal disease in just over one year. The sequence of categories listed above corresponded to the severity of renal dysfunction at one and five years, with the best and worst renal function associated with focal and sclerotic lesions, respectively. Assessment of tubulointerstitial lesions did not independently alter the prognosis.",
"   </p>",
"   <p>",
"    In contrast, this histopathologic classification system performed less well in a Chinese population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, the serum creatinine at presentation appears to better predict outcomes in patients with ANCA-positive glomerulonephritis than the histologic classification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3403468\">",
"    <span class=\"h3\">",
"     ANCA-negative pauci-immune crescentic glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ANCA-negative, pauci-immune crescentic glomerulonephritis are considered part of the spectrum of GPA and MPA, and have similar renal biopsy findings and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there may be some differences in clinical manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121321784\">",
"    <span class=\"h3\">",
"     Renal-limited vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pauci-immune necrotizing glomerulonephritis typically occurs in association with involvement of other organs in both GPA and MPA, some patients present with a renal-limited, ANCA-positive (75 to 80 percent MPO-ANCA) vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/28,41-43\">",
"     28,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal-limited vasculitis is considered to be part of the",
"    <span class=\"nowrap\">",
"     GPA/MPA",
"    </span>",
"    spectrum because the histopathologic findings in the kidney are often indistinguishable from those in GPA and MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/43\">",
"     43",
"    </a>",
"    ] and some of these patients eventually develop extrarenal manifestations of GPA or MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/16,44\">",
"     16,44",
"    </a>",
"    ]. Patients with renal-limited vasculitis tend to have more glomerulosclerosis on renal biopsy than those with GPA, probably because patients with renal-limited disease present to a physician later in the course of the disease due to the absence of extrarenal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934547\">",
"    <span class=\"h3\">",
"     Concurrent glomerular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have two different types of glomerular disease at the same time. This general issue is discussed in detail elsewhere but it is useful to briefly review the settings in which ANCA-associated glomerulonephritis and another glomerular disease (such as membranous nephropathy) are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H96871475#H96871475\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Concurrent glomerular disease'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The following are some of the glomerular diseases that have been associated with concurrent ANCA-associated glomerulonephritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membranous nephropathy, which may represent a chance occurrence of two unrelated disease processes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link&amp;anchor=H22#H22\">",
"       \"Causes and diagnosis of membranous nephropathy\", section on 'Crescentic glomerulonephritis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lupus nephritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link&amp;anchor=H573393#H573393\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Overlap of lupus and ANCA glomerulonephritis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anti-glomerular basement membrane (GBM) antibody disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Anti-GBM antibody disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\", section on 'Antineutrophil cytoplasm antibodies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IgA nephropathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\", section on 'Clinical associations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bacterial infection-related glomerulonephritis (mostly poststreptococcal or Staphylococcus-associated) in adults",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698566\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-half of patients with GPA or MPA have cutaneous manifestations. The most common skin lesion is leukocytoclastic angiitis, which causes purpura involving the lower extremities that may be accompanied by focal necrosis and ulceration. [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/45\">",
"     45",
"    </a>",
"    ]. Skin lesions may also include urticaria, livida reticularis, and tender nodules. Occasional patients with erythema nodosum, pyoderma gangrenosum and Sweet syndrome may also have ANCA-positive disease (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=see_link\">",
"     \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698573\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other organ systems that may become involved include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/18,46,47\">",
"     18,46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eyes (conjunctivitis, corneal ulceration,",
"      <span class=\"nowrap\">",
"       episcleritis/scleritis,",
"      </span>",
"      optic neuropathy, nasolacrimal duct obstruction, proptosis, diplopia, retinal vasculitis, and uveitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/19,48,49\">",
"       19,48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nervous system (mononeuritis multiplex, cranial nerve abnormalities, central nervous system mass lesions, external ophthalmoplegia, hearing loss) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Meningeal disease is most commonly associated with granulomatous inflammation of the central nervous system. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"       \"Clinical manifestations of vasculitic neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Less commonly, the gastrointestinal tract, heart (pericarditis, myocarditis, conduction system abnormalities), lower genitourinary tract (including the ureters and prostate), parotid glands, thyroid, liver, or breast [",
"      <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with ANCA vasculitis have a high incidence of deep venous thrombosis (DVT) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. This may be due to circulating antiplasminogen antibodies, which have been demonstrated in patients with ANCA-associated vasculitis and DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\", section on 'Autoantigen complementarity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Limited form",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited form of GPA, with clinical findings isolated to the upper respiratory tract",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the lungs at diagnosis, occurs in approximately one-fourth of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients with limited disease have the following characteristics compared with those with systemic involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are younger at disease onset and more likely to be women.",
"     </li>",
"     <li>",
"      They are less likely to be ANCA positive or to have previous autoimmune thyroid disease.",
"     </li>",
"     <li>",
"      They are more likely to have chronic, recurring disease and destructive upper respiratory tract disease (saddle-nose deformity). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"       \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Up to 80 percent of patients with limited GPA eventually develop glomerulonephritis. The absence of renal involvement does not imply benign disease since involvement of other organs such as the lungs, heart, gastrointestinal tract, and central nervous system may be serious and life-threatening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11701485\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA) is important to permit initiation of therapy that may be life-saving and organ sparing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/19\">",
"     19",
"    </a>",
"    ]. This may be difficult since presenting signs and symptoms are hard to distinguish from those of a patient with non-vasculitic processes such as infection or malignancy.",
"   </p>",
"   <p>",
"    Although neither sensitive or specific, common complaints and signs of vasculitis include fatigue, weakness, fever, arthralgias, abdominal pain, hypertension, renal insufficiency (with an active urine sediment containing red and white cell and occasionally red cell casts), and neurologic dysfunction. A positive ANCA test strongly suggests the diagnosis of vasculitis but both false positive and negative results may be seen. Ultimately, histologic examination of tissue obtained by biopsy of an affected organ (generally either skin, kidney or lung) is required to make a definitive diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Does a positive ANCA obviate the need for confirmation of the diagnosis by tissue biopsy?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1414504\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful physical examination helps to determine the extent of vascular lesions, the distribution of affected organs, and the presence of additional disease processes (such as concomitant deep venous thrombosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698609\">",
"    <span class=\"h2\">",
"     Laboratory investigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ANCA test should be performed in any adult patient who presents with symptoms suggestive of a vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H20#H20\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Clinical features suggestive of vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 82 to 94 percent of patients with either GPA or MPA are ANCA positive, depending on severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. GPA is primarily associated with PR3-ANCA, while MPA is primarily associated with MPO (myeloperoxidase)-ANCA. However, 20 percent of patients with GPA or MPA have the alternative ANCA, and at least 10 percent of patients are ANCA negative [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients with renal-limited vasculitis are ANCA-positive, with 75 to 80 percent having MPO-ANCA.",
"   </p>",
"   <p>",
"    A detailed discussion of ANCA testing, including their accuracy in GPA, MPA, and renal-limited vasculitis and other disorders in which ANCA can occur (eg, infective endocarditis, drug induced vasculitis) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine laboratory and imaging tests are generally nonspecific in either GPA or MPA and are done to exclude other processes or determine extent of disease involvement. Common abnormalities include leukocytosis, thrombocytosis",
"    <span class=\"nowrap\">",
"     (&gt;400,000/microL),",
"    </span>",
"    a marked elevation in the erythrocyte sedimentation rate and C-reactive protein levels, and normochromic, normocytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other tests, including an ANA, C3 and C4, cryoglobulins, hepatitis serology, HIV screen, liver function tests and blood cultures may exclude other processes that may present with similar constitutional symptoms.",
"   </p>",
"   <p>",
"    All patients with ANCA vasculitis should have a serum creatinine and calculated estimated glomerular filtration rate checked to determine the presence of kidney injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1414163\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who are suspected of having an ANCA vasculitis should have a urinalysis, including microscopic analysis of urinary sediment, to determine presence of hematuria and proteinuria. (See",
"    <a class=\"local\" href=\"#H11698559\">",
"     'Renal disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11698616\">",
"    <span class=\"h2\">",
"     Radiographic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest x-ray and computed tomography (CT) scan should be done in all patients who have pulmonary symptoms and are suspected of having an ANCA vasculitis. Computed tomographic (CT) scanning may disclose lesions that are not seen on the plain chest x-ray, and demonstrate previously undetected nodules (particularly behind the diaphragm), unsuspected cavitation in nodules, alveolar opacities, large-airway inflammation or stenotic lesions, and pleural-based lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55999 \" href=\"UTD.htm?42/15/43249\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/23\">",
"     23",
"    </a>",
"    ]. Some clinicians obtain baseline radiographic studies (including chest x-ray and CT) in all patients who are newly diagnosed with ANCA vasculitis, prior to initiating immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H11698552\">",
"     'Pulmonary disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, the diagnosis of MPA or GPA should be confirmed by tissue biopsy at a site of active disease. However, patients should be treated empirically if the clinical suspicion for ANCA vasculitis is high and a tissue diagnosis cannot be obtained in a timely manner. Tissue for diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prognosis is usually obtained from a skin or kidney biopsy, and less commonly a nasal biopsy. Biopsy of the skin reveals a &ldquo;non-specific&rdquo; leukocytoclastic vasculitis with little or no complement and immunoglobulin on immunofluorescence.",
"   </p>",
"   <p>",
"    Renal biopsies are commonly done in patients with overt manifestations of renal disease (such as reduced estimated glomerular filtration rate or active urine sediment). Many experts however, feel that a kidney biopsy is not required for the initiation of therapy among patients who have been diagnosed with GPA or MPA using clinical and serologic features and histology analysis of tissue of another affected organ such as skin or lung. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Others'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kidney biopsy typically reveals a segmental necrotizing glomerulonephritis, often with crescents, that is usually pauci-immune on immunofluorescence or electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef53506 \" href=\"UTD.htm?6/12/6345\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/26,40,43\">",
"     26,40,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasal biopsy, although relatively noninvasive, is limited by the high rate of false negative results due to the small amount of tissue that can be removed. A typical finding on upper respiratory tract biopsies is acute and chronic inflammation either with a capillaritis or, less commonly, granulomatous features. Granulomatous inflammation is diagnostic for GPA.",
"   </p>",
"   <p>",
"    In the absence of renal involvement, the diagnosis of ANCA vasculitis may be made by lung biopsy. Lung biopsy most often requires open or thoracoscopic lung biopsy. In a small number of cases (&lt;10 percent), sufficient tissue for diagnosis can be obtained by transbronchial biopsy of the lung; however, the absence of granulomatous vasculitis on transbronchial specimens should not be considered adequate evidence to exclude the diagnosis of GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/64\">",
"     64",
"    </a>",
"    ]. Among patients with MPA, the typical histological lesion is pulmonary capillaritis. Among patients with GPA, granulomatous inflammation may be seen. Special stains and cultures should be considered to exclude the presence of infections that can produce granulomas (eg, tuberculosis), vasculitis, or necrosis.",
"   </p>",
"   <p>",
"    A positive lung biopsy precludes the need for a kidney biopsy in many cases; a renal biopsy may be indicated in patients who are diagnosed by lung biopsy and have severe or rapidly worsening renal dysfunction since plasma exchange is often performed in addition to standard immunosuppressive therapy in such patients, and the presence of active vasculitis in the kidney should be confirmed by histologic analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H21#H21\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Role of plasma exchange'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initiation of therapy without a confirmatory biopsy may be necessary in rare cases, such as the severely ill ventilator-dependent patient without extrapulmonary involvement in whom the performance of a lung biopsy to obtain adequate tissue may result in significant morbidity or mortality. Even in this setting, an attempt should be made to confirm the diagnosis by tissue biopsy once the patient is stable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11699683\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction of ANCA vasculitis from other systemic rheumatic diseases is a frequent clinical problem. This includes diseases with similar general clinical features, similar lung",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal signs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positive ANCA serologies. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"     \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vasculitis in patients with MPA, GPA, and Churg-Strauss syndrome is pathologically indistinguishable. Asthma and eosinophilia distinguish Churg-Strauss syndrome from MPA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MPA may be distinguished from classic polyarteritis nodosa, a vasculitis of medium-sized muscular arteries, by the clinical presentation and ANCA. The cardinal features of classic polyarteritis nodosa include renal infarcts, renal artery stenosis, and visceral microaneurysms, which are not observed in MPA. Glomerulonephritis is observed in MPA but",
"    <strong>",
"     not",
"    </strong>",
"    classic PAN [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whereas nearly three-fourths of patients with MPA are ANCA-positive, classic polyarteritis nodosa is not associated with antibodies to either PR3 or MPO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-glomerular basement membrane (GBM) antibody disease, substantially more rare than ANCA vasculitis, is another disorder that can present with features of a pulmonary&ndash;renal syndrome. Furthermore, these diseases can occur together; 10 to 40 percent of patients with anti-GBM antibody disease also form ANCA (mostly MPO rather than PR3), a minority of whom have manifestations compatible with a systemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/62/17386/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Anti-GBM antibody disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of diseases other than GPA and MPA are also associated with positive ANCA serologies. A detailed discussion concerning these disease associations and the clinical and laboratory features that help distinguish among the different disorders can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?27/15/27889?source=see_link\">",
"     \"Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11699923\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener&rsquo;s granulomatosis be changed to granulomatosis with polyangiitis, abbreviated as GPA. (See",
"      <a class=\"local\" href=\"#H182265351\">",
"       'New terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), the Churg-Strauss syndrome (CSS) and renal limited vasculitis. All are associated with antineutrophil cytoplasmic antibodies (ANCA) and have similar features on renal histology (eg, a focal necrotizing, often crescentic, pauci-immune glomerulonephritis). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There have been several attempts to standardize the classification and diagnostic criteria for small vessel vasculitis. However, these classification algorithms have important limitations. As an example, none of the algorithms reliably distinguish between GPA and MPA in all patients. Thus, an alternative approach to classification based upon ANCA serology uses the terms &ldquo;proteinase 3 ANCA disease&rdquo;, &ldquo;myeloperoxidase ANCA disease&rdquo;, and &ldquo;seronegative ANCA disease&rdquo;. With this approach, no diagnostic criteria are needed other than serological findings. In addition, proteinase 3 ANCA and myeloperoxidase ANCA have more prognostic significance than the terms MPA and GPA with respect to response to therapy, propensity for relapse, and patient outcome (See",
"      <a class=\"local\" href=\"#H11698510\">",
"       'Classification and diagnostic criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H271324763\">",
"       'Limitations of classification algorithms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GPA and MPA mostly occur in older adults and both genders are equally affected. The disease is far more common among white individuals. Patients typically present with constitutional symptoms including fever, migratory arthralgias, malaise, anorexia and weight loss. Prodromal symptoms may last for weeks to months without evidence of specific organ involvement. (See",
"      <a class=\"local\" href=\"#H11698538\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other common manifestations include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ear, nose, and throat (ENT) manifestations such as crusting, sinusitis, otitis media, persistent rhinorrhea, and",
"      <span class=\"nowrap\">",
"       purulent/bloody",
"      </span>",
"      nasal discharge occur more commonly in patients with GPA than MPA. (See",
"      <a class=\"local\" href=\"#H11698545\">",
"       'Ear, nose, and throat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with either GPA or MPA may present with involvement of airways or pulmonary parenchyma causing hoarseness, cough, dyspnea, stridor, wheezing, hemoptysis or pleuritic pain, sometimes accompanied by signs of tracheal or subglottic stenosis, pulmonary consolidation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pleural effusion. (See",
"      <a class=\"local\" href=\"#H11698552\">",
"       'Pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal involvement is common in GPA and MPA, and can present as asymptomatic hematuria or acute kidney injury with hematuria and cellular casts, and with a variable degree of proteinuria that is usually subnephrotic. Histologically, renal biopsy findings in GPA and MPA generally parallel the severity of the clinical presentation, ranging from mild focal and segmental glomerulonephritis in patients with asymptomatic hematuria and normal or near-normal renal function to a diffuse necrotizing and crescentic glomerulonephritis with patients with acute kidney injury (",
"      <a class=\"graphic graphic_picture graphicRef53506 \" href=\"UTD.htm?6/12/6345\">",
"       picture 2",
"      </a>",
"      ). In most patients, the glomerulonephritis is associated with few or no immune deposits in the glomeruli (pauci-immune glomerulonephritis). (See",
"      <a class=\"local\" href=\"#H11698559\">",
"       'Renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous manifestations occur in about one-half of patients with GPA or MPA. The most common skin lesion is leukocytoclastic angiitis, which causes purpura involving the lower extremities that may be accompanied by focal necrosis and ulceration. (See",
"      <a class=\"local\" href=\"#H11698566\">",
"       'Cutaneous manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prompt diagnosis of GPA or MPA is important to permit initiation of therapy that may be life saving and organ sparing. In patients with suggestive clinical findings, a positive ANCA test strongly suggests the diagnosis of vasculitis but both false positive and negative results may be obtained. Ultimately histologic examination of tissue obtained by biopsy of an affected organ (generally either skin, kidney or lung) is required to make a definitive diagnosis. However, patients should be treated empirically if the clinical suspicion for ANCA vasculitis is high and a tissue diagnosis cannot be obtained in a timely manner. (See",
"      <a class=\"local\" href=\"#H11701485\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The distinction of ANCA vasculitis from other systemic rheumatic diseases is a frequent clinical problem. This includes diseases with similar general clinical features, similar lung",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal signs,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      positive ANCA serologies. This is discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H11699683\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/1\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol 2011; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/3\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/4\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/5\">",
"      Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/6\">",
"      Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/7\">",
"      Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/8\">",
"      Liu LJ, Chen M, Yu F, et al. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford) 2008; 47:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/9\">",
"      Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/10\">",
"      Hoffman GS, Langford CA. Are there different forms of life in the antineutrophil cytoplasmic antibody universe? Ann Intern Med 2005; 143:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/11\">",
"      Pepper RJ, Salama AD. Classifying and predicting outcomes in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2012; 27:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/12\">",
"      Hogan SL, Falk RJ, Nachman PH, Jennette JC. Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med 2006; 144:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/13\">",
"      Falk RJ, Jennette JC. ANCA disease: where is this field heading? J Am Soc Nephrol 2010; 21:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/14\">",
"      Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/15\">",
"      Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/16\">",
"      Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/17\">",
"      Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990; 113:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/18\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/19\">",
"      Jayne D. The diagnosis of vasculitis. Best Pract Res Clin Rheumatol 2009; 23:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/20\">",
"      G&oacute;mez-Puerta JA, Hern&aacute;ndez-Rodr&iacute;guez J, L&oacute;pez-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 2009; 136:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/21\">",
"      Solans-Laqu&eacute; R, Bosch-Gil J, Canela M, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Lupus 2008; 17:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/22\">",
"      Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/23\">",
"      Cordier JF, Valeyre D, Guillevin L, et al. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest 1990; 97:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/24\">",
"      Kariv R, Sidi Y, Gur H. Systemic vasculitis presenting as a tumorlike lesion. Four case reports and an analysis of 79 reported cases. Medicine (Baltimore) 2000; 79:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/25\">",
"      Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/26\">",
"      Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int 2004; 65:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/27\">",
"      Neumann I, Regele H, Kain R, et al. Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis. Nephrol Dial Transplant 2003; 18:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/28\">",
"      Niles JL, Pan GL, Collins AB, et al. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis. J Am Soc Nephrol 1991; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/29\">",
"      Kitching AR, Hutchinson P, Atkins RC, Holdsworth SR. The role of flow cytometric ANCA detection in screening for acute pauci-immune crescentic glomerulonephritis. Nephrol Dial Transplant 2004; 19:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/30\">",
"      Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. Am J Kidney Dis 1994; 24:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/31\">",
"      Banerjee A, McKane W, Thiru S, Farrington K. Wegener's granulomatosis presenting as acute suppurative interstitial nephritis. J Clin Pathol 2001; 54:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/32\">",
"      Wen YK, Chen ML. Transformation from tubulointerstitial nephritis to crescentic glomerulonephritis: an unusual presentation of ANCA-associated renal vasculitis. Ren Fail 2006; 28:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/33\">",
"      Bir K, Herzenberg AM, Carette S. Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener's granulomatosis. J Rheumatol 2006; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/34\">",
"      Tamei N, Sugiura H, Takei T, et al. Ruptured arterial aneurysm of the kidney in a patient with microscopic polyangiitis. Intern Med 2008; 47:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/35\">",
"      Senf R, J&uuml;rgensen JS, Teichgr&auml;ber U, et al. Ruptured arterial aneurysm of the kidney in a patient with Wegener's granulomatosis. Nephrol Dial Transplant 2003; 18:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/36\">",
"      Inatsu A, Shimizu J, Ooshima S, et al. Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis with intrarenal aneurysms and renal arteriovenous fistulaes. Intern Med 2002; 41:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/37\">",
"      Hauer HA, Bajema IM, Van Houwelingen HC, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002; 62:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/38\">",
"      de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006; 17:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/39\">",
"      Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/40\">",
"      Eisenberger U, Fakhouri F, Vanhille P, et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005; 20:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/41\">",
"      Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/42\">",
"      Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM 2005; 98:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/43\">",
"      Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002; 61:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/44\">",
"      Woodworth TG, Abuelo JG, Austin HA 3rd, Esparza A. Severe glomerulonephritis with late emergence of classic Wegener's granulomatosis. Report of 4 cases and review of the literature. Medicine (Baltimore) 1987; 66:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/45\">",
"      Daoud MS, Gibson LE, DeRemee RA, et al. Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol 1994; 31:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/46\">",
"      Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/47\">",
"      Cannady SB, Batra PS, Koening C, et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope 2009; 119:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/48\">",
"      Harper SL, Letko E, Samson CM, et al. Wegener's granulomatosis: the relationship between ocular and systemic disease. J Rheumatol 2001; 28:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/49\">",
"      Fechner FP, Faquin WC, Pilch BZ. Wegener's granulomatosis of the orbit: a clinicopathological study of 15 patients. Laryngoscope 2002; 112:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/50\">",
"      Garovic VD, Clarke BL, Chilson TS, Specks U. Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. Am J Kidney Dis 2001; 37:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/51\">",
"      Czarnecki EJ, Spickler EM. MR demonstration of Wegener granulomatosis of the infundibulum, a cause of diabetes insipidus. AJNR Am J Neuroradiol 1995; 16:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/52\">",
"      Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 2005; 84:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/53\">",
"      Ravanan R, Weale AR, Lear PA, et al. Hemoperitoneum in a patient with ANCA-associated polyangiitis syndrome. Am J Kidney Dis 2004; 44:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/54\">",
"      Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/55\">",
"      Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006; 55:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/56\">",
"      Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors. Rheumatology (Oxford) 2008; 47:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/57\">",
"      Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008; 19:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/58\">",
"      Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003; 48:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/59\">",
"      Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/60\">",
"      Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 120:643.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/61\">",
"      Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol 1997; 8:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/62\">",
"      Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/63\">",
"      Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol 2005; 19:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/64\">",
"      Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 1997; 10:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/65\">",
"      Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/66\">",
"      Yang G, Tang Z, Chen Y, et al. Antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with anti-GBM crescentic glomerulonephritis. Clin Nephrol 2005; 63:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/62/17386/abstract/67\">",
"      Rutgers A, Slot M, van Paassen P, et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005; 46:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3117 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17386=[""].join("\n");
var outline_f16_62_17386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11699923\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H182265351\">",
"      NEW TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11698510\">",
"      CLASSIFICATION AND DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698517\">",
"      ACR criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698524\">",
"      Chapel Hill Consensus Conference (CHCC) criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698531\">",
"      European Medicines Agency algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H271324763\">",
"      Limitations of classification algorithms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11698538\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698545\">",
"      Ear, nose, and throat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698552\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698559\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H934555\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H934033\">",
"      - Histologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16241149\">",
"      Pauci-immune glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16241014\">",
"      Histologic variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H377577\">",
"      Histopathologic classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3403468\">",
"      - ANCA-negative pauci-immune crescentic glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H121321784\">",
"      - Renal-limited vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H934547\">",
"      - Concurrent glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698566\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698573\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Limited form",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11701485\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1414504\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698609\">",
"      Laboratory investigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1414163\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11698616\">",
"      Radiographic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11699683\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11699923\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3117|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/31/35327\" title=\"diagnostic image 1\">",
"      Tracheal stenosis in GPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/55/18288\" title=\"diagnostic image 2\">",
"      Tracheal wall involvement in GPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/20/25926\" title=\"diagnostic image 3\">",
"      Pulmonary nodules in GPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/15/43249\" title=\"diagnostic image 4\">",
"      Pulmonary hemorrhage in GPA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3117|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/27/8638\" title=\"picture 1\">",
"      Saddle nose in RPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/12/6345\" title=\"picture 2\">",
"      Necrotizing GN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/15/27889?source=related_link\">",
"      Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=related_link\">",
"      Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=related_link\">",
"      Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_62_17387="Vaginal CA stage distribution";
var content_f16_62_17387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primary vaginal carcinoma: distribution by stage of disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        358",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        511",
"       </td>",
"       <td>",
"        37.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        331",
"       </td>",
"       <td>",
"        24.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        12.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        1375",
"       </td>",
"       <td>",
"        100.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Berek JS, Hacker NF. Practical Gynecologic Oncology. 3rd ed, Williams and Wilkins, Baltimore, 2000. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17387=[""].join("\n");
var outline_f16_62_17387=null;
var title_f16_62_17388="Disorders associated with acquired vWD";
var content_f16_62_17388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with acquired von Willebrand disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignant diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monoclonal gammopathy of undetermined significance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic lymphocytic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Waldenstr&ouml;m macroglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Essential thrombocythemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycythemia vera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic myeloid leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wilms tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other carcinomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other autoimmune diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve prolapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal angiodyplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs and other agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyethyl starch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotics: griseofulvin, ciprofloxacin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The table includes a disorder only if there were three or more reports in the literature on its association with acquired von Willebrand disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Veyradier A, Jenkins CS, Fressinaud E, et al. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000; 84:175 and Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84:346.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17388=[""].join("\n");
var outline_f16_62_17388=null;
var title_f16_62_17389="CT studies to detect CVT";
var content_f16_62_17389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Computed tomography studies on detection of cardiac allograft vasculopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gold standard",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Romeo, 2005",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        <p>",
"         Angiography",
"        </p>",
"        <p>",
"         &gt;50 percent stenosis",
"        </p>",
"       </td>",
"       <td>",
"        0.83",
"       </td>",
"       <td>",
"        0.95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iyengar, 2006",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        <p>",
"         Angiography",
"        </p>",
"        <p>",
"         &gt;50 pecent stenosis",
"        </p>",
"       </td>",
"       <td>",
"        1/1 detected",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sigurdsson, 2006",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        <p>",
"         Angiography",
"        </p>",
"        <p>",
"         &gt;50 percent stenosis",
"        </p>",
"       </td>",
"       <td>",
"        0.86",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gregory, 2006",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        IVUS",
"       </td>",
"       <td>",
"        0.70",
"       </td>",
"       <td>",
"        0.92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pichler, 2008",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        <p>",
"         Angiography",
"        </p>",
"        <p>",
"         &gt;70 percent stenosis",
"        </p>",
"       </td>",
"       <td>",
"        0.59",
"       </td>",
"       <td>",
"        0.94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schepis, 2009",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        IVUS",
"       </td>",
"       <td>",
"        0.85",
"       </td>",
"       <td>",
"        0.84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mastrobuoni, 2009",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Angiography*",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        0.92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Von Ziegler, 2009",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        <p>",
"         Angiography",
"        </p>",
"        <p>",
"         &gt;50 percent stenosis",
"        </p>",
"       </td>",
"       <td>",
"        0.88",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Only performed when CT abnormal.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Romeo, G, Houyel, L, Angel, CY, et al. Coronary stenosis detection by 16-slice computed tomography in heart transplant patients: comparison with conventional angiography and impact on clinical management. J Am Coll Cardiol 2005; 45:1826.",
"       </li>",
"       <li>",
"        Iyengar, S, Feldman, DS, Cooke, GE, et al. Detection of coronary artery disease in orthotopic heart transplant recipients with 64-detector row computed tomography angiography. J Heart Lung Transplant 2006; 25:1363.",
"       </li>",
"       <li>",
"        Sigurdsson, G, Carrascosa, P, Yamani, MH, et al. Detection of transplant coronary artery disease using multidetector computed tomography with adaptative multisegment reconstruction. J Am Coll Cardiol 2006; 48:772.",
"       </li>",
"       <li>",
"        Gregory, SA, Ferencik, M, Achenbach, S, et al. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol 2006; 98:877.",
"       </li>",
"       <li>",
"        Pichler, P, Loewe, C, Roedler, S, et al. Detection of high-grade stenoses with multislice computed tomography in heart transplant patients. J Heart Lung Transplant 2008; 27:310.",
"       </li>",
"       <li>",
"        Schepis, T, Achenbach, S, Weyand, M, et al. Comparison of dual source computed tomography versus intravascular ultrasound for evaluation of coronary arteries at least one year after cardiac transplantation. Am J Cardiol 2009; 104:1351.",
"       </li>",
"       <li>",
"        Mastrobuoni, S, Bastarrika, G, Ubilla, M, et al. Dual-source CT coronary angiogram in heart transplant recipients in comparison with dobutamine stress echocardiography for detection of cardiac allograft vasculopathy. Transplantation 2009; 87:587.",
"       </li>",
"       <li>",
"        von Ziegler, F, Leber, AW, Becker, A, et al. Detection of significant coronary artery stenosis with 64-slice computed tomography in heart transplant recipients: a comparative study with conventional coronary angiography. Int J Cardiovasc Imaging 2009; 25:91.",
"       </li>",
"      </ol>",
"      <br>",
"       Courtesy of Dr. Finn Gustafsson.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17389=[""].join("\n");
var outline_f16_62_17389=null;
var title_f16_62_17390="Hamstring injury rehabilitation program";
var content_f16_62_17390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hamstring injury rehabilitation program",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phase 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Protect scar development",
"         </li>",
"         <li>",
"          Minimize atrophy",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Protection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid excessive active or passive lengthening of the hamstrings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 to 3 times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Therapeutic exercise (performed daily)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Stationary bike x 10 minutes",
"         </li>",
"         <li>",
"          Side-step x 10 meters, 3 x 1 minute, low to moderate intensity, pain-free speed and stride",
"         </li>",
"         <li>",
"          Grapevine x 10 meters, 3 x 1 minute, low to moderate intensity, pain-free speed and stride",
"         </li>",
"         <li>",
"          Fast feet stepping in place, 2 x 1 min",
"         </li>",
"         <li>",
"          Prone body bridge, 5 x 10 seconds",
"         </li>",
"         <li>",
"          Side body bridge, 5 x 10 seconds",
"         </li>",
"         <li>",
"          Supine bent knee bridge, 10 x 5 seconds",
"         </li>",
"         <li>",
"          Single-limb balance progressing from eyes open to closed, 4 x 20 seconds",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Criteria for progression to next phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Normal walking stride without pain",
"         </li>",
"         <li>",
"          Very low-speed jog without pain",
"         </li>",
"         <li>",
"          Pain-free isometric contraction against submaximal (50-70 percent) resistance during prone knee flexion (90&deg;) manual strength test",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phase 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Regain pain-free hamstring strength, beginning in mid-range and progressing to a longer hamstring length",
"         </li>",
"         <li>",
"          Develop neuromuscular control of trunk and pelvis with progressive increase in movement speed",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Protection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid end-range lengthening of hamstrings while hamstring weakness is present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post-exercise, 10-15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Therapeutic exercise (performed 5-7 d/wk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Stationary bike x 10 min",
"         </li>",
"         <li>",
"          Side-shuffle x 10 meters, 3 x 1 minute, moderate to high intensity, pain-free speed and stride",
"         </li>",
"         <li>",
"          Grapevine jog x 10 meters, 3 x 1 minute, moderate to high intensity, pain-free speed and stride",
"         </li>",
"         <li>",
"          Boxer shuffle x 10 meters, 2 x 1 minute, low to moderate intensity, pain-free speed and stride",
"         </li>",
"         <li>",
"          Rotating body bridge, 5 second hold each side, 2 x 10 reps",
"         </li>",
"         <li>",
"          Supine bent knee bridge with walk-outs, 3 x 10 reps",
"         </li>",
"         <li>",
"          Single-limb balance windmill touches without weight, 4 x 8 reps per arm each limb",
"         </li>",
"         <li>",
"          Lunge walk with trunk rotation, opposite hand-toe touch and T-lift, 2 x 10 steps per limb",
"         </li>",
"         <li>",
"          Single-limb balance with forward trunk lean and opposite hip extension, 5 x 10 seconds per limb",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Criteria for progression to next phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Full strength (5/5) without pain during prone knee flexion (90&deg;) manual strength test",
"         </li>",
"         <li>",
"          Pain-free forward and backward jog, moderate intensity",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phase 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Symptom-free (eg, pain and tightness) during all activities",
"         </li>",
"         <li>",
"          Normal concentric and eccentric hamstring strength through full range of motion and speeds",
"         </li>",
"         <li>",
"          Improve neuromuscular control of trunk and pelvis",
"         </li>",
"         <li>",
"          Integrate postural control into sport-specific movements",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Protection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid full intensity if pain/tightness/stiffness is present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post-exercise, 10-15 minutes, as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Therapeutic exercise (performed 4-5 d/wk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Stationary bike x 10 min",
"         </li>",
"         <li>",
"          Side-shuffle x 30 meters, 3 x 1 minute, moderate to high intensity, pain-free speed and stride",
"         </li>",
"         <li>",
"          Grapevine jog x 30 meters, 3 x 1 minute moderate to high intensity, pain-free speed and stride",
"         </li>",
"         <li>",
"          Boxer shuffle x 10 meters, 2 x 1 minute moderate to high intensity, pain-free speed and stride",
"         </li>",
"         <li>",
"          A and B skips, starting at low knee height and progressively increasing, pain-free",
"          <ul>",
"           <li>",
"            a. A skip is a hop-step forward movement that alternates from leg to leg and couples with arm opposition (similar to running). During the hop, the opposite knee is lifted in a flexed position and then the knee and hip extend together to make the next step",
"           </li>",
"           <li>",
"            b. B skip is a progression of the A skip; however, the opposite knee extends prior to the hip extending recreating the terminal swing phase of running. The leg is then pulled backward in a pawing type action. The other components remain the same as the A skip.",
"           </li>",
"          </ul>",
"         </li>",
"         <li>",
"          Forward-backward accelerations, 3 x 1 minute; start at 5 meters, progress to 10 m, then 20 m",
"         </li>",
"         <li>",
"          Rotating body bridge with dumbbells, 5 seconds hold each side, 2 x 10 reps",
"         </li>",
"         <li>",
"          Supine single-limb chair-bridge, 3 x 15 reps, slow to fast speed",
"         </li>",
"         <li>",
"          Single-limb balance windmill touches with dumbbells, 4 x 8 reps per arm for each leg",
"         </li>",
"         <li>",
"          Lunge walk with trunk rotation, opposite hand dumbbell toe touch and T-lift, 2 x 10 steps per limb",
"         </li>",
"         <li>",
"          Sport-specific drills that incorporate postural control and progressive speed",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Criteria for return to sport",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Full strength without pain",
"          <ul>",
"           <li>",
"            a. 4 consecutive repetitions of maximum effort manual strength test in each prone knee flexion position (90&deg; and 15&deg;)",
"           </li>",
"           <li>",
"            b. Less than 5 percent bilateral deficit in eccentric hamstrings (30&deg;/second): concentric quadriceps (240&deg;/second) ratio during isokinetic testing",
"           </li>",
"           <li>",
"            c. Bilateral symmetry in knee flexion angle of peak isokinetic concentric knee flexion torque at 60&deg;/second",
"           </li>",
"          </ul>",
"         </li>",
"         <li>",
"          Full range of motion without pain",
"         </li>",
"         <li>",
"          Replication of sport specific movements near maximal speed without pain (eg, incremental sprint test for running athletes)",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Proposed guide for the rehabilitation of acute hamstring strain injuries. Suggested exercises, including sets and repetitions, should be individualized. Progression through the 3-phase program is estimated to take from 2 to 6 weeks but should be adjusted to the patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Appendix reproduced from: Heiderscheit BC, Sherry MA, Silder A, Chumanov ES, Thelen DG. Hamstring strain injuries: recommendations for diagnosis, rehabilitation, and injury prevention. J Orthop Sports Phys Ther 2010; 40(2):67-81. doi:10.2519/jospt.2010.3047, with permission of JOSPT and the Orthopaedic and Sports Physical Therapy Sections of the American Physical Therapy Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17390=[""].join("\n");
var outline_f16_62_17390=null;
var title_f16_62_17391="Systolic murmurs and S2";
var content_f16_62_17391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Diagrammatic representation of the character of the systolic murmur and of the second heart sound in several abnormalities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 466px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effects of posture on the intensity of the murmurs are shown.",
"    <div class=\"footnotes\">",
"     MSC: mid-systolic click; -: no change from control.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Barlow JB. Perspectives on the Mitral Valve. F.A. Davis, Philadelphia 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_62_17391=[""].join("\n");
var outline_f16_62_17391=null;
